pyrans - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	pyrans	go back to main search page
Accession:	CHEBI:26407	browse the term

show annotations for term's descendants Sort by:
Rat (1167) Mouse (1166) Human (1188) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (6) Green Monkey (0) Naked Mole-rat (0) All
Genes (1167)

5,6-Dehydrokawain

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

5,6-dehydrokawain results in increased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

asperentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily F member 1

increases expression

cladosporin results in increased expression of ABCF1 mRNA

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,802,488...2,815,433

G

aminoacyl tRNA synthetase complex-interacting multifunctional protein 1

increases expression

cladosporin results in increased expression of AIMP1 mRNA

NCBI chr 2:223,825,930...223,849,477
Ensembl chr 2:221,151,904...221,175,728

G

biliverdin reductase B

increases expression

cladosporin results in increased expression of BLVRB mRNA

NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375

G

C-C motif chemokine ligand 12

increases expression

cladosporin results in increased expression of CCL12 mRNA

NCBI chr10:67,567,876...67,569,426
Ensembl chr10:67,070,230...67,071,780

G

C-C motif chemokine ligand 19

increases expression

cladosporin results in increased expression of CCL19 mRNA

NCBI chr 5:61,759,220...61,761,164
Ensembl chr 5:56,963,364...56,965,308

G

C-C motif chemokine ligand 20

increases expression
decreases expression

cladosporin results in increased expression of CCL20 mRNA
cladosporin results in decreased expression of CCL20 mRNA

PMID:19818335 PMID:21356202

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 25

increases expression

cladosporin results in increased expression of CCL25 mRNA

NCBI chr12:7,505,231...7,514,402
Ensembl chr12:2,707,398...2,716,554

G

C-C motif chemokine ligand 3

decreases expression

cladosporin results in decreased expression of CCL3 mRNA

PMID:19818335 PMID:21356202

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression

cladosporin results in decreased expression of CCL4 mRNA

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 7

decreases expression

cladosporin results in decreased expression of CCL7 mRNA

NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,016,446...67,018,303

G

C-C motif chemokine receptor 1

increases expression

cladosporin results in increased expression of CCR1 mRNA

NCBI chr 8:132,433,711...132,439,266

G

C-C motif chemokine receptor 10

increases expression

cladosporin results in increased expression of CCR10 mRNA

NCBI chr10:86,608,836...86,611,273
Ensembl chr10:86,108,551...86,110,988

G

C-C motif chemokine receptor 2

increases expression

cladosporin results in increased expression of CCR2 mRNA

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 3

increases expression

cladosporin results in increased expression of CCR3 mRNA

NCBI chr 8:132,463,533...132,511,601
Ensembl chr 8:123,616,236...123,634,990

G

C-C motif chemokine receptor 4

increases expression

cladosporin results in increased expression of CCR4 mRNA

NCBI chr 8:123,054,505...123,060,244
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 6

increases expression

cladosporin results in increased expression of CCR6 mRNA

NCBI chr 1:55,022,037...55,055,857
Ensembl chr 1:52,474,168...52,498,603

G

C-C motif chemokine receptor 7

increases expression

cladosporin results in increased expression of CCR7 mRNA

NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,097,381...84,108,309

G

C-C motif chemokine receptor 9

increases expression

cladosporin results in increased expression of CCR9 mRNA

NCBI chr 8:132,273,581...132,287,651
Ensembl chr 8:123,395,813...123,413,969

G

CD40 ligand

increases expression

cladosporin results in increased expression of CD40LG mRNA

NCBI chr X:140,164,341...140,176,057
Ensembl chr X:135,126,969...135,138,306

G

C-X3-C motif chemokine ligand 1

increases expression

cladosporin results in increased expression of CX3CL1 mRNA

NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,227,340...10,236,833

G

C-X-C motif chemokine ligand 10

decreases expression
increases expression

cladosporin results in decreased expression of CXCL10 mRNA
cladosporin results in increased expression of CXCL10 protein

PMID:19818335 PMID:21356202

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

decreases expression

cladosporin results in decreased expression of CXCL11 mRNA

NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,689,424...15,692,271

G

C-X-C motif chemokine ligand 12

increases expression

cladosporin results in increased expression of CXCL12 mRNA

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 13

increases expression

cladosporin results in increased expression of CXCL13 mRNA

NCBI chr14:13,912,858...13,917,920
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine ligand 2

increases expression

cladosporin results in increased expression of CXCL2 mRNA; cladosporin results in increased expression of CXCL2 protein

PMID:19818335 PMID:21356202

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

decreases expression
increases expression

cladosporin results in decreased expression of CXCL1 mRNA
cladosporin results in increased expression of CXCL1 mRNA

PMID:19818335 PMID:21356202

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 2

decreases expression
increases expression

cladosporin results in decreased expression of CXCR2 mRNA
cladosporin results in increased expression of CXCR2 mRNA

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:75,729,115...75,739,425

G

C-X-C motif chemokine receptor 3

increases expression

cladosporin results in increased expression of CXCR3 mRNA

NCBI chr X:70,884,293...70,886,944
Ensembl chr X:66,844,318...66,846,969

G

C-X-C motif chemokine receptor 5

increases expression

cladosporin results in increased expression of CXCR5 mRNA

NCBI chr 8:53,738,878...53,756,813
Ensembl chr 8:44,843,413...44,857,893

G

interferon gamma

increases expression

cladosporin results in increased expression of IFNG mRNA

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

increases expression

cladosporin results in increased expression of IL10 mRNA

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313

G

interleukin 10 receptor subunit alpha

increases expression

cladosporin results in increased expression of IL10RA mRNA

NCBI chr 8:54,459,754...54,474,786
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 10 receptor subunit beta

increases expression

cladosporin results in increased expression of IL10RB mRNA

NCBI chr11:44,132,471...44,154,062
Ensembl chr11:30,652,096...30,668,074

G

interleukin 15

increases expression

cladosporin results in increased expression of IL15 mRNA

NCBI chr19:42,536,160...42,611,349
Ensembl chr19:25,640,251...25,706,820

G

interleukin 16

increases expression

cladosporin results in increased expression of IL16 mRNA

NCBI chr 1:147,026,852...147,127,177
Ensembl chr 1:137,617,944...137,718,130

G

interleukin 18

increases expression

cladosporin results in increased expression of IL18 mRNA

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

increases expression
decreases expression

cladosporin results in increased expression of IL1B mRNA
cladosporin results in decreased expression of IL1B mRNA

PMID:19818335 PMID:21356202

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 1

increases expression

cladosporin results in increased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 2 receptor subunit beta

increases expression

cladosporin results in increased expression of IL2RB mRNA

NCBI chr 7:111,913,828...111,928,537
Ensembl chr 7:110,033,341...110,048,054

G

interleukin 4

increases expression

cladosporin results in increased expression of IL4 mRNA

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5 receptor subunit alpha

increases expression

cladosporin results in increased expression of IL5RA mRNA

NCBI chr 4:141,186,749...141,221,348
Ensembl chr 4:139,632,066...139,668,544

G

interleukin 6

increases expression

cladosporin results in increased expression of IL6 mRNA

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 receptor

increases expression

cladosporin results in increased expression of IL6RA mRNA

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:175,298,686...175,347,536

G

interleukin 6 cytokine family signal transducer

decreases expression

cladosporin results in decreased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:44,066,130...44,109,936

G

integrin subunit alpha M

increases expression

cladosporin results in increased expression of ITGAM mRNA

NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:182,659,000...182,709,503

G

lymphotoxin alpha

increases expression

cladosporin results in increased expression of LTA mRNA

NCBI chr20:3,622,291...3,625,852
Ensembl chr20:3,618,853...3,620,859

G

lymphotoxin beta

increases expression

cladosporin results in increased expression of LTB mRNA

NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,627,537...3,629,381

G

macrophage migration inhibitory factor

increases expression

cladosporin results in increased expression of MIF mRNA

NCBI chr20:12,767,138...12,791,222
Ensembl chr20:12,790,902...12,799,504
Ensembl chr 4:12,790,902...12,799,504

G

secreted phosphoprotein 1

increases expression

cladosporin results in increased expression of SPP1 mRNA

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162

G

tumor necrosis factor

decreases expression
increases expression

cladosporin results in decreased expression of TNF mRNA
cladosporin results in increased expression of TNF mRNA

PMID:19818335 PMID:21356202

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1A

increases expression

cladosporin results in increased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:158,150,820...158,163,591

Citreoviridin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

Rosiglitazone inhibits the reaction [citreoviridin results in decreased phosphorylation of AKT1 protein]; Sodium Selenite inhibits the reaction [citreoviridin results in decreased phosphorylation of AKT1 protein]; Thiamine inhibits the reaction [citreoviridin results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

aquaporin 7

multiple interactions
decreases expression

Sodium Selenite inhibits the reaction [citreoviridin results in decreased expression of AQP7 mRNA]; Thiamine inhibits the reaction [citreoviridin results in decreased expression of AQP7 mRNA]

NCBI chr 5:60,968,495...60,982,618
Ensembl chr 5:56,172,519...56,186,642

G

activity-regulated cytoskeleton-associated protein

increases expression

citreoviridin results in increased expression of ARC mRNA

NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:106,555,785...106,559,378

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

citreoviridin results in increased expression of BAX protein
Sodium Selenite inhibits the reaction [citreoviridin results in increased expression of BAX protein]; Thiamine inhibits the reaction [citreoviridin results in increased expression of BAX protein]
3-methyladenine inhibits the reaction [citreoviridin results in increased expression of BAX protein]; Rosiglitazone inhibits the reaction [citreoviridin results in increased expression of BAX protein]; Sodium Selenite inhibits the reaction [citreoviridin results in increased expression of BAX protein]; Thiamine inhibits the reaction [citreoviridin results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

citreoviridin results in decreased expression of BCL2 protein
3-methyladenine inhibits the reaction [citreoviridin results in decreased expression of BCL2 protein]; Rosiglitazone inhibits the reaction [citreoviridin results in decreased expression of BCL2 protein]; Sodium Selenite inhibits the reaction [citreoviridin results in decreased expression of BCL2 protein]; Thiamine inhibits the reaction [citreoviridin results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

affects expression

citreoviridin affects the expression of BDNF mRNA

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615

G

cholinergic receptor nicotinic alpha 4 subunit

affects expression

citreoviridin affects the expression of CHRNA4 mRNA

NCBI chr 3:188,506,802...188,535,558
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

decreases expression

citreoviridin results in decreased expression of CHRNA7 mRNA

NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

increases expression

citreoviridin results in increased expression of CHRNB2 mRNA

NCBI chr 2:177,479,091...177,487,306
Ensembl chr 2:175,181,402...175,189,619

G

creatine kinase B

multiple interactions

citreoviridin results in increased secretion of [CKM protein binds to CKB protein]; Sodium Selenite inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]
3-methyladenine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; citreoviridin results in increased secretion of [CKM protein binds to CKB protein]; Rosiglitazone inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Sodium Selenite inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:130,729,423...130,732,315

G

creatine kinase, M-type

multiple interactions

3-methyladenine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; citreoviridin results in increased secretion of [CKM protein binds to CKB protein]; Rosiglitazone inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Sodium Selenite inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]
citreoviridin results in increased secretion of [CKM protein binds to CKB protein]; Sodium Selenite inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]

NCBI chr 1:88,189,382...88,199,717
Ensembl chr 1:79,061,456...79,071,720

G

doublecortin

affects expression

citreoviridin affects the expression of DCX mRNA

NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476

G

eomesodermin

increases expression

citreoviridin results in increased expression of EOMES mRNA

NCBI chr 8:127,059,215...127,067,070
Ensembl chr 8:118,181,777...118,188,316

G

fatty acid binding protein 4

multiple interactions
decreases expression

Sodium Selenite inhibits the reaction [citreoviridin results in decreased expression of FABP4 mRNA]; Thiamine inhibits the reaction [citreoviridin results in decreased expression of FABP4 mRNA]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578

G

fibroblast growth factor 21

decreases expression

citreoviridin results in decreased expression of FGF21 mRNA

NCBI chr 1:105,219,825...105,221,376
Ensembl chr 1:96,083,441...96,090,454

G

glial fibrillary acidic protein

affects expression

citreoviridin affects the expression of GFAP mRNA

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:87,852,890...87,861,589

G

glutamate ionotropic receptor AMPA type subunit 1

decreases expression

citreoviridin results in decreased expression of GRIA1 mRNA

NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

affects expression

citreoviridin affects the expression of GRIA2 mRNA

NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor AMPA type subunit 3

increases expression

citreoviridin results in increased expression of GRIA3 mRNA

NCBI chr X:125,103,975...125,369,690
Ensembl chr X:120,238,534...120,504,096

G

glutamate ionotropic receptor NMDA type subunit 2D

decreases expression

citreoviridin results in decreased expression of GRIN2D mRNA

NCBI chr 1:105,443,317...105,483,400
Ensembl chr 1:96,308,365...96,344,793

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

Sodium Selenite inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form]; Thiamine inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form]
Rosiglitazone inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form]; Sodium Selenite inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form]; Thiamine inhibits the reaction [citreoviridin results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

neuronal differentiation 1

affects expression

citreoviridin affects the expression of NEUROD1 mRNA

NCBI chr 3:84,766,483...84,770,454
Ensembl chr 3:64,359,395...64,363,649

G

neurotrophic receptor tyrosine kinase 2

increases expression

citreoviridin results in increased expression of NTRK2 mRNA

NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,559,043...5,869,136

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases activity

Sodium Selenite inhibits the reaction [citreoviridin results in decreased activity of PPARG protein]; Thiamine inhibits the reaction [citreoviridin results in decreased activity of PPARG protein]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468

G

parvalbumin

increases expression

citreoviridin results in increased expression of PVALB mRNA

NCBI chr 7:111,653,820...111,668,469
Ensembl chr 7:109,772,593...109,784,561

G

solute carrier family 17 member 6

decreases expression

citreoviridin results in decreased expression of SLC17A6 mRNA

NCBI chr 1:110,348,447...110,388,499
Ensembl chr 1:101,212,489...101,252,542

G

solute carrier family 17 member 7

affects expression

citreoviridin affects the expression of SLC17A7 mRNA

NCBI chr 1:104,786,172...104,798,049
Ensembl chr 1:95,649,745...95,661,588

G

SRY-box transcription factor 2

increases expression

citreoviridin results in increased expression of SOX2 mRNA

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:117,536,929...117,539,338

G

sequestosome 1

multiple interactions
decreases expression

Sodium Selenite inhibits the reaction [citreoviridin results in decreased expression of SQSTM1 protein]; Thiamine inhibits the reaction [citreoviridin results in decreased expression of SQSTM1 protein]
Rosiglitazone inhibits the reaction [citreoviridin results in decreased expression of SQSTM1 protein]; Sodium Selenite inhibits the reaction [citreoviridin results in decreased expression of SQSTM1 protein]; Thiamine inhibits the reaction [citreoviridin results in decreased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673

G

somatostatin

increases expression

citreoviridin results in increased expression of SST mRNA

NCBI chr11:90,461,546...90,462,823
Ensembl chr11:76,956,896...76,958,173

G

troponin T2, cardiac type

multiple interactions
increases secretion

3-methyladenine inhibits the reaction [citreoviridin results in increased secretion of TNNT2 protein]; Rosiglitazone inhibits the reaction [citreoviridin results in increased secretion of TNNT2 protein]; Sodium Selenite inhibits the reaction [citreoviridin results in increased secretion of TNNT2 protein]; Thiamine inhibits the reaction [citreoviridin results in increased secretion of TNNT2 protein]

NCBI chr13:49,819,123...49,837,125
Ensembl chr13:47,267,204...47,285,388

G

vanin 1

decreases expression

citreoviridin results in decreased expression of VNN1 mRNA

NCBI chr 1:23,356,324...23,366,629
Ensembl chr 1:21,537,094...21,547,395

dehydroacetic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

increases expression

dehydroacetic acid results in increased expression of ALB protein

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836

G

coagulation factor IX

multiple interactions

dehydroacetic acid results in decreased expression of and results in decreased secretion of F9 protein; VKORC1 protein inhibits the reaction [dehydroacetic acid results in decreased secretion of F9 protein]; VKORC1L1 protein inhibits the reaction [dehydroacetic acid results in decreased secretion of F9 protein]

NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835

G

glutamic--pyruvic transaminase

decreases expression

dehydroacetic acid results in decreased expression of GPT protein

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

FR 180204 inhibits the reaction [dehydroacetic acid results in increased phosphorylation of MAPK1 protein]; Sirolimus inhibits the reaction [dehydroacetic acid results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

FR 180204 inhibits the reaction [dehydroacetic acid results in increased phosphorylation of MAPK3 protein]; Sirolimus inhibits the reaction [dehydroacetic acid results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mechanistic target of rapamycin kinase

multiple interactions

dehydroacetic acid results in increased expression of and results in increased phosphorylation of MTOR protein; Sirolimus inhibits the reaction [dehydroacetic acid results in increased expression of and results in increased phosphorylation of MTOR protein]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311

G

vitamin K epoxide reductase complex, subunit 1

decreases activity
multiple interactions
decreases expression

dehydroacetic acid results in decreased activity of VKORC1 protein
FR 180204 inhibits the reaction [dehydroacetic acid results in decreased expression of VKORC1 protein]; VKORC1 protein inhibits the reaction [dehydroacetic acid results in decreased secretion of F9 protein]

PMID:17941040 PMID:36403723 PMID:38103582

NCBI chr 1:191,932,969...191,935,490
Ensembl chr 1:182,500,844...182,505,008

G

vitamin K epoxide reductase complex, subunit 1-like 1

multiple interactions
decreases expression

FR 180204 inhibits the reaction [dehydroacetic acid results in decreased expression of VKORC1L1 protein]; VKORC1L1 protein inhibits the reaction [dehydroacetic acid results in decreased secretion of F9 protein]

PMID:36403723 PMID:38103582

NCBI chr12:32,354,078...32,404,327
Ensembl chr12:26,623,976...26,768,225

Dihydrokavain

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carboxylesterase 1D

decreases activity
multiple interactions

dihydrokavain results in decreased activity of CES1 protein
dihydrokavain inhibits the reaction [[CES1 protein results in increased metabolism of Oseltamivir] which results in increased abundance of oseltamivir carboxylate]

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035

Ethyl maltol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein

multiple interactions

[APP protein co-treated with ethyl maltol] results in increased expression of CDKN1A mRNA; APP protein inhibits the reaction [ethyl maltol results in increased expression of H2AX protein]; APP protein inhibits the reaction [ethyl maltol results in increased expression of SFN mRNA]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561

G

ATM serine/threonine kinase

multiple interactions

[ethyl maltol results in increased susceptibility to [Copper Sulfate results in increased abundance of Copper]] which results in increased phosphorylation of ATM protein

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

ethyl maltol results in increased expression of CDKN1A mRNA
[APP protein co-treated with ethyl maltol] results in increased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

ferritin light chain 1

multiple interactions
decreases expression

[ethyl maltol results in increased susceptibility to [Copper Sulfate results in increased abundance of Copper]] which results in increased expression of FTL mRNA
ethyl maltol results in decreased expression of FTL protein

PMID:33271249 PMID:37606557

NCBI chr 1:105,072,858...105,074,705
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
Ensembl chr 2:95,936,387...95,939,725

G

H2A.X variant histone

multiple interactions
increases expression

APP protein inhibits the reaction [ethyl maltol results in increased expression of H2AX protein]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

heme oxygenase 1

multiple interactions

[ethyl maltol results in increased susceptibility to [Copper Sulfate results in increased abundance of Copper]] which results in increased expression of HMOX1 mRNA; [ethyl maltol results in increased susceptibility to [Copper Sulfate results in increased abundance of Copper]] which results in increased expression of HMOX1 protein

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079

G

stratifin

increases expression
multiple interactions

ethyl maltol results in increased expression of SFN mRNA
APP protein inhibits the reaction [ethyl maltol results in increased expression of SFN mRNA]

NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:145,826,201...145,831,314

G

transferrin receptor

increases expression

ethyl maltol results in increased expression of TFRC mRNA

NCBI chr11:81,668,478...81,690,318
Ensembl chr11:68,163,413...68,185,257

fostriecin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl-2 binding component 3

multiple interactions

fostriecin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased expression of BBC3 protein]]

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:77,014,543...77,022,509

G

caspase 3

multiple interactions

fostriecin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein]]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

forkhead box O3

multiple interactions

fostriecin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of FOXO3 protein]]

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561

G

tumor protein p53

multiple interactions

fostriecin promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

hispidin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 9

multiple interactions
increases activity

hispidin inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein]
hispidin results in increased activity of CASP9 protein

Ensembl chr 5:154,109,046...154,126,626

G

SHC adaptor protein 1

multiple interactions

hispidin inhibits the reaction [Doxorubicin results in increased expression of and results in decreased phosphorylation of and affects the localization of SHC1 protein]

NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:174,837,930...174,849,536

G

SMAD family member 2

multiple interactions

hispidin inhibits the reaction [Cyclosporine results in increased phosphorylation of and results in increased activity of SMAD2 protein]

NCBI chr18:72,124,792...72,193,345
Ensembl chr18:69,850,377...69,912,323

kojic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 13

decreases expression

kojic acid results in decreased expression of ABCA13 mRNA

NCBI chr14:83,873,397...84,376,138
Ensembl chr14:83,873,940...84,375,075

G

ATP binding cassette subfamily C member 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of ABCC2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 6

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCC6 mRNA
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABCC6 mRNA

PMID:17917374 PMID:18544905

NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily C member 9

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCC9 mRNA

NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:175,532,547...175,655,356

G

ATP binding cassette subfamily D member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCD1 mRNA

NCBI chr X:156,579,669...156,601,448
Ensembl chr X:151,428,578...151,450,115

G

ATP binding cassette subfamily F member 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCF2 mRNA

NCBI chr 4:11,485,865...11,500,067
Ensembl chr 4:10,594,907...10,607,606

G

abhydrolase domain containing 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABHD1 mRNA

NCBI chr 6:25,422,526...25,427,514
Ensembl chr 6:25,422,526...25,427,514

G

alkaline ceramidase 3

increases expression

kojic acid results in increased expression of ACER3 mRNA

NCBI chr 1:161,915,397...162,017,802
Ensembl chr 1:152,504,186...152,606,591

G

aminocarboxymuconate semialdehyde decarboxylase

decreases expression

kojic acid results in decreased expression of ACMSD mRNA

NCBI chr13:41,752,894...41,798,427
Ensembl chr13:39,200,314...39,245,209

G

activin A receptor like type 1

decreases expression

kojic acid results in decreased expression of ACVRL1 mRNA

NCBI chr 7:134,117,917...134,135,306
Ensembl chr 7:132,239,729...132,256,591

G

adrenoceptor beta 3

decreases expression

kojic acid results in decreased expression of ADRB3 mRNA

NCBI chr16:71,544,603...71,547,410
Ensembl chr16:64,841,788...64,844,552

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 3

increases expression

kojic acid results in increased expression of AGAP3 mRNA

NCBI chr 4:11,567,191...11,617,610
Ensembl chr 4:10,674,064...10,725,244

G

AGBL carboxypeptidase 4

decreases expression

kojic acid results in decreased expression of AGBL4 mRNA

NCBI chr 5:125,254,963...126,534,367
Ensembl chr 5:125,254,956...126,534,367

G

AHNAK nucleoprotein

decreases expression

kojic acid results in decreased expression of AHNAK mRNA

NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:205,882,273...205,970,926

G

AKT serine/threonine kinase 1

decreases expression

kojic acid results in decreased expression of AKT1 mRNA

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

alkaline phosphatase, intestinal

decreases expression

kojic acid results in decreased expression of ALPI mRNA

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:87,773,411...87,776,877

G

amelotin

decreases expression

kojic acid results in decreased expression of AMTN mRNA

NCBI chr14:19,648,624...19,661,181
Ensembl chr14:19,648,625...19,661,181

G

annexin A1

decreases expression

kojic acid results in decreased expression of ANXA1 mRNA

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:217,861,175...217,877,343

G

annexin A5

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ANXA5 mRNA

NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:119,314,007...119,353,369

G

adaptor related protein complex 1 subunit sigma 1

decreases expression

kojic acid results in decreased expression of AP1S1 mRNA

NCBI chr12:25,261,958...25,272,483
Ensembl chr12:19,625,332...19,756,713

G

apolipoprotein B mRNA editing enzyme catalytic subunit 1

decreases expression

kojic acid results in decreased expression of APOBEC1 mRNA

NCBI chr 4:157,472,879...157,500,496
Ensembl chr 4:155,800,887...155,827,390

G

amyloid beta precursor protein

increases expression

kojic acid results in increased expression of APP mRNA

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561

G

aprataxin

decreases expression

kojic acid results in decreased expression of APTX mRNA

NCBI chr 5:55,798,896...55,822,963
Ensembl chr 5:55,800,248...55,822,855

G

aquaporin 1

increases expression

kojic acid results in increased expression of AQP1 mRNA

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:84,482,512...84,494,690

G

ARF interacting protein 2

decreases expression

kojic acid results in decreased expression of ARFIP2 mRNA

NCBI chr 1:169,387,484...169,392,290
Ensembl chr 1:159,974,201...159,980,336

G

Rho guanine nucleotide exchange factor 16

decreases expression

kojic acid results in decreased expression of ARHGEF16 mRNA

NCBI chr 5:170,126,573...170,148,624
Ensembl chr 5:164,844,161...164,866,212

G

ARF like GTPase 6 interacting protein 5

increases expression

kojic acid results in increased expression of ARL6IP5 mRNA

NCBI chr 4:131,365,320...131,395,311
Ensembl chr 4:129,810,645...129,838,608

G

asparagine synthetase domain containing 1

decreases expression

kojic acid results in decreased expression of ASNSD1 mRNA

NCBI chr 9:55,618,799...55,631,064
Ensembl chr 9:48,126,808...48,139,073

G

activating transcription factor 6 beta

decreases expression

kojic acid results in decreased expression of ATF6B mRNA

NCBI chr20:4,095,534...4,103,534
Ensembl chr20:4,090,921...4,098,894

G

ATM serine/threonine kinase

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ATM mRNA

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437

G

beta-1,4-N-acetyl-galactosaminyl transferase 4

decreases expression

kojic acid results in decreased expression of B4GALNT4 mRNA

NCBI chr 1:205,600,989...205,611,889
Ensembl chr 1:196,171,394...196,182,294

G

BAG cochaperone 5

decreases expression

kojic acid results in decreased expression of BAG5 mRNA

NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970

G

BCL2-related protein A1

increases expression

kojic acid results in increased expression of BCL2A1 mRNA

NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of BCL2L2 mRNA

NCBI chr15:32,326,686...32,337,834
Ensembl chr15:28,356,807...28,361,624

G

baculoviral IAP repeat-containing 2

decreases expression

kojic acid results in decreased expression of BIRC2 mRNA

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:4,968,842...4,988,732

G

bone morphogenetic protein 5

decreases expression

kojic acid results in decreased expression of BMP5 mRNA

NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:76,517,164...76,639,925

G

BR serine/threonine kinase 1

decreases expression

kojic acid results in decreased expression of BRSK1 mRNA

NCBI chr 1:78,162,944...78,193,598
Ensembl chr 1:69,134,565...69,160,365

G

bone marrow stromal cell antigen 2

decreases expression

kojic acid results in decreased expression of BST2 mRNA

NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979

G

similar to human chromosome 1 open reading frame 54

increases expression

kojic acid results in increased expression of C1ORF54 mRNA

NCBI chr 2:183,424,989...183,434,713
Ensembl chr 2:183,424,984...183,435,089

G

similar to human chromosome 1 open reading frame 87

decreases expression

kojic acid results in decreased expression of C1ORF87 mRNA

NCBI chr 5:111,342,381...111,411,576
Ensembl chr 5:111,342,387...111,411,590

G

calcium binding protein 39-like

increases expression

kojic acid results in increased expression of CAB39L mRNA

NCBI chr15:37,782,778...37,885,191
Ensembl chr15:33,606,694...33,743,545

G

calreticulin

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CALR mRNA

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:23,308,351...23,313,414

G

carbonic anhydrase 13

increases expression

kojic acid results in increased expression of CAR13 mRNA

NCBI chr 2:88,649,643...88,680,763
Ensembl chr 2:86,928,383...86,959,525

G

carbonic anhydrase 14

increases expression

kojic acid results in increased expression of CA14 mRNA

NCBI chr 2:186,131,196...186,138,164
Ensembl chr 2:183,441,667...183,449,693

G

caspase 4

multiple interactions

[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CASP4 mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CASP4 mRNA]

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:2,598,876...2,635,092

G

caspase 8

multiple interactions

[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

catalase

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CAT mRNA

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

cell division cycle and apoptosis regulator 1

increases expression

kojic acid results in increased expression of CCAR1 mRNA

NCBI chr20:31,228,624...31,271,233
Ensembl chr20:30,685,916...30,728,526

G

coiled-coil domain containing 50

increases expression

kojic acid results in increased expression of CCDC50 mRNA

NCBI chr11:86,837,624...86,900,164
Ensembl chr11:73,334,248...73,395,150

G

C-C motif chemokine ligand 21

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL21A mRNA

NCBI chr 5:61,776,411...61,777,515
Ensembl chr 5:56,980,558...56,981,686

G

C-C motif chemokine ligand 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL3 mRNA

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938

G

cyclin B1

increases expression

kojic acid results in increased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172

G

cyclin C

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNC mRNA

NCBI chr 5:40,063,589...40,081,731
Ensembl chr 5:35,266,823...35,296,584

G

cyclin D1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CCND1 mRNA
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCND1 mRNA

PMID:17917374 PMID:18544905

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

cyclin G1

multiple interactions

[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of CCNG1 mRNA
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNG1 mRNA

PMID:17917374 PMID:18544905

NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,176,234...25,181,641

G

cell cycle progression 1

decreases expression

kojic acid results in decreased expression of CCPG1 mRNA

NCBI chr 8:82,600,677...82,633,082
Ensembl chr 8:73,719,955...73,752,430

G

C-C motif chemokine receptor 4

decreases expression

kojic acid results in decreased expression of CCR4 mRNA

NCBI chr 8:123,054,505...123,060,244
Ensembl chr 8:114,176,974...114,178,056

G

CD22 molecule

decreases expression

kojic acid results in decreased expression of CD22 mRNA

NCBI chr 1:95,243,785...95,270,430
Ensembl chr 1:86,117,459...86,132,322

G

CD274 molecule

increases expression

kojic acid results in increased expression of CD274 mRNA

NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:227,116,649...227,134,450

G

CD3 gamma subunit of T-cell receptor complex

decreases expression

kojic acid results in decreased expression of CD3G mRNA

NCBI chr 8:54,177,572...54,184,087
Ensembl chr 8:45,281,204...45,287,147

G

CDAN1 interacting nuclease 1

increases expression

kojic acid results in increased expression of CDIN1 mRNA

NCBI chr 3:102,441,553...102,646,935
Ensembl chr 3:102,441,704...102,646,682

G

cyclin-dependent kinase 10

decreases expression

kojic acid results in decreased expression of CDK10 mRNA

NCBI chr19:51,260,012...51,273,009
Ensembl chr19:51,261,356...51,269,078

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CDKN1A mRNA
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of CDKN1A mRNA

PMID:17917374 PMID:18544905

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CDKN1B mRNA; [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CDKN1B mRNA

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982

G

CEA cell adhesion molecule 1

decreases expression

kojic acid results in decreased expression of CEACAM1 mRNA

NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:81,043,595...81,059,992

G

CCAAT/enhancer binding protein delta

increases expression

kojic acid results in increased expression of CEBPD mRNA

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:84,764,565...84,765,829

G

centromere protein Q

decreases expression

kojic acid results in decreased expression of CENPQ mRNA

NCBI chr 9:27,454,339...27,469,371
Ensembl chr 9:19,957,048...19,972,789

G

centrosomal protein 192

increases expression

kojic acid results in increased expression of CEP192 mRNA

NCBI chr18:63,643,816...63,728,264
Ensembl chr18:61,332,158...61,458,379

G

centrosomal protein 72

increases expression

kojic acid results in increased expression of CEP72 mRNA

NCBI chr 1:31,053,884...31,083,863
Ensembl chr 1:29,225,361...29,255,271

G

carboxylesterase 1D

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of CES1 mRNA

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035

G

checkpoint kinase 2

multiple interactions

[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CHEK2 mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CHEK2 mRNA]

NCBI chr12:51,448,838...51,481,159
Ensembl chr12:45,788,827...45,821,286

G

carbohydrate sulfotransferase 4

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CHST4 mRNA

NCBI chr19:54,900,914...54,911,735
Ensembl chr19:37,991,417...38,003,608

G

CBY1 interacting BAR domain containing 1

increases expression

kojic acid results in increased expression of CIBAR1 mRNA

NCBI chr 5:25,613,993...25,632,440
Ensembl chr 5:25,614,033...25,632,489

G

claudin 3

decreases expression

kojic acid results in decreased expression of CLDN3 mRNA

NCBI chr12:27,345,075...27,346,547
Ensembl chr12:21,708,398...21,711,001

G

claudin domain containing 2

decreases expression

kojic acid results in decreased expression of CLDND2 mRNA

NCBI chr 1:93,848,533...93,851,693
Ensembl chr 1:93,848,533...93,851,217

G

C-type lectin domain family 4, member B2

decreases expression

kojic acid results in decreased expression of CLEC4C mRNA

NCBI chr 4:158,148,434...158,171,933
Ensembl chr 4:156,462,742...156,486,240

G

CXADR-like membrane protein

decreases expression

kojic acid results in decreased expression of CLMP mRNA

NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838

G

clusterin

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CLU mRNA

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:40,174,617...40,200,315

G

cornichon family member 1

increases expression

kojic acid results in increased expression of CNIH1 mRNA

NCBI chr15:22,517,755...22,529,651
Ensembl chr15:20,037,885...20,049,761

G

connector enhancer of kinase suppressor of Ras 2

decreases expression

kojic acid results in decreased expression of CNKSR2 mRNA

NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555

G

collagen type XVII alpha 1 chain

decreases expression

kojic acid results in decreased expression of COL17A1 mRNA

NCBI chr 1:256,472,648...256,518,857
Ensembl chr 1:246,531,367...246,577,632

G

collagen type XXIV alpha 1 chain

decreases expression

kojic acid results in decreased expression of COL24A1 mRNA

NCBI chr 2:236,872,583...237,129,768
Ensembl chr 2:234,212,324...234,469,441

G

collagen like tail subunit of asymmetric acetylcholinesterase

increases expression

kojic acid results in increased expression of COLQ mRNA

NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107

G

catechol-O-methyltransferase

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of COMT mRNA

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642

G

COP9 signalosome subunit 2

decreases expression

kojic acid results in decreased expression of COPS2 mRNA

NCBI chr 3:133,537,729...133,563,493
Ensembl chr 3:113,084,176...113,109,947

G

coenzyme Q10A

increases expression

kojic acid results in increased expression of COQ10A mRNA

NCBI chr 7:792,089...798,392
Ensembl chr 7:792,089...800,161

G

coenzyme Q8A

increases expression

kojic acid results in increased expression of COQ8A mRNA

NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431

G

carboxypeptidase B1

decreases expression

kojic acid results in decreased expression of CPB1 mRNA

NCBI chr 2:102,755,241...102,785,628
Ensembl chr 2:102,755,241...102,785,628

G

carboxypeptidase E

increases expression

kojic acid results in increased expression of CPE mRNA

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:25,030,276...25,142,233

G

copine 5

increases expression

kojic acid results in increased expression of CPNE5 mRNA

NCBI chr20:7,208,389...7,290,959
Ensembl chr20:7,206,742...7,288,883

G

cAMP responsive element binding protein 1

decreases phosphorylation

kojic acid results in decreased phosphorylation of CREB1 protein

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

chromosome segregation 1 like

decreases expression

kojic acid results in decreased expression of CSE1L mRNA

NCBI chr 3:176,060,183...176,097,909
Ensembl chr 3:155,641,166...155,678,865

G

catenin alpha-like 1

decreases expression

kojic acid results in decreased expression of CTNNAL1 mRNA

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

cathepsin Z

increases expression

kojic acid results in increased expression of CTSZ mRNA

NCBI chr 3:183,643,077...183,653,847
Ensembl chr 3:163,224,875...163,235,645

G

cytochrome b5 reductase 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYB5R3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYB5R3 mRNA

NCBI chr 7:116,186,729...116,204,290
Ensembl chr 7:114,306,685...114,324,298

G

cytochrome P450, family 26, subfamily b, polypeptide 1

increases expression

kojic acid results in increased expression of CYP26B1 mRNA

NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:117,041,808...117,058,628

G

cytochrome P450, family 2, subfamily b, polypeptide 15

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2B15 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2B15 mRNA

NCBI chr 1:91,221,865...91,234,169
Ensembl chr 1:82,094,180...82,106,492

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C mRNA

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily c, polypeptide 13

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C13 mRNA

NCBI chr 1:248,706,787...248,787,239
Ensembl chr 1:238,786,765...238,867,191

G

cytochrome P450, family 2, subfamily c, polypeptide 7

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C7 mRNA

NCBI chr 1:247,966,295...248,022,393
Ensembl chr 1:237,332,659...237,388,709

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2D22 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2D22 mRNA

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2E1 mRNA

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily f, polypeptide 4

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2F2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2F2 mRNA

NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:82,416,130...82,429,896

G

cytochrome P450, family 4, subfamily a, polypeptide 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4A22 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP4A22 mRNA

NCBI chr 5:134,360,096...134,374,233
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CYP4B1 mRNA
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4B1 mRNA

PMID:17917374 PMID:18544905

NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:129,139,038...129,156,348

G

cytochrome P450, family 4, subfamily f, polypeptide 4

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4F2 mRNA

NCBI chr 7:12,367,711...12,384,010
Ensembl chr 7:11,717,208...11,733,506

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP7A1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP7A1 mRNA

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:121,557,062...121,580,166

G

cytohesin 3

increases expression

kojic acid results in increased expression of CYTH3 mRNA

NCBI chr12:10,840,137...10,933,792
Ensembl chr12:10,840,157...10,933,812

G

cytohesin 1 interacting protein

increases expression

kojic acid results in increased expression of CYTIP mRNA

NCBI chr 3:63,106,895...63,183,769
Ensembl chr 3:42,698,768...42,725,993

G

diacylglycerol lipase, alpha

increases expression

kojic acid results in increased expression of DAGLA mRNA

NCBI chr 1:216,315,515...216,372,219
Ensembl chr 1:206,890,638...206,947,232

G

DAZ associated protein 2

increases expression

kojic acid results in increased expression of DAZAP2 mRNA

NCBI chr 7:133,593,503...133,599,044
Ensembl chr 7:131,714,745...131,720,265

G

DDB1 and CUL4 associated factor 13

decreases expression

kojic acid results in decreased expression of DCAF13 mRNA

NCBI chr 7:72,045,828...72,081,039
Ensembl chr 7:70,160,941...70,196,142

G

dopachrome tautomerase

decreases expression

kojic acid results in decreased expression of DCT protein

NCBI chr15:101,469,159...101,508,029
Ensembl chr15:95,062,003...95,100,836

G

DNA-damage inducible transcript 3

multiple interactions

[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DDIT3 mRNA

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

DEK proto-oncogene

decreases expression

kojic acid results in decreased expression of DEK mRNA

NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,580,843...17,602,808

G

DLG associated protein 4

increases expression

kojic acid results in increased expression of DLGAP4 mRNA

NCBI chr 3:165,584,271...165,731,868
Ensembl chr 3:145,175,479...145,270,490

G

distal-less homeobox 1

decreases expression

kojic acid results in decreased expression of DLX1 mRNA

NCBI chr 3:56,356,190...56,360,780
Ensembl chr 3:56,356,190...56,360,780

G

Dmx-like 1

decreases expression

kojic acid results in decreased expression of DMXL1 mRNA

NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DNAJA1 mRNA

NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:55,842,426...55,853,967

G

DnaJ heat shock protein family (Hsp40) member A2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DNAJA2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of DNAJA2 mRNA

NCBI chr19:37,671,019...37,689,163
Ensembl chr19:21,497,729...21,516,901

G

deoxynucleotidyltransferase, terminal, interacting protein 2

decreases expression

kojic acid results in decreased expression of DNTTIP2 mRNA

NCBI chr 2:210,374,321...210,386,366
Ensembl chr 2:210,374,289...210,385,581

G

dedicator of cytokinesis 4

increases expression

kojic acid results in increased expression of DOCK4 mRNA

NCBI chr 6:63,240,050...63,629,772
Ensembl chr 6:57,512,908...57,901,855

G

docking protein 4

decreases expression

kojic acid results in decreased expression of DOK4 mRNA

NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203

G

dihydropyrimidine dehydrogenase

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of DPYD mRNA

NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:206,609,122...207,474,982

G

dentin sialophosphoprotein

decreases expression

kojic acid results in decreased expression of DSPP mRNA

NCBI chr14:5,870,232...5,876,339
Ensembl chr14:5,565,629...5,571,672

G

destrin, actin depolymerizing factor

increases expression

kojic acid results in increased expression of DSTN mRNA

NCBI chr 3:151,737,711...151,764,752
Ensembl chr 3:131,284,648...131,311,379

G

dynein light chain Tctex-type 3

decreases expression

kojic acid results in decreased expression of DYNLT3 mRNA

NCBI chr X:16,000,425...16,009,632
Ensembl chr X:13,327,892...13,337,139

G

E2F transcription factor 3

increases expression

kojic acid results in increased expression of E2F3 mRNA

NCBI chr17:34,810,355...34,887,725
Ensembl chr17:34,601,830...34,676,253

G

E2F transcription factor 8

increases expression

kojic acid results in increased expression of E2F8 mRNA

NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:98,565,717...98,584,098

G

ephrin A3

decreases expression

kojic acid results in decreased expression of EFNA3 mRNA

NCBI chr 2:177,026,928...177,035,838
Ensembl chr 2:174,729,764...174,738,736

G

early growth response 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of EGR1 mRNA

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 4E

decreases expression

kojic acid results in decreased expression of EIF4E mRNA

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:227,066,673...227,098,683

G

eukaryotic translation initiation factor 5A2

increases expression

kojic acid results in increased expression of EIF5A2 mRNA

NCBI chr 2:111,728,587...111,746,087
Ensembl chr 2:111,729,323...111,746,087

G

elastase, neutrophil expressed

decreases expression

kojic acid results in decreased expression of ELANE mRNA

NCBI chr 7:10,467,877...10,469,725
Ensembl chr 7:9,817,252...9,819,100

G

E1A binding protein p300

increases expression

kojic acid results in increased expression of EP300 mRNA

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

EPH receptor A10

decreases expression

kojic acid results in decreased expression of EPHA10 mRNA

NCBI chr 5:137,139,588...137,175,637
Ensembl chr 5:137,140,735...137,174,157

G

Eph receptor A4

increases expression

kojic acid results in increased expression of EPHA4 mRNA

NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:78,815,460...78,958,139

G

epoxide hydrolase 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of EPHX1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of EPHX1 mRNA

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:92,714,315...92,790,235

G

epoxide hydrolase 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of EPHX2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of EPHX2 mRNA

NCBI chr15:44,465,447...44,503,157
Ensembl chr15:40,289,902...40,327,615

G

ERCC excision repair 2, TFIIH core complex helicase subunit

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC2 mRNA

NCBI chr 1:88,161,342...88,175,102
Ensembl chr 1:79,033,326...79,047,102

G

ERCC excision repair 3, TFIIH core complex helicase subunit

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of ERCC3 mRNA

NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329

G

ERCC excision repair 4, endonuclease catalytic subunit

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC4 mRNA

NCBI chr10:2,926,085...2,958,176
Ensembl chr10:2,419,038...2,448,369
Ensembl chr10:2,419,038...2,448,369

G

ERCC excision repair 5, endonuclease

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC5 mRNA

NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472

G

endothelial cell adhesion molecule

increases expression

kojic acid results in increased expression of ESAM mRNA

NCBI chr 8:45,426,985...45,437,976
Ensembl chr 8:37,238,287...37,249,215

G

epithelial splicing regulatory protein 1

increases expression

kojic acid results in increased expression of ESRP1 mRNA

NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062

G

exonuclease 3'-5' domain containing 1

decreases expression

kojic acid results in decreased expression of EXD1 mRNA

NCBI chr 3:106,507,839...106,535,922
Ensembl chr 3:106,508,076...106,535,922

G

exocyst complex component 2

increases expression

kojic acid results in increased expression of EXOC2 mRNA

NCBI chr17:33,714,949...33,906,901
Ensembl chr17:33,506,338...33,693,289

G

coagulation factor X

increases expression

kojic acid results in increased expression of F10 mRNA

NCBI chr16:83,170,973...83,190,280
Ensembl chr16:76,468,838...76,488,141

G

family with sequence similarity 241 member A

increases expression

kojic acid results in increased expression of FAM241A mRNA

NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242

G

fibrillin 2

increases expression

kojic acid results in increased expression of FBN2 mRNA

NCBI chr18:53,696,197...53,901,992
Ensembl chr18:51,499,737...51,703,976

G

F-box protein 16

increases expression

kojic acid results in increased expression of FBXO16 mRNA

NCBI chr15:39,492,268...39,541,493
Ensembl chr15:39,492,377...39,541,480

G

FERRY endosomal RAB5 effector complex subunit 3

decreases expression

kojic acid results in decreased expression of FERRY3 mRNA

NCBI chr 4:161,458,942...161,494,213
Ensembl chr 4:159,772,786...159,806,382

G

fibroblast growth factor 12

increases expression

kojic acid results in increased expression of FGF12 mRNA

NCBI chr11:85,501,947...86,069,543
Ensembl chr11:71,997,099...72,562,607

G

fibroblast growth factor 5

decreases expression

kojic acid results in decreased expression of FGF5 mRNA

NCBI chr14:11,627,906...11,650,243
Ensembl chr14:11,325,334...11,345,997

G

fibroblast growth factor receptor 3

decreases expression

kojic acid results in decreased expression of FGFR3 mRNA

NCBI chr14:81,211,800...81,227,215
Ensembl chr14:76,987,993...77,003,341

G

fibrinogen C domain containing 1

decreases expression

kojic acid results in decreased expression of FIBCD1 mRNA

NCBI chr 3:15,092,682...15,126,371
Ensembl chr 3:15,092,681...15,126,399

G

FKBP prolyl isomerase 10

increases expression

kojic acid results in increased expression of FKBP10 mRNA

NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of FMO1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of FMO1 mRNA

NCBI chr13:77,715,405...77,747,666
Ensembl chr13:75,182,176...75,214,647

G

fucose-1-phosphate guanylyltransferase

decreases expression

kojic acid results in decreased expression of FPGT mRNA

NCBI chr 2:246,757,982...246,778,896
Ensembl chr 2:244,099,076...244,119,899

G

FERM and PDZ domain containing 4

decreases expression

kojic acid results in decreased expression of FRMPD4 mRNA

NCBI chr X:25,853,849...26,814,642
Ensembl chr X:25,853,934...26,814,637

G

40S small subunit processome assembly factor 1

decreases expression

kojic acid results in decreased expression of FSAF1 mRNA

NCBI chr19:52,807,932...52,822,259
Ensembl chr19:52,807,934...52,822,267

G

ferritin heavy chain 1

increases expression

kojic acid results in increased expression of FTH1 mRNA; kojic acid results in increased expression of FTH1 protein

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:206,627,103...206,725,424

G

frizzled class receptor 8

increases expression

kojic acid results in increased expression of FZD8 mRNA

NCBI chr17:62,007,849...62,015,485
Ensembl chr17:57,314,450...57,320,650

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GADD45B mRNA

NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:8,778,007...8,780,046

G

polypeptide N-acetylgalactosaminyltransferase 1

decreases expression

kojic acid results in decreased expression of GALNT1 mRNA

NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,489,020...15,568,245

G

Gfo/Idh/MocA-like oxidoreductase domain containing 1

decreases expression

kojic acid results in decreased expression of GFOD1 mRNA

NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938

G

GLE1 RNA export mediator

decreases expression

kojic acid results in decreased expression of GLE1 mRNA

NCBI chr 3:33,607,160...33,638,879
Ensembl chr 3:13,209,322...13,237,379

G

guanosine monophosphate reductase

decreases expression

kojic acid results in decreased expression of GMPR mRNA

NCBI chr17:19,357,992...19,395,807
Ensembl chr17:19,151,815...19,189,621

G

G protein subunit beta 1

increases expression

kojic acid results in increased expression of GNB1 mRNA

NCBI chr 5:171,357,778...171,424,489
Ensembl chr 5:166,075,629...166,142,124

G

G protein-coupled receptor 146

decreases expression

kojic acid results in decreased expression of GPR146 mRNA

NCBI chr12:20,365,790...20,381,122
Ensembl chr12:15,251,813...15,267,206

G

G protein-coupled receptor 26

decreases expression

kojic acid results in decreased expression of GPR26 mRNA

NCBI chr 1:196,196,138...196,235,574
Ensembl chr 1:186,767,062...186,784,568

G

G protein-coupled receptor 32

increases expression

kojic acid results in increased expression of GPR32 mRNA

NCBI chr 1:94,756,863...94,757,895

G

G protein-coupled receptor 61

decreases expression

kojic acid results in decreased expression of GPR61 mRNA

NCBI chr 2:198,471,430...198,477,827
Ensembl chr 2:195,782,752...195,789,621

G

glutathione peroxidase 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GPX1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GPX1 mRNA

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024

G

gasdermin A

decreases expression

kojic acid results in decreased expression of GSDMA mRNA

NCBI chr10:83,614,336...83,639,543
Ensembl chr10:83,627,051...83,639,543

G

glutathione-disulfide reductase

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTA2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA2 mRNA

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTA3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA3 mRNA

NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:23,658,574...23,684,240

G

glutathione S-transferase alpha 4

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA4 mRNA

NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase mu 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM1 mRNA

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM2 mRNA

NCBI chr 2:198,312,179...198,316,962
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase, mu 5

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM3 mRNA
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM3 mRNA

PMID:17917374 PMID:18544905

NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:195,531,495...195,534,553

G

guanylate cyclase 1 soluble subunit alpha 2

decreases expression

kojic acid results in decreased expression of GUCY1A2 mRNA

NCBI chr 8:8,785,212...9,174,322
Ensembl chr 8:500,212...889,203

G

H1.1 linker histone, cluster member

increases expression

kojic acid results in increased expression of H1-1 mRNA

NCBI chr17:41,762,278...41,794,876
Ensembl chr17:41,366,268...41,367,011

G

heart and neural crest derivatives expressed 1

increases expression

kojic acid results in increased expression of HAND1 mRNA

NCBI chr10:42,507,117...42,509,684
Ensembl chr10:42,006,651...42,009,213

G

harbinger transposase derived 1

decreases expression

kojic acid results in decreased expression of HARBI1 mRNA

NCBI chr 3:77,681,431...77,689,749
Ensembl chr 3:77,681,431...77,689,724

G

3-hydroxyisobutyryl-CoA hydrolase

decreases expression

kojic acid results in decreased expression of HIBCH mRNA

NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:48,590,099...48,669,824

G

histidine triad nucleotide binding protein 3

increases expression

kojic acid results in increased expression of HINT3 mRNA

NCBI chr 1:27,035,936...27,045,799
Ensembl chr 1:27,035,905...27,047,721

G

huntingtin interacting protein 1

increases expression

kojic acid results in increased expression of HIP1 mRNA

NCBI chr12:26,769,868...26,904,367
Ensembl chr12:21,133,406...21,267,725

G

histone cluster 1 H2A family like 1

increases expression

kojic acid results in increased expression of H2AC6 mRNA

NCBI chr17:47,403,701...47,404,167

G

HLF transcription factor, PAR bZIP family member

decreases expression

kojic acid results in decreased expression of HLF mRNA

NCBI chr10:75,651,320...75,708,979
Ensembl chr10:75,154,507...75,211,935

G

hyaluronan-mediated motility receptor

decreases expression

kojic acid results in decreased expression of HMMR mRNA

NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,132,977...25,163,060

G

heme oxygenase 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HMOX2 mRNA

NCBI chr10:11,303,512...11,337,640
Ensembl chr10:10,797,055...10,831,148

G

heterogeneous nuclear ribonucleoprotein H2

increases expression

kojic acid results in increased expression of HNRNPH2 mRNA

NCBI chr X:102,074,175...102,080,115
Ensembl chr X:97,780,785...97,787,041

G

HPS3, biogenesis of lysosomal organelles complex 2 subunit 1

decreases expression

kojic acid results in decreased expression of HPS3 mRNA

NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047

G

heat shock protein 90 alpha family class A member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSP90AA1 mRNA

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein 90 alpha family class B member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSP90AB1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of HSP90AB1 mRNA

NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPA1A mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of HSPA1A mRNA

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 5

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPA5 mRNA

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family B (small) member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPB1 mRNA

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family D (Hsp60) member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPD1 mRNA

NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662

G

heat shock protein family E (Hsp10) member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPE1 mRNA
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of HSPE1 mRNA

PMID:17917374 PMID:18544905

NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:56,589,789...56,593,089

G

hypoxia up-regulated 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HYOU1 mRNA

NCBI chr 8:53,602,882...53,614,998
Ensembl chr 8:44,706,263...44,718,186

G

insulin-like growth factor 2 receptor

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of IGF2R mRNA

NCBI chr 1:50,526,878...50,615,265
Ensembl chr 1:47,979,109...48,067,501

G

interleukin 1 alpha

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor-like 1

increases expression

kojic acid results in increased expression of IL1RL1 mRNA

NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:42,697,192...42,727,256

G

interleukin 22 receptor subunit alpha 1

increases expression

kojic acid results in increased expression of IL22RA1 mRNA

NCBI chr 5:153,245,067...153,269,865
Ensembl chr 5:147,961,349...147,986,296

G

interleukin 6

decreases expression

kojic acid results in decreased expression of IL6 protein

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 cytokine family signal transducer

decreases expression

kojic acid results in decreased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:44,066,130...44,109,936

G

inner centromere protein

increases expression

kojic acid results in increased expression of INCENP mRNA

NCBI chr 1:215,945,558...216,017,247
Ensembl chr 1:206,523,380...206,553,265

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

kojic acid results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

lysyl-tRNA synthetase 1

decreases expression

kojic acid results in decreased expression of KARS1 mRNA

NCBI chr19:56,867,096...56,886,151
Ensembl chr19:39,957,846...39,977,632

G

potassium voltage-gated channel subfamily A regulatory beta subunit 3

decreases expression

kojic acid results in decreased expression of KCNAB3 mRNA

NCBI chr10:54,047,830...54,056,401
Ensembl chr10:54,047,825...54,054,174

G

potassium channel tetramerization domain containing 17

decreases expression

kojic acid results in decreased expression of KCTD17 mRNA

NCBI chr 7:111,859,556...111,891,869
Ensembl chr 7:109,979,060...110,008,927

G

lysine demethylase 4D

increases expression

kojic acid results in increased expression of KDM4D mRNA

NCBI chr 8:19,561,253...19,586,412
Ensembl chr 8:11,268,859...11,305,290

G

KLF transcription factor 5

increases expression

kojic acid results in increased expression of KLF5 mRNA

NCBI chr15:82,472,081...82,487,267
Ensembl chr15:76,064,258...76,079,445

G

kelch-like family member 13

increases expression

kojic acid results in increased expression of KLHL13 mRNA

NCBI chr X:113,942,309...114,107,299
Ensembl chr X:113,942,309...114,107,321

G

kallikrein B1

decreases expression

kojic acid results in decreased expression of KLKB1 mRNA

NCBI chr16:53,690,180...53,714,570
Ensembl chr16:46,958,707...46,982,053

G

keratin 7

increases expression

kojic acid results in increased expression of KRT7 mRNA

NCBI chr 7:134,407,626...134,423,787
Ensembl chr 7:132,528,895...132,545,052

G

kinectin 1

decreases expression

kojic acid results in decreased expression of KTN1 mRNA

NCBI chr15:23,392,570...23,485,061
Ensembl chr15:20,914,642...21,002,578

G

La ribonucleoprotein 7, transcriptional regulator

decreases expression

kojic acid results in decreased expression of LARP7 mRNA

NCBI chr 2:218,672,145...218,687,332
Ensembl chr 2:215,997,649...216,012,865

G

leukocyte immunoglobulin like receptor B3

decreases expression

kojic acid results in decreased expression of LILRB5 mRNA

NCBI chr 1:69,928,948...69,939,461
Ensembl chr 1:69,928,945...69,939,048

G

LDL receptor related protein 6

decreases expression

kojic acid results in decreased expression of LRP6 mRNA

NCBI chr 4:168,997,937...169,131,716
Ensembl chr 4:167,270,353...167,400,497

G

leucine rich repeat containing 4

decreases expression

kojic acid results in decreased expression of LRRC4 mRNA

NCBI chr 4:58,398,942...58,402,538
Ensembl chr 4:57,433,428...57,437,911

G

leucine rich repeat containing 9

increases expression

kojic acid results in increased expression of LRRC9 mRNA

NCBI chr 6:91,017,739...91,095,847
Ensembl chr 6:91,017,736...91,100,237

G

macrophage erythroblast attacher, E3 ubiquitin ligase

increases expression

kojic acid results in increased expression of MAEA mRNA

NCBI chr14:77,357,261...77,390,683
Ensembl chr14:77,357,264...77,390,671

G

MAF bZIP transcription factor K

decreases expression

kojic acid results in decreased expression of MAFK mRNA

NCBI chr12:19,948,473...19,970,351
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048

G

MAGE family member C2

increases expression

kojic acid results in increased expression of MAGEC2 mRNA

NCBI chr X:145,646,856...145,651,730
Ensembl chr X:140,606,825...140,615,471

G

monoamine oxidase A

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MAOA mRNA

NCBI chr X:8,615,239...8,681,372
Ensembl chr X:6,030,795...6,099,593

G

monoamine oxidase B

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MAOB mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of MAOB mRNA

NCBI chr X:8,490,405...8,594,065
Ensembl chr X:5,907,266...6,011,003

G

MAP7 domain containing 2

decreases expression

kojic acid results in decreased expression of MAP7D2 mRNA

NCBI chr X:35,372,453...35,488,073
Ensembl chr X:35,372,700...35,488,091

G

mitogen activated protein kinase 1

decreases phosphorylation

kojic acid results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation

kojic acid results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

decreases expression

kojic acid results in decreased expression of MAPK8 mRNA

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981

G

muscleblind-like splicing regulator 1

decreases expression

kojic acid results in decreased expression of MBNL1 mRNA

NCBI chr 2:146,789,570...146,964,136
Ensembl chr 2:144,670,285...144,814,368

G

melanocortin 1 receptor

decreases expression
increases expression

kojic acid results in decreased expression of MC1R protein
kojic acid results in increased expression of MC1R protein

PMID:23738040 PMID:27586645

NCBI chr19:68,360,950...68,363,877
Ensembl chr19:51,453,239...51,454,192

G

MyoD family inhibitor

decreases expression

kojic acid results in decreased expression of MDFI mRNA

NCBI chr 9:13,156,806...13,175,218
Ensembl chr 9:13,156,866...13,175,217

G

MDM2 proto-oncogene

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MDM2 mRNA

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:53,290,664...53,314,915

G

malic enzyme 3

decreases expression

kojic acid results in decreased expression of ME3 mRNA

NCBI chr 1:152,946,595...153,148,026
Ensembl chr 1:143,534,139...143,733,132

G

mediator complex subunit 14

increases expression

kojic acid results in increased expression of MED14 mRNA

NCBI chr X:12,709,406...12,800,642
Ensembl chr X:10,036,805...10,126,240

G

mex-3 RNA binding family member B

increases expression

kojic acid results in increased expression of MEX3B mRNA

NCBI chr 1:136,855,130...136,859,365
Ensembl chr 1:136,855,130...136,859,354

G

microfibril associated protein 4

decreases expression

kojic acid results in decreased expression of MFAP4 mRNA

NCBI chr10:46,666,552...46,669,613
Ensembl chr10:46,167,217...46,170,155

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

[kojic acid co-treated with Diethylnitrosamine] results in increased expression of MGMT mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of MGMT mRNA]

NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:191,710,930...191,937,756

G

microsomal glutathione S-transferase 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MGST1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of MGST1 mRNA

NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:171,029,630...171,044,892

G

midnolin

decreases expression

kojic acid results in decreased expression of MIDN mRNA

NCBI chr 7:10,198,761...10,210,563
Ensembl chr 7:9,549,650...9,559,752

G

macrophage migration inhibitory factor

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MIF mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of MIF mRNA

NCBI chr20:12,767,138...12,791,222
Ensembl chr20:12,790,902...12,799,504
Ensembl chr 4:12,790,902...12,799,504

G

meiotic nuclear divisions 1

increases expression

kojic acid results in increased expression of GAJ mRNA

NCBI chr 2:171,731,523...171,794,124
Ensembl chr 2:169,433,540...169,496,096

G

mitochondrial ribosomal protein L30

decreases expression

kojic acid results in decreased expression of MRPL30 mRNA

NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257

G

mitochondrially encoded cytochrome c oxidase I

increases expression

kojic acid results in increased expression of COX1 mRNA; kojic acid results in increased expression of COX1 protein

NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

Mtr4 exosome RNA helicase

decreases expression

kojic acid results in decreased expression of MTREX mRNA

NCBI chr 2:46,233,528...46,293,827
Ensembl chr 2:44,461,444...44,560,627

G

major vault protein

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MVP mRNA

NCBI chr 1:191,025,259...191,052,866
Ensembl chr 1:181,594,734...181,622,380

G

N(alpha)-acetyltransferase 25, NatB auxiliary subunit

increases expression

kojic acid results in increased expression of NAA25 mRNA

NCBI chr12:35,098,256...35,150,498
Ensembl chr12:35,098,075...35,150,467

G

neurocalcin delta

decreases expression

kojic acid results in decreased expression of NCALD mRNA

NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496

G

NADH:ubiquinone oxidoreductase subunit A1

increases expression

kojic acid results in increased expression of NDUFA1 mRNA

NCBI chr X:121,289,904...121,293,555
Ensembl chr X:116,424,223...116,428,633

G

nectin cell adhesion molecule 4

increases expression

kojic acid results in increased expression of NECTIN4 mRNA

NCBI chr13:86,335,027...86,354,152
Ensembl chr13:83,803,184...83,821,709

G

nuclear factor, interleukin 3 regulated

increases expression

kojic acid results in increased expression of NFIL3 mRNA

NCBI chr17:12,432,376...12,447,605
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor alpha

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of NFKBIA mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of NFKBIA mRNA

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor epsilon

increases expression

kojic acid results in increased expression of NFKBIE mRNA

NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437

G

NK6 homeobox 1

decreases expression

kojic acid results in decreased expression of NKX6-1 mRNA

NCBI chr14:8,274,238...8,281,171
Ensembl chr14:7,969,756...7,976,681

G

neuroligin 2

decreases expression

kojic acid results in decreased expression of NLGN2 mRNA

NCBI chr10:55,042,175...55,056,578
Ensembl chr10:54,544,588...54,558,434

G

NOC3-like DNA replication regulator

decreases expression

kojic acid results in decreased expression of NOC3L mRNA

NCBI chr 1:236,556,037...236,585,372
Ensembl chr 1:236,556,789...236,585,318

G

nucleolar protein 11

decreases expression

kojic acid results in decreased expression of NOL11 mRNA

NCBI chr10:92,119,000...92,141,688
Ensembl chr10:92,121,833...92,141,677

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of NR1I2 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of NR1I3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of NR1I3 mRNA

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906

G

outer dynein arm docking complex subunit 2

increases expression

kojic acid results in increased expression of ODAD2 mRNA

NCBI chr17:55,216,877...55,409,872
Ensembl chr17:55,218,991...55,409,399

G

olfactomedin-like 1

decreases expression

kojic acid results in decreased expression of OLFML1 mRNA

NCBI chr 1:161,478,129...161,502,541
Ensembl chr 1:161,478,242...161,502,537

G

olfactory receptor family 51 subfamily B member 4

decreases expression

kojic acid results in decreased expression of OR51B4 mRNA

NCBI chr 1:167,729,117...167,730,040
Ensembl chr 1:158,317,228...158,318,151

G

oxysterol binding protein 2

decreases expression

kojic acid results in decreased expression of OSBP2 mRNA

NCBI chr14:82,808,693...82,970,386
Ensembl chr14:78,585,089...78,746,786

G

osteoclastogenesis associated transmembrane protein 1

decreases expression

kojic acid results in decreased expression of OSTM1 mRNA

NCBI chr20:47,653,696...47,769,248
Ensembl chr20:46,153,075...46,187,023

G

orthodenticle homeobox 1

increases expression

kojic acid results in increased expression of OTX1 mRNA

NCBI chr14:100,283,406...100,290,421
Ensembl chr14:96,082,151...96,089,086

G

PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1

increases expression

kojic acid results in increased expression of PABIR1 mRNA

NCBI chr 1:222,114,988...222,116,294
Ensembl chr 1:222,112,591...222,116,396

G

Paxip1-associated glutamate-rich protein 1

increases expression

kojic acid results in increased expression of PAGR1 mRNA

NCBI chr 1:191,053,228...191,055,554

G

phenylalanine hydroxylase

decreases expression

kojic acid results in decreased expression of PAH mRNA

NCBI chr 7:23,793,096...23,885,631
Ensembl chr 7:21,933,179...21,998,130

G

poly (ADP-ribose) glycohydrolase

increases expression

kojic acid results in increased expression of PARG mRNA

NCBI chr16:7,442,696...7,550,585
Ensembl chr16:7,436,476...7,544,273

G

PDZ binding kinase

decreases expression

kojic acid results in decreased expression of PBK mRNA

NCBI chr15:44,198,506...44,209,572
Ensembl chr15:40,023,002...40,034,014

G

proliferating cell nuclear antigen

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of PCNA protein
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of PCNA protein

PMID:17917374 PMID:18544905

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995

G

pecanex 3

decreases expression

kojic acid results in decreased expression of PCNX3 mRNA

NCBI chr 1:212,380,657...212,402,967
Ensembl chr 1:202,951,322...202,976,561

G

proprotein convertase subtilisin/kexin type 4

decreases expression

kojic acid results in decreased expression of PCSK4 mRNA

NCBI chr 7:9,381,366...9,389,589
Ensembl chr 7:9,381,361...9,389,585

G

phosducin like

increases expression

kojic acid results in increased expression of PDCL mRNA

NCBI chr 3:41,519,953...41,529,545
Ensembl chr 3:21,110,167...21,119,715
Ensembl chr 3:21,110,167...21,119,715

G

pyruvate dehydrogenase E1 subunit alpha 1

increases expression

kojic acid results in increased expression of PDHA1 mRNA

NCBI chr X:38,509,158...38,522,986
Ensembl chr X:34,700,409...34,714,311

G

protein disulfide isomerase family A, member 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of PDIA3 mRNA

NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:108,388,245...108,413,236

G

PDZ and LIM domain 2

increases expression

kojic acid results in increased expression of PDLIM2 mRNA

NCBI chr15:45,235,421...45,250,187
Ensembl chr15:45,237,477...45,249,242

G

PPARGC1 and ESRR induced regulator, muscle 1

decreases expression

kojic acid results in decreased expression of PERM1 mRNA

NCBI chr 5:166,800,030...166,805,323
Ensembl chr 5:166,800,030...166,805,323

G

peroxisomal biogenesis factor 5-like

decreases expression

kojic acid results in decreased expression of PEX5L mRNA

NCBI chr 2:117,623,199...117,836,772
Ensembl chr 2:115,700,972...115,913,628

G

phosphoglucomutase 2

increases expression

kojic acid results in increased expression of PGM2 mRNA

NCBI chr14:44,519,906...44,553,420
Ensembl chr14:44,164,425...44,199,967

G

phosphatidylinositol glycan anchor biosynthesis, class Q

decreases expression

kojic acid results in decreased expression of PIGQ mRNA

NCBI chr10:14,942,571...14,958,584
Ensembl chr10:14,942,577...14,958,584

G

phosphatidylinositol transfer protein, beta

increases expression

kojic acid results in increased expression of PITPNB mRNA

NCBI chr12:50,909,140...50,958,193
Ensembl chr12:45,249,333...45,298,314

G

PLAG1 like zinc finger 1

increases expression

kojic acid results in increased expression of PLAGL1 mRNA

NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228

G

protein O-glucosyltransferase 2

increases expression

kojic acid results in increased expression of POGLUT2 mRNA

NCBI chr 9:46,256,388...46,268,714
Ensembl chr 9:46,256,390...46,268,532

G

paraoxonase 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of PON3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of PON3 mRNA

NCBI chr 4:34,323,546...34,350,244
Ensembl chr 4:33,349,168...33,383,855

G

cytochrome p450 oxidoreductase

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of POR mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of POR mRNA

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:20,951,058...20,999,245

G

POU class 2 homeobox 3

decreases expression

kojic acid results in decreased expression of POU2F3 mRNA

NCBI chr 8:43,495,408...43,577,795
Ensembl chr 8:43,495,527...43,577,795

G

protein phosphatase 4, regulatory subunit 1

increases expression

kojic acid results in increased expression of PPP4R1 mRNA

NCBI chr 9:105,391,271...105,450,626
Ensembl chr 9:105,391,412...105,450,633

G

peroxiredoxin 1

multiple interactions

[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of PRDX1 mRNA

NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:130,147,204...130,162,856

G

peroxiredoxin 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of PRDX2 mRNA

NCBI chr19:40,085,788...40,091,083
Ensembl chr19:23,180,930...23,186,194

G

proteoglycan 2, pro eosinophil major basic protein

decreases expression

kojic acid results in decreased expression of PRG2 mRNA

NCBI chr 3:90,469,192...90,472,759
Ensembl chr 3:70,062,535...70,066,101

G

prickle planar cell polarity protein 3

decreases expression

kojic acid results in decreased expression of PRICKLE3 mRNA

NCBI chr X:14,837,647...14,849,305
Ensembl chr X:14,837,650...14,848,218

G

DNA primase subunit 1

decreases expression

kojic acid results in decreased expression of PRIM1 mRNA

NCBI chr 7:1,031,436...1,047,134
Ensembl chr 7:431,805...462,526

G

protein arginine methyltransferase 2

decreases expression

kojic acid results in decreased expression of PRMT2 mRNA

NCBI chr20:12,391,388...12,420,096
Ensembl chr20:12,394,798...12,420,643

G

pre-mRNA processing factor 40 homolog A

decreases expression

kojic acid results in decreased expression of PRPF40A mRNA

NCBI chr 3:58,036,779...58,098,996
Ensembl chr 3:37,627,690...37,690,886

G

phosphoribosyl pyrophosphate synthetase 2

increases expression

kojic acid results in increased expression of PRPS2 mRNA

NCBI chr X:30,592,845...30,630,127
Ensembl chr X:26,976,061...27,013,181

G

proline rich 18

decreases expression

kojic acid results in decreased expression of PRR18 mRNA

NCBI chr 1:52,400,215...52,403,998
Ensembl chr 1:52,400,215...52,404,309

G

proline-rich coiled-coil 2C

increases expression

kojic acid results in increased expression of PRRC2C mRNA

NCBI chr13:77,537,226...77,606,926
Ensembl chr13:75,004,010...75,073,643

G

paired related homeobox 1

decreases expression

kojic acid results in decreased expression of PRRX1 mRNA

NCBI chr13:78,136,783...78,205,379
Ensembl chr13:75,601,706...75,670,866

G

proteasome 26S subunit, ATPase 6

decreases expression

kojic acid results in decreased expression of PSMC6 mRNA

NCBI chr15:21,022,314...21,043,785
Ensembl chr15:18,542,563...18,564,055

G

proteasome 26S subunit, non-ATPase 3

decreases expression

kojic acid results in decreased expression of PSMD3 mRNA

NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618

G

pseudouridine synthase 7 like

decreases expression

kojic acid results in decreased expression of PUS7L mRNA

NCBI chr 7:125,659,507...125,706,582
Ensembl chr 7:125,659,507...125,682,333

G

RAB3 GTPase activating protein catalytic subunit 1

increases expression

kojic acid results in increased expression of RAB3GAP1 mRNA

NCBI chr13:41,908,179...41,981,611
Ensembl chr13:39,352,247...39,429,169

G

RAB6B, member RAS oncogene family

decreases expression

kojic acid results in decreased expression of RAB6B mRNA

NCBI chr 8:112,574,223...112,642,911
Ensembl chr 8:103,695,631...103,805,732

G

RAD1 checkpoint DNA exonuclease

increases expression

kojic acid results in increased expression of RAD1 mRNA

NCBI chr 2:61,188,755...61,196,868
Ensembl chr 2:59,461,607...59,469,689

G

RAD23 homolog A, nucleotide excision repair protein

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of RAD23A mRNA

NCBI chr19:40,219,235...40,225,543
Ensembl chr19:23,314,797...23,320,695

G

RAD50 double strand break repair protein

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of RAD50 mRNA

NCBI chr10:38,310,147...38,362,100
Ensembl chr10:37,808,726...37,861,396

G

retinoic acid receptor, alpha

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of RARA mRNA

NCBI chr10:84,379,780...84,424,371
Ensembl chr10:83,893,384...83,928,142

G

retinoic acid receptor, beta

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of RARB mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of RARB mRNA

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:8,406,492...9,051,288

G

ras related dexamethasone induced 1

increases expression

kojic acid results in increased expression of RASD1 mRNA

NCBI chr10:45,265,975...45,275,279
Ensembl chr10:44,766,455...44,768,186

G

RasGEF domain family, member 1B

decreases expression

kojic acid results in decreased expression of RASGEF1B mRNA

NCBI chr14:10,164,366...10,684,184
Ensembl chr14:9,860,247...10,379,741

G

Ras association domain family member 3

increases expression

kojic acid results in increased expression of RASSF3 mRNA

NCBI chr 7:56,935,888...57,000,554
Ensembl chr 7:56,935,973...57,000,553

G

RB1-inducible coiled-coil 1

decreases expression

kojic acid results in decreased expression of RB1CC1 mRNA

NCBI chr 5:17,948,522...18,012,434
Ensembl chr 5:13,161,648...13,225,560

G

RNA binding motif protein 38

decreases expression

kojic acid results in decreased expression of RBM38 mRNA

NCBI chr 3:161,801,577...161,814,381
Ensembl chr 3:161,801,577...161,814,381

G

RecQ like helicase

decreases expression

kojic acid results in decreased expression of RECQL mRNA

NCBI chr 4:175,308,337...175,332,965
Ensembl chr 4:175,304,117...175,332,945

G

regulating synaptic membrane exocytosis 2

decreases expression

kojic acid results in decreased expression of RIMS2 mRNA

NCBI chr 7:72,133,004...72,644,059
Ensembl chr 7:70,243,872...70,757,491

G

round spermatid basic protein 1

decreases expression

kojic acid results in decreased expression of RSBN1 mRNA

NCBI chr 2:191,416,631...191,470,711
Ensembl chr 2:191,416,631...191,470,711

G

serum amyloid A4

decreases expression

kojic acid results in decreased expression of SAA4 mRNA

NCBI chr 1:106,383,856...106,388,158

G

scavenger receptor class B, member 1

increases expression

kojic acid results in increased expression of SCARB1 mRNA

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647

G

sodium voltage-gated channel alpha subunit 10

decreases expression

kojic acid results in decreased expression of SCN10A mRNA

NCBI chr 8:128,228,424...128,340,749
Ensembl chr 8:119,350,724...119,462,614

G

sterol carrier protein 2

decreases expression

kojic acid results in decreased expression of SCP2 mRNA

NCBI chr 5:128,035,714...128,110,015
Ensembl chr 5:122,776,549...122,881,287

G

syndecan 4

decreases expression

kojic acid results in decreased expression of SDC4 mRNA

NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:153,154,896...153,173,580

G

SEC24 homolog B, COPII coat complex component

increases expression

kojic acid results in increased expression of SEC24B mRNA

NCBI chr 2:221,236,897...221,306,986
Ensembl chr 2:218,562,676...218,632,699

G

SEC62 homolog, preprotein translocation factor

decreases expression

kojic acid results in decreased expression of SEC62 mRNA

NCBI chr 2:114,499,317...114,526,705
Ensembl chr 2:112,570,819...112,601,814

G

secreted and transmembrane 1B

decreases expression

kojic acid results in decreased expression of SECTM1 mRNA

NCBI chr10:106,822,397...106,832,105
Ensembl chr10:106,325,203...106,333,769

G

septin 7

decreases expression

kojic acid results in decreased expression of SEPTIN7 mRNA

NCBI chr 8:23,719,448...23,783,247
Ensembl chr 8:23,716,030...23,783,243

G

serpin family A member 5

decreases expression

kojic acid results in decreased expression of SERPINA5 mRNA

NCBI chr 6:128,774,006...128,793,187
Ensembl chr 6:123,023,306...123,028,407

G

SHC binding and spindle associated 1

increases expression

kojic acid results in increased expression of SHCBP1 mRNA

NCBI chr16:91,373,843...91,405,409
Ensembl chr16:84,672,321...84,703,844

G

SIN3 transcription regulator family member B

decreases expression

kojic acid results in decreased expression of SIN3B mRNA

NCBI chr16:17,157,352...17,194,051
Ensembl chr16:17,123,434...17,159,978

G

solute carrier family 17, member 2

decreases expression

kojic acid results in decreased expression of SLC17A2 mRNA

NCBI chr17:41,318,312...41,339,012
Ensembl chr17:41,319,701...41,336,325

G

solute carrier family 25 member 2

decreases expression

kojic acid results in decreased expression of SLC25A2 mRNA

NCBI chr18:29,704,182...29,707,563
Ensembl chr18:29,453,582...29,460,383

G

solute carrier family 38, member 4

decreases expression

kojic acid results in decreased expression of SLC38A4 mRNA

NCBI chr 7:130,022,039...130,082,169
Ensembl chr 7:128,144,807...128,202,995

G

structural maintenance of chromosomes 6

decreases expression

kojic acid results in decreased expression of SMC6 mRNA

NCBI chr 6:39,697,810...39,752,275
Ensembl chr 6:33,978,716...34,031,746

G

small integral membrane protein 8

decreases expression

kojic acid results in decreased expression of SMIM8 mRNA

NCBI chr 5:49,336,617...49,345,625
Ensembl chr 5:49,336,617...49,345,441

G

sorting nexin 10

decreases expression

kojic acid results in decreased expression of SNX10 mRNA

NCBI chr 4:81,943,262...82,007,667
Ensembl chr 4:80,612,669...80,676,996

G

sterol O-acyltransferase 2

increases expression

kojic acid results in increased expression of SOAT2 mRNA

NCBI chr 7:135,160,424...135,173,521
Ensembl chr 7:133,281,818...133,294,915

G

superoxide dismutase 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SOD1 mRNA

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SOD2 mRNA

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

spermatogenesis associated 25

decreases expression

kojic acid results in decreased expression of SPATA25 mRNA

NCBI chr 3:153,562,479...153,566,508
Ensembl chr 3:153,562,528...153,564,480

G

secreted phosphoprotein 1

increases expression

kojic acid results in increased expression of SPP1 mRNA

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162

G

serine palmitoyltransferase, long chain base subunit 1

increases expression

kojic acid results in increased expression of SPTLC1 mRNA

NCBI chr17:12,029,189...12,068,234
Ensembl chr17:11,877,249...11,916,295

G

serine and arginine rich splicing factor 2

increases expression

kojic acid results in increased expression of SRSF2 mRNA

NCBI chr10:102,550,962...102,554,200
Ensembl chr10:102,052,314...102,055,338

G

SSX family member 1

increases expression

kojic acid results in increased expression of SSX1 mRNA

NCBI chr X:16,603,888...16,612,203
Ensembl chr X:13,931,470...13,939,720

G

ST13, Hsp70 interacting protein

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of ST13 mRNA

NCBI chr 7:114,769,758...114,805,877
Ensembl chr 7:112,844,375...112,925,945

G

ST18 C2H2C-type zinc finger transcription factor

decreases expression

kojic acid results in decreased expression of ST18 mRNA

NCBI chr 5:12,582,493...12,914,221
Ensembl chr 5:12,584,110...12,671,790

G

StAR-related lipid transfer domain containing 8

decreases expression

kojic acid results in decreased expression of STARD8 mRNA

NCBI chr X:64,079,079...64,196,052
Ensembl chr X:64,124,574...64,196,052

G

syntaxin 6

increases expression

kojic acid results in increased expression of STX6 mRNA

NCBI chr13:69,882,647...69,928,895
Ensembl chr13:67,332,314...67,378,576

G

sulfotransferase family 1A member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SULT1A1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of SULT1A1 mRNA

NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:181,272,023...181,275,562

G

sulfotransferase family 1B member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SULT1B1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of SULT1B1 mRNA

NCBI chr14:20,771,917...20,784,665
Ensembl chr14:20,492,708...20,505,483

G

sulfotransferase family 1C member 2A

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SULT1C2 mRNA

NCBI chr 9:7,075,873...7,103,316
Ensembl chr 9:6,874,249...6,904,734

G

sulfotransferase family 1C member 3

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SULT1C1 mRNA

NCBI chr 9:7,221,580...7,266,991
Ensembl chr 9:7,221,578...7,267,030

G

sulfotransferase family 1E member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SULT1E1 mRNA
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of SULT1E1 mRNA

PMID:17917374 PMID:18544905

NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 4A, member 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of SULT4A1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in decreased expression of SULT4A1 mRNA

NCBI chr 7:117,096,064...117,120,714
Ensembl chr 7:115,216,066...115,240,085

G

SUZ12 polycomb repressive complex 2 subunit

decreases expression

kojic acid results in decreased expression of SUZ12 mRNA

NCBI chr10:64,967,035...65,012,916
Ensembl chr10:64,966,967...65,012,738

G

switching B-cell complex subunit SWAP70

increases expression

kojic acid results in increased expression of SWAP70 mRNA

NCBI chr 1:164,267,588...164,328,796
Ensembl chr 1:164,267,609...164,328,794

G

SYF2 pre-mRNA-splicing factor

decreases expression

kojic acid results in decreased expression of SYF2 mRNA

NCBI chr 5:152,440,171...152,448,094
Ensembl chr 5:147,156,480...147,164,414

G

symplekin scaffold protein

decreases expression

kojic acid results in decreased expression of SYMPK mRNA

NCBI chr 1:78,672,372...78,700,684
Ensembl chr 1:78,672,378...78,700,684

G

synaptotagmin binding, cytoplasmic RNA interacting protein

increases expression

kojic acid results in increased expression of SYNCRIP mRNA

NCBI chr 8:98,282,358...98,315,412
Ensembl chr 8:89,402,866...89,435,515

G

TATA-box binding protein associated factor 15

decreases expression

kojic acid results in decreased expression of TAF15 mRNA

NCBI chr10:68,770,408...68,802,458
Ensembl chr10:68,272,969...68,304,949

G

TAL bHLH transcription factor 1, erythroid differentiation factor

decreases expression

kojic acid results in decreased expression of TAL1 mRNA

NCBI chr 5:133,823,093...133,837,737
Ensembl chr 5:128,587,701...128,600,976

G

thromboxane A synthase 1

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of TBXAS1 mRNA

NCBI chr 4:68,631,841...68,803,959
Ensembl chr 4:67,665,007...67,837,096

G

transcription factor 21

decreases expression

kojic acid results in decreased expression of TCF21 mRNA

NCBI chr 1:24,520,499...24,523,358
Ensembl chr 1:22,701,353...22,704,202

G

terminal nucleotidyltransferase 4B

decreases expression

kojic acid results in decreased expression of TENT4B mRNA

NCBI chr19:18,807,616...18,868,969
Ensembl chr19:18,807,525...18,869,537

G

transforming growth factor, beta 1

multiple interactions

[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of TGFB1 mRNA

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

thyroid hormone receptor beta

decreases expression

kojic acid results in decreased expression of THRB mRNA

NCBI chr15:10,115,954...10,465,231
Ensembl chr15:7,685,180...7,882,916

G

tyrosine kinase with immunoglobulin-like and EGF-like domains 1

decreases expression

kojic acid results in decreased expression of TIE mRNA

NCBI chr 5:132,000,013...132,019,658
Ensembl chr 5:132,000,015...132,019,592

G

TIR domain containing adaptor protein

decreases expression

kojic acid results in decreased expression of TIRAP mRNA

NCBI chr 8:41,789,557...41,805,903
Ensembl chr 8:33,531,725...33,547,432

G

transmembrane and coiled-coil domains 5A

increases expression

kojic acid results in increased expression of TMCO5 mRNA

NCBI chr 3:103,732,936...103,746,242
Ensembl chr 3:103,732,945...103,746,249

G

transmembrane protein 217

increases expression

kojic acid results in increased expression of TMEM217 mRNA

NCBI chr20:7,584,177...7,619,023
Ensembl chr20:7,592,627...7,619,111
Ensembl chr20:7,592,627...7,619,111

G

transmembrane protein 59-like

decreases expression

kojic acid results in decreased expression of TMEM59L mRNA

NCBI chr16:18,941,370...18,945,381
Ensembl chr16:18,941,567...18,945,381

G

thioredoxin-related transmembrane protein 1

decreases expression

kojic acid results in decreased expression of TMX1 mRNA

NCBI chr 6:94,696,699...94,707,751
Ensembl chr 6:88,960,695...88,971,301

G

tumor necrosis factor

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of TNF mRNA

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 8 like 1

decreases expression

kojic acid results in decreased expression of TNFAIP8L1 mRNA

NCBI chr 9:988,587...999,342
Ensembl chr 9:988,594...1,002,254

G

TNF superfamily member 10

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:112,136,550...112,155,903
Ensembl chr 2:110,207,916...110,225,135

G

torsin family 4, member A

decreases expression

kojic acid results in decreased expression of TOR4A mRNA

NCBI chr 3:8,004,292...8,007,979
Ensembl chr 3:8,002,023...8,008,042

G

tumor protein p53

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of TP53 mRNA
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of TRP53 mRNA

PMID:17917374 PMID:18544905

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 binding protein, 2

increases expression

kojic acid results in increased expression of TP53BP2 mRNA

NCBI chr13:96,620,429...96,677,090
Ensembl chr13:94,088,709...94,145,432

G

two pore segment channel 1

increases expression

kojic acid results in increased expression of TPCN1 mRNA

NCBI chr12:41,633,399...41,690,200
Ensembl chr12:35,972,846...36,029,626

G

tyrosylprotein sulfotransferase 2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of TPST2 mRNA

NCBI chr12:44,321,875...44,363,892
Ensembl chr12:44,321,875...44,362,329

G

TNFRSF1A-associated via death domain

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of TRADD mRNA; [Diethylnitrosamine co-treated with kojic acid] results in decreased expression of TRADD mRNA

NCBI chr19:50,046,057...50,048,158
Ensembl chr19:33,136,138...33,142,638

G

translocation associated membrane protein 1

decreases expression

kojic acid results in decreased expression of TRAM1 mRNA

NCBI chr 5:10,425,710...10,450,669
Ensembl chr 5:5,642,546...5,686,971

G

translocation associated membrane protein 2

decreases expression

kojic acid results in decreased expression of TRAM2 mRNA

NCBI chr 9:30,915,624...30,995,162
Ensembl chr 9:23,424,232...23,498,689

G

triggering receptor expressed on myeloid cells 1

decreases expression

kojic acid results in decreased expression of TREM1 mRNA

NCBI chr 9:20,259,227...20,276,879
Ensembl chr 9:12,763,819...12,779,203

G

tRNA methyltransferase 10C, mitochondrial RNase P subunit

decreases expression

kojic acid results in decreased expression of TRMT10C mRNA

NCBI chr11:44,584,388...44,589,466
Ensembl chr11:44,584,113...44,589,568

G

tetraspanin 8

increases expression

kojic acid results in increased expression of TSPAN8 mRNA

NCBI chr 7:53,331,019...53,365,402
Ensembl chr 7:51,445,074...51,479,356

G

tetratricopeptide repeat domain 9

increases expression

kojic acid results in increased expression of TTC9 mRNA

NCBI chr 6:107,064,527...107,099,361
Ensembl chr 6:101,333,141...101,368,110

G

Ttk protein kinase

decreases expression

kojic acid results in decreased expression of TTK mRNA

NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:84,754,315...84,792,651

G

TUB like protein 3

decreases expression

kojic acid results in decreased expression of TULP3 mRNA

NCBI chr 4:163,276,583...163,318,297
Ensembl chr 4:161,590,479...161,632,149

G

twinfilin actin-binding protein 1

decreases expression

kojic acid results in decreased expression of TWF1 mRNA

NCBI chr 7:127,595,210...127,607,821
Ensembl chr 7:125,716,015...125,727,894

G

tyrosinase

decreases activity
increases expression

kojic acid results in decreased activity of TYR protein
kojic acid results in increased expression of TYR mRNA; kojic acid results in increased expression of TYR protein

PMID:23738040 PMID:27586645

NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:141,115,036...141,210,207

G

tyrosinase-related protein 1

decreases expression

kojic acid results in decreased expression of TYRP1 protein

NCBI chr 5:100,327,111...100,345,657
Ensembl chr 5:95,280,982...95,299,516

G

ubiquitin-conjugating enzyme E2D 2B

decreases expression

kojic acid results in decreased expression of UBE2D4 mRNA

NCBI chr14:2,060,926...2,062,400
Ensembl chr14:1,916,845...1,917,416

G

ubiquitin-conjugating enzyme E2E 1

decreases expression

kojic acid results in decreased expression of UBE2E1 mRNA

NCBI chr15:9,870,528...9,924,194
Ensembl chr15:7,439,759...7,493,400

G

ubiquitin-conjugating enzyme E2M

decreases expression

kojic acid results in decreased expression of UBE2M mRNA

NCBI chr 1:82,734,761...82,738,298
Ensembl chr 1:73,662,576...73,666,026

G

ubiquitin protein ligase E3 component n-recognin 7

increases expression

kojic acid results in increased expression of UBR7 mRNA

NCBI chr 6:121,898,613...121,918,480
Ensembl chr 6:121,898,623...121,918,477

G

ubiquitin recognition factor in ER associated degradation 1

increases expression

kojic acid results in increased expression of UFD1 mRNA

NCBI chr11:95,665,971...95,689,423
Ensembl chr11:82,161,619...82,185,087

G

UDP glucuronosyltransferase 1 family, polypeptide A2

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of UGT1A2 mRNA

NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of UGT1A6 mRNA

NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:88,713,184...88,808,465

G

unc-5 netrin receptor C

decreases expression

kojic acid results in decreased expression of UNC5C mRNA

NCBI chr 2:230,180,353...230,535,219
Ensembl chr 2:230,180,951...230,535,217

G

uracil-DNA glycosylase

multiple interactions

[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of UNG mRNA

NCBI chr12:48,145,838...48,154,789
Ensembl chr12:42,485,276...42,494,206

G

ubiquitin specific peptidase 1

decreases expression

kojic acid results in decreased expression of USP1 mRNA

NCBI chr 5:118,703,056...118,714,426
Ensembl chr 5:113,587,564...113,598,932

G

ubiquitin specific peptidase 44

decreases expression

kojic acid results in decreased expression of USP44 mRNA

NCBI chr 7:30,251,142...30,301,185
Ensembl chr 7:28,364,033...28,410,053

G

UTP11, small subunit processome component

increases expression

kojic acid results in increased expression of UTP11 mRNA

NCBI chr 5:142,215,974...142,230,859
Ensembl chr 5:136,931,008...136,946,191

G

Wnt family member 10A

decreases expression

kojic acid results in decreased expression of WNT10A mRNA

NCBI chr 9:83,798,594...83,811,060
Ensembl chr 9:76,349,931...76,362,400

G

YEATS domain containing 2

increases expression

kojic acid results in increased expression of YEATS2 mRNA

NCBI chr11:94,247,538...94,333,652
Ensembl chr11:80,743,134...80,829,208

G

zinc finger CCCH-type containing 15

decreases expression

kojic acid results in decreased expression of ZC3H15 mRNA

NCBI chr 3:68,744,591...68,764,335
Ensembl chr 3:68,744,604...68,764,333

G

zinc finger DHHC-type palmitoyltransferase 20

decreases expression

kojic acid results in decreased expression of ZDHHC20 mRNA

NCBI chr15:36,095,624...36,154,546
Ensembl chr15:31,983,155...32,038,989

G

zinc finger AN1-type containing 1

decreases expression

kojic acid results in decreased expression of ZFAND1 mRNA

NCBI chr 2:93,351,918...93,364,959
Ensembl chr 2:91,444,508...91,453,246

G

zinc finger protein 146

decreases expression

kojic acid results in decreased expression of ZNF146 mRNA

NCBI chr 1:85,409,570...85,421,835
Ensembl chr 1:85,409,373...85,436,275

G

zinc finger protein 414

decreases expression

kojic acid results in decreased expression of ZNF414 mRNA

NCBI chr 7:14,420,232...14,422,939
Ensembl chr 7:14,420,165...14,438,166

G

zinc finger protein 438

increases expression

kojic acid results in increased expression of ZNF438 mRNA

NCBI chr17:52,426,221...52,547,472
Ensembl chr17:52,426,221...52,547,472

G

zinc finger protein 483

decreases expression

kojic acid results in decreased expression of ZNF483 mRNA

NCBI chr 5:73,763,201...73,780,511
Ensembl chr 5:73,763,179...73,776,223

G

zinc finger with KRAB and SCAN domains 8

decreases expression

kojic acid results in decreased expression of ZKSCAN8 mRNA

NCBI chr17:43,039,383...43,057,391
Ensembl chr17:43,039,383...43,057,391

G

zinc finger, MYND-type containing 15

decreases expression

kojic acid results in decreased expression of ZMYND15 mRNA

NCBI chr10:55,171,198...55,177,812
Ensembl chr10:55,171,198...55,177,812

G

zona pellucida glycoprotein 2

decreases expression

kojic acid results in decreased expression of ZP2 mRNA

NCBI chr 1:183,944,840...183,956,619
Ensembl chr 1:174,513,511...174,525,288

lovastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression
decreases expression
multiple interactions

Lovastatin results in increased expression of ABCA1 mRNA
lovastatin decreases expression of ABCA1 mRNA in HepG2 cells
[Dietary Fats co-treated with Lovastatin] affects the expression of ABCA1 mRNA
Lovastatin results in decreased expression of ABCA1 mRNA

CTD
RGD

PMID:19260826 PMID:29852127 PMID:27765770

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Lovastatin results in decreased activity of ABCB11 protein

PMID:23956101 PMID:24014644

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases activity
increases transport

Lovastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]
Lovastatin analog results in decreased activity of ABCB1 protein
ABCB1 protein results in increased transport of Lovastatin; ABCB1 protein results in increased transport of Lovastatin analog

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

decreases activity
multiple interactions

Lovastatin results in decreased activity of ABCC1 protein
[Lovastatin results in decreased activity of ABCC1 protein] which results in increased susceptibility to Antimony Sodium Gluconate; Doxorubicin inhibits the reaction [Lovastatin results in increased expression of ABCC1 mRNA]

PMID:18056276 PMID:22712078

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions
increases expression
decreases activity

ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]
Lovastatin results in increased expression of ABCC2 mRNA
Lovastatin analog results in decreased activity of ABCC2 protein
ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]; Lovastatin promotes the reaction [Cisplatin results in decreased expression of ABCC2 mRNA]

PMID:15616150 PMID:23562342 PMID:26739623

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily G member 5

affects expression
multiple interactions

Lovastatin affects the expression of ABCG5 mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of ABCG5 mRNA

PMID:27208389 PMID:29852127

NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

affects expression

Lovastatin affects the expression of ABCG8 mRNA

NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA carboxylase alpha

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA oxidase 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of ACOX1 mRNA

NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase short-chain family member 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of ACSS2 mRNA

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:144,004,336...144,059,675

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
Lovastatin results in decreased expression of ACTA2 protein

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

actin, beta

decreases expression
increases expression

Lovastatin results in decreased expression of ACTB mRNA
Lovastatin results in increased expression of ACTB mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:11,663,109...11,672,877

G

actin related protein 3

increases expression

Lovastatin results in increased expression of ACTR3 mRNA

NCBI chr13:39,353,413...39,396,509
Ensembl chr13:36,800,093...36,844,124

G

ADAM metallopeptidase domain 10

increases expression
multiple interactions

Lovastatin results in increased expression of ADAM10 protein
[Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein

NCBI chr 8:80,226,862...80,358,728
Ensembl chr 8:71,345,837...71,477,889

G

adiponectin, C1Q and collagen domain containing

affects expression
multiple interactions

Lovastatin affects the expression of ADIPOQ mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of ADIPOQ mRNA

PMID:27208389 PMID:29852127

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564

G

adenosylhomocysteinase

decreases expression

Lovastatin results in decreased expression of AHCY mRNA

NCBI chr 3:164,029,338...164,044,562
Ensembl chr 3:143,569,094...143,584,393

G

A-kinase anchoring protein 7

decreases response to substance

AKAP7 SNP results in decreased susceptibility to Lovastatin

NCBI chr 1:21,906,503...22,168,663
Ensembl chr 1:20,087,373...20,217,797

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of AKT1 protein]
Lovastatin results in decreased phosphorylation of AKT1 protein

PMID:16425225 PMID:17472962 PMID:19760159 PMID:20578043 PMID:35734936

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

arachidonate 15-lipoxygenase

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased activity of ALOX15 protein]

NCBI chr10:55,559,060...55,567,535
Ensembl chr10:55,060,412...55,068,874

G

ankyrin 2

decreases response to substance

ANK2 SNP results in decreased susceptibility to Lovastatin

NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:215,379,680...215,862,923

G

annexin A4

decreases expression

Lovastatin results in decreased expression of ANXA4 mRNA

NCBI chr 4:120,741,750...120,798,534
Ensembl chr 4:119,184,374...119,241,161

G

annexin A5

decreases expression

Lovastatin results in decreased expression of ANXA5 mRNA

NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:119,314,007...119,353,369

G

apolipoprotein A1

multiple interactions

[Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein

PMID:12633795 PMID:17319473

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein B

multiple interactions
decreases secretion

[Niacin co-treated with Lovastatin] results in decreased expression of APOB protein
Lovastatin results in decreased secretion of APOB protein

PMID:11728391 PMID:12633795

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein E

affects expression
multiple interactions

Lovastatin affects the expression of APOE mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of APOE mRNA

PMID:27208389 PMID:29852127

NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions
increases cleavage
increases secretion

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; TAPI-2 inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; U 0126 inhibits the reaction [Lovastatin results in increased secretion of APP protein]
[APP protein co-treated with Lovastatin] results in increased secretion of APP protein; [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein; [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein; [Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein; [Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[APP protein co-treated with Lovastatin] results in increased secretion of APP protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein]
Lovastatin results in increased cleavage of APP protein
Lovastatin results in increased secretion of APP protein; Lovastatin results in increased secretion of APP protein modified form

PMID:19741129 PMID:29341888

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561

G

Rho GDP dissociation inhibitor alpha

increases expression

Lovastatin results in increased expression of ARHGDIA mRNA

NCBI chr10:106,352,858...106,356,347
Ensembl chr10:105,854,533...105,858,023

G

acid sensing ion channel subunit 3

increases expression

Lovastatin results in increased expression of ASIC3 mRNA

NCBI chr 4:11,652,946...11,657,415
Ensembl chr 4:10,760,597...10,764,643

G

ATM serine/threonine kinase

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATM protein modified form]

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437

G

ATR serine/threonine kinase

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATR protein modified form]

NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:96,426,724...96,524,136

G

beta-secretase 1

decreases expression
multiple interactions

Lovastatin results in decreased expression of BACE1 protein
[Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein

NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:46,142,116...46,165,876

G

beta-secretase 2

multiple interactions
increases expression

[Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein
Lovastatin results in increased expression of BACE2 protein

NCBI chr11:50,176,852...50,258,948
Ensembl chr11:36,707,458...36,789,546

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions
affects localization

Lovastatin results in increased expression of BAX protein
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BAX protein]; Lovastatin promotes the reaction [Cisplatin results in increased expression of BAX mRNA]
Lovastatin affects the localization of BAX protein

PMID:10473109 PMID:15180944 PMID:26739623 PMID:35734936

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCAR1 scaffold protein, Cas family member

increases cleavage
multiple interactions

Lovastatin results in increased cleavage of BCAR1 protein
Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of BCAR1 protein]

NCBI chr19:56,588,500...56,623,190
Ensembl chr19:39,679,204...39,713,907

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Lovastatin results in decreased expression of BCL2 protein
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein]

PMID:10473109 PMID:11178870 PMID:12094262 PMID:35734936

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression
multiple interactions

Lovastatin results in decreased expression of BCL2L1 protein
Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein]

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

Bcl2-like 11

multiple interactions
increases expression

pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein]

PMID:18766339 PMID:35734936

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068

G

brain-derived neurotrophic factor

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein]

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

farnesyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]

PMID:17472962 PMID:18815881

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

BRCA2, DNA repair associated

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA]

NCBI chr12:4,895,092...4,939,340
Ensembl chr12:59,819...100,567

G

complement C1q binding protein

increases expression

Lovastatin results in increased expression of C1QBP mRNA

NCBI chr10:56,198,534...56,203,185
Ensembl chr10:55,699,954...55,704,649

G

calreticulin

increases expression

Lovastatin results in increased expression of CALR mRNA

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase II beta

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein]

NCBI chr14:85,059,166...85,148,121
Ensembl chr14:80,845,238...80,933,994

G

caspase 2

increases activity
multiple interactions

Lovastatin results in increased activity of CASP2 protein
Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein]

PMID:12933658 PMID:16234849

NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

multiple interactions
increases cleavage
increases activity
decreases expression

farnesyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]
Lovastatin analog results in increased cleavage of CASP3 protein
Lovastatin results in increased activity of CASP3 protein
Lovastatin results in decreased expression of CASP3 mRNA
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CASP3 protein]; Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]

PMID:11720884 PMID:12933658 PMID:15180944 PMID:16367743 PMID:18034278 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

increases activity

Lovastatin results in increased activity of CASP6 protein

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:218,466,076...218,478,502

G

caspase 8

increases activity

Lovastatin results in increased activity of CASP8 protein

PMID:15180944 PMID:15705602

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity
multiple interactions

Lovastatin results in increased activity of CASP9 protein
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of CASP9 protein]

PMID:12933658 PMID:15180944 PMID:15705602 PMID:35734936

Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased activity of CAT protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]; Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA]

PMID:22712078 PMID:28710503

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734

G

cyclin D1

decreases expression
increases expression

Lovastatin results in decreased expression of CCND1 protein
Lovastatin results in increased expression of CCND1 mRNA; Lovastatin results in increased expression of CCND1 protein

PMID:18034278 PMID:20578043

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

decreases expression

Lovastatin results in decreased expression of CCND3 protein

NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:13,394,169...13,489,371

G

chaperonin containing TCP1 subunit 5

increases expression

Lovastatin results in increased expression of CCT5 mRNA

NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:82,590,630...82,602,930

G

chaperonin containing TCP1 subunit 6A

increases expression

Lovastatin results in increased expression of CCT6A mRNA

NCBI chr12:32,508,842...32,519,072
Ensembl chr12:26,872,574...26,883,337

G

chaperonin containing TCP1 subunit 8

decreases expression

Lovastatin results in decreased expression of CCT8 mRNA

NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079

G

CD40 molecule

multiple interactions

Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:153,790,449...153,805,534

G

CD44 molecule

decreases expression

Lovastatin results in decreased expression of CD44 mRNA; Lovastatin results in decreased expression of CD44 protein

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620

G

cell division cycle 42

increases expression
decreases expression

Lovastatin results in increased expression of CDC42 protein
Lovastatin results in decreased expression of CDC42 mRNA

PMID:18766339 PMID:20493250

NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:149,553,724...149,593,111

G

cyclin dependent kinase 2

decreases activity

Lovastatin results in decreased activity of CDK2 protein

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

Lovastatin results in decreased expression of CDK4 mRNA; Lovastatin results in decreased expression of CDK4 protein

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 5

decreases cleavage

Lovastatin results in decreased cleavage of CDK5 protein

NCBI chr 4:11,647,098...11,651,606
Ensembl chr 4:10,754,687...10,760,112

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

Lovastatin results in increased expression of CDKN1A protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]

PMID:18034278 PMID:22712078

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

Lovastatin results in increased expression of CDKN1B mRNA; Lovastatin results in increased expression of CDKN1B protein

PMID:9848777 PMID:10502407 PMID:15118409 PMID:18034278 PMID:20578043

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 3

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of CDKN3 protein modified form]

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:20,022,664...20,033,945

G

centromere protein F

increases expression
multiple interactions

Lovastatin results in increased expression of CENPF protein
Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of CENPF protein]

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

cofilin 1

decreases phosphorylation

Lovastatin results in decreased phosphorylation of CFL1 protein

NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:202,786,627...202,817,587

G

checkpoint kinase 1

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of CHEK1 protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of CHEK1 protein]
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK1 protein modified form]

PMID:17088865 PMID:21356574 PMID:26739623

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK2 protein modified form]

NCBI chr12:51,448,838...51,481,159
Ensembl chr12:45,788,827...45,821,286

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions
increases expression

[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]
Lovastatin results in increased expression of CHRNA7 mRNA; Lovastatin results in increased expression of CHRNA7 protein
U 0126 inhibits the reaction [Lovastatin results in increased expression of CHRNA7 protein]

NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:116,714,711...116,837,240

G

chloride intracellular channel 1

decreases expression

Lovastatin results in decreased expression of CLIC1 mRNA

NCBI chr20:3,769,522...3,778,367
Ensembl chr20:3,761,461...3,773,712

G

cytochrome c oxidase subunit 5A

increases expression

Lovastatin results in increased expression of COX5A mRNA

NCBI chr 8:66,818,284...66,829,691
Ensembl chr 8:57,922,290...57,933,781

G

ceruloplasmin

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CP protein]

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:102,439,624...102,498,075

G

cAMP responsive element binding protein 1

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

CRK proto-oncogene, adaptor protein

increases expression

Lovastatin results in increased expression of CRK mRNA

NCBI chr10:61,028,736...61,054,971
Ensembl chr10:60,530,464...60,553,406

G

C-reactive protein

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CRP protein]

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178

G

catenin beta 1

decreases degradation
increases expression
multiple interactions

Lovastatin results in decreased degradation of CTNNB1 protein
Lovastatin results in increased expression of CTNNB1 mRNA
Lovastatin affects the localization of and results in increased expression of CTNNB1 protein

PMID:17234346 PMID:19741129 PMID:24742230

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CYP1A1 mRNA]; Lovastatin results in increased expression of and results in increased activity of CYP1A1 protein
Lovastatin results in increased expression of CYP1A1 mRNA

PMID:1311272 PMID:22712078

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Lovastatin results in decreased activity of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity

Lovastatin results in decreased activity of CYP2C8 protein

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
Lovastatin results in increased expression of CYP3A4 mRNA

PMID:12505310 PMID:17041008

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008

G

dynactin subunit 2

decreases expression

Lovastatin results in decreased expression of DCTN2 mRNA

NCBI chr 7:64,977,338...64,992,875
Ensembl chr 7:63,092,057...63,108,543

G

D-dopachrome tautomerase

decreases expression

Lovastatin results in decreased expression of DDT mRNA

NCBI chr20:12,883,025...12,886,121
Ensembl chr20:12,884,243...12,888,482

G

discs large MAGUK scaffold protein 3

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein]

NCBI chr X:69,899,694...69,951,928
Ensembl chr X:65,860,172...65,910,322

G

dihydrolipoamide S-succinyltransferase

decreases expression

Lovastatin results in decreased expression of DLST mRNA

NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296

G

dedicator of cytokinesis 7

increases expression

Lovastatin results in increased expression of DOCK7 mRNA

NCBI chr 5:118,714,863...118,898,362
Ensembl chr 5:113,600,198...113,782,813

G

dihydropyrimidinase-like 2

increases expression

Lovastatin results in increased expression of DPYSL2 mRNA

NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829

G

destrin, actin depolymerizing factor

decreases expression

Lovastatin results in decreased expression of DSTN mRNA

NCBI chr 3:151,737,711...151,764,752
Ensembl chr 3:131,284,648...131,311,379

G

ELL associated factor 2

decreases response to substance

EAF2 SNP results in decreased susceptibility to Lovastatin

NCBI chr11:77,465,585...77,509,993
Ensembl chr11:63,960,200...64,004,610

G

eukaryotic translation elongation factor 2

decreases expression

Lovastatin results in decreased expression of EEF2 mRNA

NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:8,533,116...8,559,183

G

epidermal growth factor

multiple interactions

Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein]

PMID:12942316 PMID:19760159

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions

Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]

PMID:12942316 PMID:19760159

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 3, subunit I

decreases expression

Lovastatin results in decreased expression of EIF3I mRNA

NCBI chr 5:147,219,457...147,226,910
Ensembl chr 5:141,935,044...141,942,676

G

ERCC excision repair 1, endonuclease non-catalytic subunit

increases expression
multiple interactions

Lovastatin results in increased expression of ERCC1 mRNA
Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA]

NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 5, endonuclease

multiple interactions
increases expression

Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC5 mRNA]
Lovastatin results in increased expression of ERCC5 mRNA

NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472

G

ERCC excision repair 6, chromatin remodeling factor

increases expression

Lovastatin results in increased expression of ERCC6 mRNA

NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,765,013...7,835,587

G

endoplasmic reticulum protein 29

decreases expression

Lovastatin results in decreased expression of ERP29 mRNA

NCBI chr12:40,750,177...40,756,607
Ensembl chr12:35,089,707...35,096,376

G

fatty acid desaturase 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of FADS2 mRNA

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of FAS protein]

PMID:17088865 PMID:35734936

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FASLG mRNA]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

increases expression

Lovastatin results in increased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

F-box protein 32

multiple interactions
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]; Lovastatin promotes the reaction [Fenofibrate results in increased expression of FBXO32 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]
Lovastatin results in increased expression of FBXO32 mRNA; Lovastatin results in increased expression of FBXO32 protein

PMID:19406843 PMID:33408297

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:89,730,232...89,765,436

G

farnesyl diphosphate farnesyl transferase 1

increases activity

Lovastatin results in increased activity of FDFT1 protein

NCBI chr15:41,588,114...41,616,168
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of FDPS mRNA
[Cholestyramine Resin co-treated with Lovastatin] results in increased expression of FDPS mRNA; Mevalonic Acid inhibits the reaction [[Cholestyramine Resin co-treated with Lovastatin] results in increased expression of FDPS mRNA]

PMID:3670308 PMID:29852127

NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:174,486,665...174,507,776

G

flotillin 1

decreases expression

Lovastatin results in decreased expression of FLOT1 protein

NCBI chr20:2,922,662...2,932,906
Ensembl chr20:2,917,137...2,927,978

G

Fos proto-oncogene, AP-1 transcription factor subunit

affects expression
multiple interactions
decreases expression

Lovastatin affects the expression of FOS protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FOS mRNA]
Lovastatin results in decreased expression of FOS

PMID:10412747 PMID:12392621 PMID:22712078

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased expression of FOSB protein]

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465

G

forkhead box O1

multiple interactions
decreases phosphorylation

Lovastatin promotes the reaction [Fenofibrate results in increased expression of FOXO1 protein]
Lovastatin results in decreased phosphorylation of FOXO1 protein

PMID:33034787 PMID:33408297

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790

G

fascin actin-bundling protein 1

decreases expression

Lovastatin results in decreased expression of FSCN1 mRNA

NCBI chr12:16,710,601...16,723,734
Ensembl chr12:11,597,048...11,610,211

G

G3BP stress granule assembly factor 1

increases expression

Lovastatin results in increased expression of G3BP1 mRNA

NCBI chr10:40,087,533...40,120,931
Ensembl chr10:39,586,864...39,620,268

G

glucose-6-phosphate dehydrogenase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of G6PD mRNA

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:152,201,098...152,220,801

G

UDP-galactose-4-epimerase

decreases expression

Lovastatin results in decreased expression of GALE mRNA

NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388

G

growth associated protein 43

increases expression

Lovastatin results in increased expression of GAP43 protein

NCBI chr11:71,882,131...71,975,799
Ensembl chr11:58,376,371...58,470,045

G

GDP dissociation inhibitor 2

increases expression

Lovastatin results in increased expression of GDI2 mRNA

NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366

G

glycerol kinase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of GK mRNA

NCBI chr X:54,106,708...54,189,940
Ensembl chr X:50,163,123...50,238,631

G

guanine monophosphate synthase

increases expression

Lovastatin results in increased expression of GMPS mRNA

NCBI chr 2:150,587,824...150,641,564
Ensembl chr 2:148,435,643...148,485,875

G

glutamic--pyruvic transaminase

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; Lovastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]

PMID:29852127 PMID:30853469

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of GPX1 mRNA]

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein]

NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:168,599,546...169,042,279

G

glycogen synthase kinase 3 beta

decreases phosphorylation
increases phosphorylation

Lovastatin results in decreased phosphorylation of GSK3B protein
Lovastatin results in increased phosphorylation of GSK3B protein

PMID:17234346 PMID:19741129

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

H2A.X variant histone

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein]
Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]
Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of H2AX protein]

PMID:21356574 PMID:22712078 PMID:26739623 PMID:28710503

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

hyaluronan synthase 1

increases expression

Lovastatin results in increased expression of HAS1 mRNA; Lovastatin results in increased expression of HAS1 protein

NCBI chr 1:58,693,411...58,705,653
Ensembl chr 1:58,693,411...58,705,397

G

hyaluronan synthase 2

increases expression

Lovastatin results in increased expression of HAS2 mRNA

NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:88,113,326...88,128,933

G

histone deacetylase 1

increases expression

Lovastatin results in increased expression of HDAC1 mRNA

NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:141,853,989...141,881,111

G

histidine triad nucleotide binding protein 1

increases expression

Lovastatin results in increased expression of HINT1 mRNA

NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
affects expression
decreases activity
increases expression

[Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of farnesyl pyrophosphate; [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of geranylgeranyl pyrophosphate; Lovastatin inhibits the reaction [HMGCR protein results in increased abundance of geranyl diphosphate]
[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCR mRNA
Lovastatin affects the expression of HMGCR mRNA
Lovastatin results in increased expression of HMGCR mRNA

PMID:8517861 PMID:8593127 PMID:17208200 PMID:19260826 PMID:19699819 More...

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCS1 mRNA

NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

increases expression
multiple interactions

Lovastatin results in increased expression of HMOX1 protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA]

PMID:20594940 PMID:21910007 PMID:28710503

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A/B

increases expression

Lovastatin results in increased expression of HNRNPAB mRNA

NCBI chr10:36,358,004...36,363,898
Ensembl chr10:35,857,041...35,863,344

G

heterogeneous nuclear ribonucleoprotein D-like

decreases expression

Lovastatin results in decreased expression of HNRNPDL mRNA

NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506

G

heterogeneous nuclear ribonucleoprotein F

increases expression

Lovastatin results in increased expression of HNRNPF mRNA

NCBI chr 4:152,755,668...152,776,867
Ensembl chr 4:151,083,062...151,109,038

G

heterogeneous nuclear ribonucleoprotein K

decreases expression
increases expression

Lovastatin results in decreased expression of HNRNPK mRNA
Lovastatin results in increased expression of HNRNPK mRNA

NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,262,998...6,274,997

G

HRas proto-oncogene, GTPase

decreases prenylation
multiple interactions

Lovastatin results in decreased prenylation of HRAS protein
Lovastatin results in decreased prenylation of and results in decreased localization of HRAS protein

PMID:16156861 PMID:19360310

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:196,296,263...196,300,615

G

heat shock protein 90 alpha family class B member 1

decreases expression

Lovastatin results in decreased expression of HSP90AB1 mRNA

NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 8

increases expression

Lovastatin results in increased expression of HSPA8 mRNA

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family D (Hsp60) member 1

increases expression

Lovastatin results in increased expression of HSPD1 mRNA

NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662

G

interferon gamma

multiple interactions

Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

decreases response to substance

IGF1 protein results in decreased susceptibility to Lovastatin

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

multiple interactions

Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:121,550,743...121,831,777

G

interleukin 18

multiple interactions

[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]

PMID:18809656 PMID:21430599

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

multiple interactions

Lovastatin inhibits the reaction [Particulate Matter results in increased expression of IL24 protein]
Lovastatin inhibits the reaction [IL24 protein results in increased phosphorylation of STAT3 protein]; Lovastatin inhibits the reaction [Particulate Matter results in increased expression of and results in increased secretion of IL24 protein]; Lovastatin inhibits the reaction [Particulate Matter results in increased expression of IL24 mRNA]

NCBI chr13:44,905,362...44,910,760
Ensembl chr13:42,353,090...42,358,487

G

interleukin 6

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein]

PMID:28710503 PMID:35734936

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

multiple interactions

Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]; Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein]

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:197,843,281...197,864,775

G

insulin induced gene 1

increases expression
multiple interactions

Lovastatin results in increased expression of INSIG1 mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG1 mRNA

PMID:19260826 PMID:29852127

NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952

G

insulin induced gene 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG2 mRNA

NCBI chr13:35,025,160...35,052,937
Ensembl chr13:32,473,742...32,494,923

G

insulin receptor

multiple interactions

Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein]

NCBI chr12:5,991,135...6,129,275
Ensembl chr12:1,197,100...1,330,883

G

importin 5

decreases expression

Lovastatin results in decreased expression of IPO5 mRNA

NCBI chr15:104,397,626...104,447,985
Ensembl chr15:98,005,299...98,041,126

G

interferon regulatory factor 4

decreases expression

Lovastatin results in decreased expression of IRF4 protein

NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,721,811...33,740,070

G

insulin receptor substrate 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of IRS1 mRNA

NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:83,548,944...83,606,122

G

insulin receptor substrate 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of IRS2 mRNA

NCBI chr16:85,190,310...85,214,543
Ensembl chr16:78,485,045...78,512,482

G

inositol-3-phosphate synthase 1

increases expression

Lovastatin results in increased expression of ISYNA1 mRNA

NCBI chr16:18,873,119...18,876,116
Ensembl chr16:18,839,145...18,841,979

G

integrin subunit beta 1

decreases expression

Lovastatin results in decreased expression of ITGB1 protein

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195

G

Jun proto-oncogene, AP-1 transcription factor subunit

affects expression
multiple interactions
decreases expression

Lovastatin affects the expression of JUN protein
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of JUN mRNA]
Lovastatin results in decreased expression of JUN

PMID:10412747 PMID:12392621 PMID:22712078

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily H member 2

affects activity

Lovastatin affects the activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 11

increases expression

Lovastatin results in increased expression of KCNJ11 mRNA

NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:96,591,049...96,594,082

G

KRAS proto-oncogene, GTPase

decreases prenylation
increases expression
affects localization
increases activity

Lovastatin results in decreased prenylation of KRAS protein
Lovastatin results in increased expression of KRAS protein
Lovastatin affects the localization of KRAS protein
Lovastatin results in increased activity of KRAS protein

PMID:12106604 PMID:12907238 PMID:16156861 PMID:17005160

NCBI chr 4:179,916,255...179,949,613

G

keratin 18

decreases expression

Lovastatin results in decreased expression of KRT18 mRNA

NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

G

LIM and SH3 protein 1

decreases expression

Lovastatin results in decreased expression of LASP1 mRNA

NCBI chr10:83,290,820...83,331,989
Ensembl chr10:82,795,137...82,943,292

G

lipocalin 2

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:15,680,687...15,684,095

G

lactate dehydrogenase A

increases expression

Lovastatin results in increased expression of LDHA protein

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:97,366,021...97,433,472

G

low density lipoprotein receptor

multiple interactions
increases activity
increases expression

OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA]
[Dietary Fats co-treated with Lovastatin] affects the expression of LDLR mRNA
[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA]
Lovastatin results in increased activity of LDLR protein

PMID:8593127 PMID:11728391 PMID:12524230 PMID:20578043 PMID:29852127

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580

G

lymphoid enhancer binding factor 1

affects localization

Lovastatin affects the localization of LEF1 protein

NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:219,666,592...219,779,794

G

lipase C, hepatic type

affects expression

Lovastatin affects the expression of LIPC mRNA

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lamin B1

decreases farnesylation
increases degradation
affects localization

Lovastatin results in decreased farnesylation of LMNB1 protein
Lovastatin results in increased degradation of LMNB1 protein
Lovastatin affects the localization of LMNB1 protein

PMID:10203554 PMID:11720884

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:50,175,874...50,214,502

G

lipin 2

decreases response to substance

LPIN2 SNP results in decreased susceptibility to Lovastatin

NCBI chr 9:118,529,988...118,604,796
Ensembl chr 9:111,083,745...111,158,193

G

lipoprotein lipase

affects expression
multiple interactions

Lovastatin affects the expression of LPL mRNA
[Dietary Fats co-treated with Lovastatin] affects the expression of LPL mRNA

PMID:27208389 PMID:29852127

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 5

increases expression

Lovastatin results in increased expression of LRP5 mRNA

NCBI chr 1:210,243,499...210,346,886
Ensembl chr 1:200,814,250...200,917,581

G

mitogen activated protein kinase 1

multiple interactions
increases expression
increases phosphorylation
decreases activity
decreases phosphorylation

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK1 protein]
Lovastatin results in increased expression of MAPK1 protein
Lovastatin results in decreased activity of MAPK1 protein
[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]

PMID:12213976 PMID:16952276 PMID:19360310 PMID:19760159 PMID:20578043 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

increases expression

Lovastatin results in increased expression of MAPK14 protein

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases expression
increases phosphorylation
decreases activity
decreases phosphorylation

[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein]
Lovastatin results in increased expression of MAPK3 protein
Lovastatin results in increased phosphorylation of MAPK3 protein
Lovastatin results in decreased activity of MAPK3 protein
Lovastatin results in decreased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK3 protein]

PMID:16952276 PMID:18434508 PMID:19360310 PMID:19760159 PMID:20578043 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK8 protein modified form]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions

Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK9 protein modified form]

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178

G

myelin basic protein

multiple interactions
increases expression

2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:75,855,878...75,966,404

G

mitofusin 2

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MFN2 mRNA]

NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:158,304,287...158,335,342

G

microRNA 133b

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA

NCBI chr 9:30,594,582...30,594,665
Ensembl chr 9:23,098,134...23,098,217

G

microRNA 206

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA

NCBI chr 9:30,590,697...30,590,780
Ensembl chr 9:23,094,249...23,094,332

G

matrix metallopeptidase 2

decreases expression

Lovastatin results in decreased expression of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MMP3 mRNA]

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

decreases expression

Lovastatin results in decreased expression of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819

G

myostatin

increases expression

Lovastatin results in increased expression of MSTN protein

NCBI chr 9:55,944,513...55,950,913
Ensembl chr 9:48,452,533...48,458,933

G

NFE2 like bZIP transcription factor 2

multiple interactions

Doxorubicin inhibits the reaction [Lovastatin results in increased expression of NFE2L2 mRNA]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA]

PMID:22712078 PMID:28710503

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737

G

NmrA like redox sensor 1

increases expression

Lovastatin results in increased expression of NMRAL1 mRNA

NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192

G

nitric oxide synthase 2

multiple interactions

Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein]

PMID:18809656 PMID:35734936

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide A

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA]

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351

G

NAD(P)H quinone dehydrogenase 1

increases expression

Lovastatin results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658

G

NRAS proto-oncogene, GTPase

decreases prenylation

Lovastatin results in decreased prenylation of NRAS protein

NCBI chr 2:193,271,399...193,282,023
Ensembl chr 2:190,582,918...190,591,626

G

nucleobindin 1

increases expression

Lovastatin results in increased expression of NUCB1 mRNA

NCBI chr 1:105,104,793...105,135,730
Ensembl chr 1:95,968,326...96,003,220

G

ornithine aminotransferase

decreases expression

Lovastatin results in decreased expression of OAT mRNA

NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:187,347,865...187,367,682

G

oncostatin M

multiple interactions

OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA]

NCBI chr14:83,327,202...83,332,073
Ensembl chr14:79,104,344...79,108,313

G

proliferation-associated 2G4

increases expression

Lovastatin results in increased expression of PA2G4 mRNA

NCBI chr 7:1,569,326...1,576,794
Ensembl chr 7:983,971...992,331

G

poly (ADP-ribose) polymerase 1

increases cleavage

Lovastatin analog results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

parvin, beta

decreases response to substance

PARVB SNP results in decreased susceptibility to Lovastatin

NCBI chr 7:117,240,238...117,325,744
Ensembl chr 7:115,360,261...115,445,766

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of PCK1 mRNA

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:161,930,256...161,936,191

G

platelet derived growth factor receptor alpha

decreases expression

Lovastatin results in decreased expression of PDGFRA mRNA

NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,005,839...33,054,335

G

protein disulfide isomerase family A, member 3

decreases expression
increases expression

Lovastatin results in decreased expression of PDIA3 mRNA
Lovastatin results in increased expression of PDIA3 mRNA

NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:108,388,245...108,413,236

G

protein disulfide isomerase family A, member 4

decreases expression

Lovastatin results in decreased expression of PDIA4 mRNA

NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:76,803,198...76,822,107

G

phosphoglycerate mutase 1

decreases expression
increases expression

Lovastatin results in decreased expression of PGAM1 mRNA
Lovastatin results in increased expression of PGAM1 mRNA

NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:240,723,920...240,738,452

G

pyruvate kinase M1/2

decreases expression

Lovastatin results in decreased expression of PKM mRNA

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:60,057,402...60,079,599

G

phospholipase A2 group 4A

increases expression

Lovastatin results in increased expression of PLA2G4A mRNA

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:61,877,813...62,022,266

G

plasminogen activator, tissue type

multiple interactions
increases secretion
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PLAT protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PLAT protein]
Lovastatin results in increased secretion of PLAT protein

PMID:10412747 PMID:12405293

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223

G

plasminogen activator, urokinase

decreases secretion

Lovastatin results in decreased secretion of PLAU protein

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775

G

paraoxonase 3

increases hydrolysis
increases metabolic processing
multiple interactions

PON3 protein results in increased hydrolysis of Lovastatin
PON3 protein results in increased metabolism of Lovastatin
7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]; Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

PMID:12615656 PMID:15772423

NCBI chr 4:34,323,546...34,350,244
Ensembl chr 4:33,349,168...33,383,855

G

peroxisome proliferator-activated receptor gamma

multiple interactions
affects localization
increases expression

2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein]
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; Lovastatin results in increased expression of and affects the localization of PPARG protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]
[Dietary Fats co-treated with Lovastatin] affects the expression of PPARG mRNA; PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein]

PMID:16425225 PMID:20578043 PMID:26863638 PMID:29852127

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of PPARGC1A mRNA]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase 1 catalytic subunit alpha

decreases expression

Lovastatin results in decreased expression of PPP1CA mRNA

NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:201,485,085...201,497,327

G

protein phosphatase 2 scaffold subunit A alpha

increases expression

Lovastatin results in increased expression of PPP2R1A mRNA

NCBI chr 1:69,213,198...69,232,441
Ensembl chr 1:60,540,194...60,560,129

G

proteoglycan 4

increases expression

Lovastatin results in increased expression of PRG4 mRNA; Lovastatin results in increased expression of PRG4 protein

NCBI chr13:65,037,363...65,054,764
Ensembl chr13:62,487,257...62,504,119

G

protein kinase C, alpha

increases expression

Lovastatin results in increased expression of PRKCA protein

NCBI chr10:93,388,991...93,787,617
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

multiple interactions
increases cleavage

benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,769,215...5,799,352

G

proteasome 20S subunit alpha 3

decreases expression

Lovastatin results in decreased expression of PSMA3 mRNA

NCBI chr 6:95,219,714...95,239,745
Ensembl chr 6:89,483,727...89,504,965

G

proteasome 20S subunit alpha 6

decreases expression

Lovastatin results in decreased expression of PSMA6 mRNA

NCBI chr 6:78,500,676...78,531,693
Ensembl chr 6:72,765,473...72,796,554

G

proteasome 26S subunit, ATPase 2

decreases expression

Lovastatin results in decreased expression of PSMC2 mRNA

NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185

G

phosphatase and tensin homolog

multiple interactions
increases expression

Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein]
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; Lovastatin results in increased expression of and results in increased phosphorylation of PTEN protein; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]
PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein]

PMID:16425225 PMID:20578043

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

decreases expression
increases expression
multiple interactions

Lovastatin results in decreased expression of PTGS2 protein
Lovastatin analog results in increased expression of PTGS2 mRNA; Lovastatin analog results in increased expression of PTGS2 protein
Mevalonic Acid affects the reaction [Lovastatin analog results in increased expression of PTGS2 protein]
Lovastatin results in increased expression of PTGS2 mRNA; Lovastatin results in increased expression of PTGS2 protein

PMID:20578043 PMID:21910007 PMID:26863638

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

RAB1A, member RAS oncogene family

decreases expression

Lovastatin results in decreased expression of RAB1A mRNA

NCBI chr14:98,623,582...98,648,766
Ensembl chr14:94,415,275...94,448,248

G

Rac family small GTPase 1

multiple interactions
affects localization
decreases activity
increases expression

geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RAC1 protein]
Lovastatin results in decreased activity of RAC1 protein
Lovastatin results in increased expression of RAC1 protein

PMID:12933658 PMID:18766339 PMID:19360310 PMID:21356574

NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions
decreases activity

Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein]
Lovastatin results in decreased activity of RAF1 protein

PMID:19360310 PMID:19760159

NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:148,679,530...148,740,317

G

RAP1A, member of RAS oncogene family

increases expression

Lovastatin results in increased expression of RAP1A protein

NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:193,208,635...193,286,501

G

RB transcriptional corepressor 1

decreases phosphorylation

Lovastatin results in decreased phosphorylation of RB1 protein

PMID:9848777 PMID:10502407 PMID:15118409

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302

G

ras homolog family member A

multiple interactions
decreases expression
decreases prenylation
affects localization

geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RHOA protein]
Lovastatin results in decreased geranoylation of and affects the localization of RHOA protein
Lovastatin results in decreased expression of RHOA mRNA
Lovastatin results in decreased prenylation of RHOA protein
Farnesol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]

PMID:9398081 PMID:11178870 PMID:12405293 PMID:12933658 PMID:16156861 More...

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746

G

ras homolog family member B

decreases prenylation
multiple interactions
increases expression

Lovastatin results in decreased prenylation of RHOB protein
Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein]
Lovastatin results in increased expression of RHOB protein

PMID:12467231 PMID:16156861 PMID:16234849

NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:31,363,548...31,366,108

G

ribosomal protein L27

increases expression

Lovastatin results in increased expression of RPL27 mRNA

NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193

G

ribosomal protein L9

increases expression

Lovastatin results in increased expression of RPL9 mRNA

NCBI chr14:43,247,536...43,250,784
Ensembl chr14:42,893,942...42,897,136
Ensembl chr 3:42,893,942...42,897,136
Ensembl chr 1:42,893,942...42,897,136

G

ribosomal protein lateral stalk subunit P0

increases expression

Lovastatin results in increased expression of RPLP0 mRNA

NCBI chr12:46,715,121...46,718,390
Ensembl chr12:41,054,179...41,057,632

G

ribosomal protein SA

increases expression

Lovastatin results in increased expression of RPSA mRNA

NCBI chr 8:128,728,761...128,732,736
Ensembl chr 8:119,851,225...119,855,247

G

RuvB-like AAA ATPase 2

decreases expression

Lovastatin results in decreased expression of RUVBL2 mRNA

NCBI chr 1:105,038,487...105,051,851
Ensembl chr 1:95,901,701...95,915,342

G

S100 calcium binding protein A8

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA

NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

multiple interactions

[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA

NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:176,190,361...176,193,230

G

SUMO1 activating enzyme subunit 1

decreases expression

Lovastatin results in decreased expression of SAE1 mRNA

NCBI chr 1:86,159,114...86,215,089
Ensembl chr 1:77,030,965...77,086,986

G

SREBF chaperone

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of SCAP mRNA

NCBI chr 8:119,184,366...119,239,086
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class B, member 1

multiple interactions
affects expression

[Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone]
Lovastatin affects the expression of SCARB1 mRNA

PMID:20404351 PMID:27208389

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647

G

stearoyl-CoA desaturase

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

selenophosphate synthetase 1

increases expression

Lovastatin results in increased expression of SEPHS1 mRNA

NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593

G

solute carrier family 31 member 1

increases expression

Lovastatin results in increased expression of SLC31A1 mRNA

NCBI chr 5:80,830,574...80,859,810
Ensembl chr 5:75,814,743...75,844,228

G

SRY-box transcription factor 10

multiple interactions
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]

NCBI chr 7:112,605,721...112,615,097
Ensembl chr 7:110,725,274...110,735,544

G

sterol regulatory element binding transcription factor 1

multiple interactions
increases expression

[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF1 mRNA
Lovastatin results in increased expression of SREBF1 mRNA

PMID:29852127 PMID:32739440

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

increases localization
multiple interactions

Lovastatin results in increased localization of SREBF2 protein
[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF2 mRNA
[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein]

PMID:11728391 PMID:20578043 PMID:29852127

NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:113,663,202...113,720,848

G

signal transducer and activator of transcription 3

multiple interactions

Lovastatin inhibits the reaction [IL24 protein results in increased phosphorylation of STAT3 protein]

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

STEAP2 metalloreductase

decreases response to substance

STEAP2 SNP results in decreased susceptibility to Lovastatin

NCBI chr 4:29,302,487...29,323,006
Ensembl chr 4:28,348,362...28,375,791

G

stress-induced phosphoprotein 1

decreases expression

Lovastatin results in decreased expression of STIP1 mRNA

NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:204,178,932...204,228,476

G

synaptic Ras GTPase activating protein 1

multiple interactions

Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein]

NCBI chr20:5,028,226...5,058,519
Ensembl chr20:5,026,364...5,056,672

G

t-complex 1

increases expression

Lovastatin results in increased expression of TCP1 mRNA

NCBI chr 1:50,376,848...50,384,527
Ensembl chr 1:47,828,652...47,836,839

G

thyroglobulin

increases secretion

Lovastatin results in increased secretion of TG protein

NCBI chr 7:100,307,349...100,492,246
Ensembl chr 7:98,418,293...98,603,210

G

transforming growth factor, beta 1

multiple interactions

Lovastatin inhibits the reaction [TGFB1 protein results in increased abundance of Reactive Oxygen Species]; Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

tyrosine hydroxylase

increases expression
multiple interactions

Lovastatin results in increased expression of TH protein
Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of TH protein]

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767

G

thimet oligopeptidase 1

increases expression

Lovastatin results in increased expression of THOP1 mRNA

NCBI chr 7:9,283,617...9,295,957
Ensembl chr 7:8,632,916...8,645,275

G

tumor necrosis factor

multiple interactions

[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein]

PMID:18809656 PMID:21430599 PMID:22712078 PMID:35734936

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

increases expression

Lovastatin results in increased expression of TNFRSF11B mRNA

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:85,566,520...85,594,538

G

TNF superfamily member 10

increases response to substance

Lovastatin results in increased susceptibility to TNFSF10 protein

NCBI chr 2:112,136,550...112,155,903
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

decreases expression

Lovastatin results in decreased expression of TNFSF11 mRNA

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:53,673,877...53,705,445

G

DNA topoisomerase II alpha

multiple interactions

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TOP2A mRNA]

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:83,945,735...83,976,874

G

tumor protein p53

multiple interactions
increases expression

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein
Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form]
Lovastatin results in increased expression of TP53 mRNA

PMID:17088865 PMID:21199873 PMID:26739623

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

tripartite motif containing 63

multiple interactions

Lovastatin promotes the reaction [Fenofibrate results in increased expression of TRIM63 protein]

NCBI chr 5:151,817,209...151,831,026
Ensembl chr 5:146,533,507...146,547,322

G

tetratricopeptide repeat domain 7A

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of FSN mRNA

NCBI chr 6:7,159,285...7,261,826
Ensembl chr 6:7,159,061...7,261,892

G

tubulin, alpha 1A

increases expression

Lovastatin results in increased expression of TUBA1A mRNA

NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, alpha 1B

increases expression
decreases expression

Lovastatin results in increased expression of TUBA1B mRNA
Lovastatin results in decreased expression of TUBA1B mRNA

NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, beta 5 class I

decreases expression

Lovastatin results in decreased expression of TUBB5 mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,912,778...2,916,940

G

Tu translation elongation factor, mitochondrial

decreases expression

Lovastatin results in decreased expression of TUFM mRNA

NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395

G

U2 small nuclear RNA auxiliary factor 2

increases expression

Lovastatin results in increased expression of U2AF2 mRNA

NCBI chr 1:77,789,752...77,807,307
Ensembl chr 1:68,760,924...68,778,492

G

uncoupling protein 2

multiple interactions

[Dietary Fats co-treated with Lovastatin] affects the expression of UCP2 mRNA

NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:154,839,209...154,845,611

G

ubiquitin specific peptidase 5

decreases expression

Lovastatin results in decreased expression of USP5 mRNA

NCBI chr 4:159,305,927...159,321,345
Ensembl chr 4:157,619,643...157,634,711

G

valosin-containing protein

decreases expression
increases expression

Lovastatin results in decreased expression of VCP mRNA
Lovastatin results in increased expression of VCP mRNA

NCBI chr 5:62,005,984...62,025,387
Ensembl chr 5:57,210,168...57,229,571

G

WEE1 G2 checkpoint kinase

multiple interactions
increases expression

Lovastatin inhibits the reaction [Doxorubicin results in increased expression of WEE1 mRNA]
Lovastatin results in increased expression of WEE1 mRNA

NCBI chr 1:173,605,609...173,632,450
Ensembl chr 1:164,174,779...164,197,688

G

X-linked inhibitor of apoptosis

increases expression

Lovastatin results in increased expression of XIAP mRNA

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:120,897,907...120,934,700

G

XPA, DNA damage recognition and repair factor

increases expression

Lovastatin results in increased expression of XPA mRNA

NCBI chr 5:65,227,281...65,275,784
Ensembl chr 5:60,431,673...60,475,726

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon

increases expression

Lovastatin results in increased expression of YWHAE mRNA

NCBI chr10:61,082,934...61,120,618
Ensembl chr10:60,584,652...60,671,589

Methysticin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

[methysticin results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; AHR protein affects the susceptibility to [methysticin results in increased activity of CYP1A1 protein]; AHR protein affects the susceptibility to [methysticin results in increased expression of CYP1A1 mRNA]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

amyloid beta precursor protein

multiple interactions

methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of IL17A protein]; methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of TNF protein]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561

G

carboxylesterase 1D

decreases activity
multiple interactions

methysticin results in decreased activity of CES1 protein
methysticin inhibits the reaction [[CES1 protein results in increased metabolism of Oseltamivir] which results in increased abundance of oseltamivir carboxylate]

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

3',4'-dimethoxyflavone inhibits the reaction [methysticin results in increased activity of CYP1A1 protein]; 3',4'-dimethoxyflavone inhibits the reaction [methysticin results in increased expression of CYP1A1 mRNA]; [methysticin results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; AHR protein affects the susceptibility to [methysticin results in increased activity of CYP1A1 protein]; AHR protein affects the susceptibility to [methysticin results in increased expression of CYP1A1 mRNA]; methysticin results in increased expression of and results in increased activity of CYP1A1 protein

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

methysticin results in decreased activity of CYP2C19 protein

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 7

decreases activity

methysticin results in decreased activity of CYP2C9 protein

NCBI chr 1:247,966,295...248,022,393
Ensembl chr 1:237,332,659...237,388,709

G

glutamate-cysteine ligase, catalytic subunit

increases expression

methysticin results in increased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544

G

heme oxygenase 1

increases expression

methysticin results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079

G

interleukin 17A

multiple interactions

methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of IL17A protein]

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889

G

NFE2 like bZIP transcription factor 2

affects localization

methysticin affects the localization of NFE2L2 protein

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737

G

presenilin 1

multiple interactions

methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of IL17A protein]; methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of TNF protein]

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650

G

tumor necrosis factor

multiple interactions

methysticin inhibits the reaction [[PSEN1 protein co-treated with APP protein] results in increased secretion of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

mevalonolactone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity

mevalonolactone results in decreased activity of HMGCR protein

PMID:3042028 PMID:12477733

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703

G

prostaglandin I2 receptor

affects binding

mevalonolactone binds to PTGIR protein

NCBI chr 1:86,707,690...86,710,073
Ensembl chr 1:77,579,596...77,581,979

G

RAP2A, member of RAS oncogene family

increases farnesylation

mevalonolactone results in increased farnesylation of RAP2A protein

NCBI chr15:104,003,744...104,004,234
Ensembl chr15:97,596,020...97,624,138

G

RAP2B, member of RAS oncogene family

increases prenylation

mevalonolactone results in increased prenylation of RAP2B protein

NCBI chr 2:147,749,387...147,749,938
Ensembl chr 2:145,599,116...145,603,069

mevastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

multiple interactions

[Cholestyramine Resin co-treated with mevastatin] results in increased expression of and results in increased activity of AACS protein; mevastatin results in increased expression of and results in increased activity of AACS protein

NCBI chr12:36,774,471...36,817,835
Ensembl chr12:31,113,098...31,160,954

G

ATP binding cassette subfamily A member 1

affects expression
decreases expression
multiple interactions

mevastatin affects the expression of ABCA1 mRNA
Mevastatin (compactin) decreases expression of abca1 mRNA in rat peripheral fibroblasts
Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]

CTD
RGD

PMID:16415093 PMID:17526932 PMID:17526932

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170

G

brain-derived neurotrophic factor

multiple interactions

mevastatin inhibits the reaction [BDNF protein results in decreased activity of HU 211]

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615

G

bone morphogenetic protein 2

increases expression

mevastatin results in increased expression of BMP2 mRNA; mevastatin results in increased expression of BMP2 protein

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397

G

CD40 molecule

multiple interactions

mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:153,790,449...153,805,534

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA]

PMID:12235278 PMID:15466163 PMID:17041008

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage inducible transcript 3

multiple interactions
decreases expression

EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation

mevastatin results in increased phosphorylation of EIF2AK3 protein

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA]

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:97,672,766...97,706,225

G

forkhead box O1

decreases phosphorylation

mevastatin results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790

G

isopentenyl-diphosphate delta isomerase 1

multiple interactions
increases expression

EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:61,629,594...61,637,357

G

interferon gamma

multiple interactions

mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interferon regulatory factor 4

decreases expression

mevastatin results in decreased expression of IRF4 protein

NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,721,811...33,740,070

G

methylsterol monooxygenase 1

increases expression
multiple interactions

mevastatin results in increased expression of MSMO1 mRNA
EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA]

NCBI chr16:29,747,113...29,764,360
Ensembl chr16:24,980,697...24,998,016

G

myostatin

increases expression

mevastatin results in increased expression of MSTN protein

NCBI chr 9:55,944,513...55,950,913
Ensembl chr 9:48,452,533...48,458,933

G

nuclear receptor subfamily 1, group H, member 3

increases expression

Mevastatin increases expression of NR1H3 mRNA in mononuclear cells

RGD

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA]

PMID:12235278 PMID:17041008

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658

G

Rac family small GTPase 1

multiple interactions

mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]

NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251

G

ras homolog family member A

decreases lipidation
multiple interactions

mevastatin results in decreased lipidation of RHOA protein
Mevalonic Acid inhibits the reaction [mevastatin results in decreased lipidation of RHOA protein]

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746

G

selectin E

multiple interactions

mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:76,403,304...76,412,741

G

sterol regulatory element binding transcription factor 1

decreases expression
increases cleavage
multiple interactions

mevastatin results in decreased expression of SREBF1 protein
mevastatin results in increased cleavage of SREBF1 protein
EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]

PMID:16330322 PMID:17526932

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

increases expression
increases cleavage

mevastatin results in increased expression of SREBF2 protein
mevastatin results in increased cleavage of SREBF2 protein

PMID:16330322 PMID:17526932

NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:113,663,202...113,720,848

G

tumor necrosis factor

multiple interactions

mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

X-box binding protein 1

multiple interactions

Tunicamycin inhibits the reaction [mevastatin results in increased cleavage of XBP1 protein]

NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693

oleuropein

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

oleuropein inhibits the reaction [Isoproterenol results in increased activity of ACE protein]

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:90,910,316...90,931,131

G

actin alpha 2, smooth muscle

multiple interactions

oleuropein inhibits the reaction [Rotenone results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

adiponectin, C1Q and collagen domain containing

multiple interactions

oleuropein inhibits the reaction [Cholesterol, Dietary results in decreased secretion of ADIPOQ protein]

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

multiple interactions

oleuropein inhibits the reaction [Rotenone results in decreased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]

PMID:34126350 PMID:36774383

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

multiple interactions

oleuropein inhibits the reaction [Acrolein results in increased expression of BAX mRNA]; oleuropein inhibits the reaction [Acrolein results in increased expression of BAX protein]
oleuropein inhibits the reaction [Rotenone results in increased expression of BAX protein]

PMID:29414845 PMID:36774383

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 mRNA]; oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 protein]; oleuropein inhibits the reaction [decamethrin results in decreased expression of BCL2 protein]
oleuropein affects the reaction [Rotenone results in decreased expression of BCL2 protein]

PMID:28595958 PMID:29414845 PMID:36774383

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

multiple interactions

oleuropein affects the reaction [Rotenone results in decreased expression of BDNF protein]

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615

G

caspase 3

multiple interactions

oleuropein inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

catalase

increases activity
multiple interactions

oleuropein results in increased activity of CAT protein
oleuropein inhibits the reaction [Rotenone results in decreased activity of CAT protein]
oleuropein inhibits the reaction [decamethrin results in decreased activity of CAT protein]

PMID:18823963 PMID:28595958 PMID:36774383

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

cAMP responsive element binding protein 1

multiple interactions

oleuropein inhibits the reaction [Rotenone results in decreased phosphorylation of CREB1 protein]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

colony stimulating factor 1 receptor

multiple interactions

oleuropein inhibits the reaction [TNF protein results in increased export of CSF1R protein]

NCBI chr18:56,834,152...56,860,804
Ensembl chr18:54,546,659...54,590,415

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

oleuropein results in decreased activity of CYP19A1 protein

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758

G

DNA-damage inducible transcript 3

multiple interactions

oleuropein inhibits the reaction [Acrolein results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

fatty acid synthase

multiple interactions

oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of FASN protein]

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

glutamic--pyruvic transaminase

multiple interactions

oleuropein inhibits the reaction [Cholesterol, Dietary results in increased activity of GPT protein]; oleuropein inhibits the reaction [decamethrin results in increased expression of GPT protein]; oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GPT protein]

PMID:26056852 PMID:27019295 PMID:28595958

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494

G

glycogen synthase kinase 3 beta

multiple interactions

oleuropein inhibits the reaction [Rotenone results in decreased expression of and results in decreased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

heat shock protein family A (Hsp70) member 5

multiple interactions

oleuropein inhibits the reaction [Acrolein results in increased expression of HSPA5 protein]

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

multiple interactions

oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 6

multiple interactions

oleuropein inhibits the reaction [TNF protein results in increased export of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

lactate dehydrogenase A

multiple interactions

oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of LDHA protein]

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:97,366,021...97,433,472

G

mitogen activated protein kinase 1

multiple interactions

oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions

oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120

G

nitric oxide synthase 2

multiple interactions

oleuropein inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

oleuropein inhibits the reaction [Rotenone results in decreased expression of and results in decreased phosphorylation of NTRK2 protein]

NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,559,043...5,869,136

G

pancreatic lipase

multiple interactions

oleuropein inhibits the reaction [Isoproterenol results in increased activity of PNLIP protein]

NCBI chr 1:267,760,073...267,797,797
Ensembl chr 1:257,798,581...257,811,654

G

peroxisome proliferator-activated receptor gamma

multiple interactions

oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of PPARG protein]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin-endoperoxide synthase 2

multiple interactions

oleuropein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]
oleuropein inhibits the reaction [decamethrin results in increased expression of PTGS2 protein]

PMID:22595400 PMID:28595958

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased localization of and results in increased activity of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

selectin E

multiple interactions

oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of SELE protein]

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:76,403,304...76,412,741

G

sterol regulatory element binding transcription factor 1

multiple interactions

oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of SREBF1 protein]

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650

G

tyrosine hydroxylase

multiple interactions

oleuropein inhibits the reaction [Rotenone results in decreased expression of TH protein]

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767

G

tumor necrosis factor

multiple interactions

oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
oleuropein inhibits the reaction [TNF protein results in increased export of CSF1R protein]; oleuropein inhibits the reaction [TNF protein results in increased export of IL6 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]

PMID:12615669 PMID:34126350

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

troponin T1, slow skeletal type

multiple interactions

oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of TNNT1 protein]

NCBI chr 1:78,349,035...78,359,394
Ensembl chr 1:69,306,362...69,316,721

G

tumor protein p53

multiple interactions

oleuropein inhibits the reaction [decamethrin results in increased expression of TP53 protein]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

vascular cell adhesion molecule 1

multiple interactions

oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA]; oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958

simvastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Simvastatin results in decreased expression of A2M mRNA

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily A member 1

decreases expression
increases expression

Simvastatin results in decreased expression of ABCA1; Simvastatin results in decreased expression of ABCA1 mRNA
Simvastatin results in increased expression of ABCA1 mRNA; Simvastatin results in increased expression of ABCA1 protein

PMID:16282522 PMID:18270459 PMID:19383813 PMID:19461118 PMID:21241519 More...

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases expression
decreases activity

Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Simvastatin results in decreased expression of ABCB11 mRNA
Simvastatin results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases transport
decreases activity
affects response to substance

ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; Simvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]
ABCB1 protein results in increased transport of Simvastatin
Simvastatin analog results in decreased activity of ABCB1 protein
ABCB1 polymorphism affects the susceptibility to Simvastatin

PMID:15616150 PMID:16321621 PMID:19802823 PMID:19891551

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression
decreases expression

Simvastatin results in increased expression of ABCB4 mRNA
Simvastatin results in decreased expression of ABCB4 mRNA

PMID:21241519 PMID:27765674

NCBI chr 4:26,106,895...26,164,440
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases expression
affects response to substance
decreases activity

ABCC2 protein binds to and results in increased uptake of Simvastatin analog; Simvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Simvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]
Simvastatin results in decreased expression of ABCC2 mRNA
ABCC2 polymorphism affects the susceptibility to Simvastatin
Simvastatin analog results in decreased activity of ABCC2 protein

PMID:15616150 PMID:22186618 PMID:23562342 PMID:27765674

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions
increases nitrosation

artemisinin inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; parthenolide inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased nitrosation of ABCC3 protein]

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 1

decreases expression

Simvastatin results in decreased expression of ABCG1 mRNA

PMID:19383813 PMID:22120639

NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 5

increases expression

Simvastatin results in increased expression of ABCG5 mRNA

NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

decreases expression

Simvastatin results in decreased expression of ABCG8 mRNA

NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA acyltransferase 2

decreases expression
multiple interactions

Simvastatin results in decreased expression of ACAA2 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of ACAA2 mRNA

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA carboxylase beta

increases expression

Simvastatin results in increased expression of ACACB mRNA

NCBI chr12:48,026,394...48,138,214
Ensembl chr12:42,366,548...42,457,655

G

aggrecan

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]

PMID:18628692 PMID:19912653

NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:132,981,582...133,043,627

G

angiotensin converting enzyme 2

decreases expression

Simvastatin results in decreased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977

G

actin alpha 2, smooth muscle

decreases expression
multiple interactions

Simvastatin results in decreased expression of ACTA2 protein
Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]

PMID:15677772 PMID:15855201

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

actin, beta

increases expression

Simvastatin results in increased expression of ACTB mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:11,663,109...11,672,877

G

actinin alpha 4

increases expression

Simvastatin results in increased expression of ACTN4 mRNA

NCBI chr 1:93,310,294...93,379,369
Ensembl chr 1:84,182,788...84,251,847

G

adiponectin, C1Q and collagen domain containing

multiple interactions

Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein]
carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]]; Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]

PMID:17641834 PMID:29071762

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564

G

adenosine A2B receptor

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B protein]

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:46,940,384...46,956,772

G

adrenoceptor beta 1

increases expression

Simvastatin results in increased expression of ADRB1 mRNA; Simvastatin results in increased expression of ADRB1 protein

NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:255,771,597...255,807,259

G

alpha-fetoprotein

increases expression

Simvastatin results in increased expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480

G

advanced glycosylation end product-specific receptor

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]
Simvastatin results in decreased expression of AGER protein

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,147,890...4,151,078

G

angiotensinogen

multiple interactions
decreases expression

[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]
Simvastatin results in decreased expression of AGT mRNA

PMID:17513949 PMID:18400235 PMID:18475152 PMID:19100119 PMID:19225232 More...

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

decreases expression

Simvastatin results in decreased expression of AGTR1 mRNA

PMID:17513949 PMID:18475152

NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,174,429...34,226,946

G

aldo-keto reductase family 1, member C1

increases expression

Simvastatin results in increased expression of AKR1C1 mRNA

NCBI chr17:70,720,397...70,747,285
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C3

decreases expression

Simvastatin results in decreased expression of AKR1C3 mRNA

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:66,110,963...66,127,873

G

aldo-keto reductase family 1, member D1

decreases expression

Simvastatin results in decreased expression of AKR1D1 mRNA

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:66,154,248...66,186,372

G

AKT serine/threonine kinase 1

decreases expression
decreases phosphorylation
increases phosphorylation
multiple interactions
decreases activity

Simvastatin results in decreased expression of AKT1 mRNA; Simvastatin results in decreased expression of AKT1 protein
Simvastatin results in decreased phosphorylation of AKT1 protein
Simvastatin results in increased phosphorylation of AKT1 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]
Simvastatin results in decreased activity of AKT1 protein
Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein; [Simvastatin co-treated with Metformin] results in decreased phosphorylation of AKT1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of AKT1 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]

PMID:12438947 PMID:17327694 PMID:17335931 PMID:18004065 PMID:18031796 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 3 family, member A1

increases expression

Simvastatin results in increased expression of ALDH3A1 mRNA

NCBI chr10:46,392,464...46,402,151
Ensembl chr10:45,892,924...45,902,681

G

ALK receptor tyrosine kinase

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA

NCBI chr 6:28,631,431...29,351,321
Ensembl chr 6:22,880,625...23,598,034

G

arachidonate 5-lipoxygenase activating protein

increases expression

Simvastatin results in increased expression of ALOX5AP mRNA

NCBI chr12:10,785,254...10,809,295
Ensembl chr12:5,748,944...5,772,986

G

alkaline phosphatase, intestinal

increases expression

Simvastatin results in increased expression of ALPI mRNA

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:87,773,411...87,776,877

G

alkaline phosphatase, biomineralization associated

increases expression
multiple interactions
affects expression

Simvastatin results in increased expression of ALPL mRNA
Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA]

PMID:20417880 PMID:28975700

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:149,951,409...150,006,446

G

angiopoietin 1

increases expression

Simvastatin results in increased expression of ANGPT1; Simvastatin results in increased expression of ANGPT1 mRNA; Simvastatin results in increased expression of ANGPT1 protein

NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

multiple interactions

Simvastatin inhibits the reaction [Streptozocin results in increased expression of ANGPT2 protein]

NCBI chr16:77,790,760...77,841,241
Ensembl chr16:71,088,364...71,138,804

G

angiopoietin-like 3

decreases expression

Simvastatin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:118,818,494...118,825,531
Ensembl chr 5:113,703,012...113,709,957

G

angiopoietin-like 4

increases expression

Simvastatin results in increased expression of ANGPTL4 mRNA

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat family A member 2

increases expression

Simvastatin results in increased expression of ANKRA2 mRNA

NCBI chr 2:31,347,158...31,358,002
Ensembl chr 2:29,612,925...29,623,730

G

alanyl aminopeptidase, membrane

increases expression

Simvastatin results in increased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

annexin A1

increases expression

Simvastatin results in increased expression of ANXA1 protein

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:217,861,175...217,877,343

G

annexin A3

decreases expression

Simvastatin results in decreased expression of ANXA3 mRNA
Simvastatin results in decreased expression of ANXA3 protein

PMID:14973129 PMID:17428261

NCBI chr14:13,031,675...13,085,678
Ensembl chr14:12,719,795...12,781,617

G

amine oxidase, copper containing 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of AOC1 mRNA]

NCBI chr 4:79,143,126...79,162,705
Ensembl chr 4:77,812,260...77,831,840

G

adipocyte plasma membrane associated protein

decreases expression

Simvastatin results in decreased expression of APMAP protein

NCBI chr 3:139,409,021...139,437,296
Ensembl chr 3:139,409,022...139,437,341

G

apolipoprotein A1

multiple interactions
decreases expression
increases expression

MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]
Simvastatin results in decreased expression of APOA1 mRNA; Simvastatin results in decreased expression of APOA1 protein
[Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Simvastatin results in increased expression of and results in increased secretion of APOA1 protein
Simvastatin results in increased expression of APOA1 mRNA; Simvastatin results in increased expression of APOA1 protein
Polystyrenes analog promotes the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Simvastatin promotes the reaction [Polystyrenes analog results in increased expression of APOA1 mRNA]

PMID:8289597 PMID:8461338 PMID:12048122 PMID:12633795 PMID:18270459 More...

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

decreases expression

Simvastatin results in decreased expression of APOA2 mRNA

NCBI chr13:86,176,767...86,178,819
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein A4

multiple interactions
decreases expression
increases expression

Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]
Simvastatin results in decreased expression of APOA4 mRNA; Simvastatin results in decreased expression of APOA4 protein
Polystyrenes analog promotes the reaction [Simvastatin results in decreased expression of APOA4 protein]; Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOA4 protein]
Simvastatin results in increased expression of APOA4 protein

PMID:8289597 PMID:8461338 PMID:18224302 PMID:25055962

NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein B

multiple interactions
decreases expression
decreases secretion
affects response to substance

[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]
Simvastatin results in decreased expression of APOB protein
Simvastatin results in decreased secretion of APOB protein
Simvastatin results in decreased expression of APOB mRNA; Simvastatin results in decreased expression of APOB protein
Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein]
APOB polymorphism affects the susceptibility to Simvastatin

PMID:1627634 PMID:8289597 PMID:8461338 PMID:9512650 PMID:10498134 More...

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C1

decreases expression

Simvastatin results in decreased expression of APOC1 mRNA

NCBI chr 1:88,475,018...88,479,052
Ensembl chr 1:79,346,136...79,350,375

G

apolipoprotein C3

decreases expression

Simvastatin results in decreased expression of APOC3 mRNA

NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:46,531,478...46,533,583

G

apolipoprotein E

decreases expression
affects response to substance
multiple interactions

Simvastatin results in decreased expression of APOE; Simvastatin results in decreased expression of APOE mRNA
Simvastatin results in decreased expression of APOE mRNA; Simvastatin results in decreased expression of APOE protein
APOE polymorphism affects the susceptibility to Simvastatin
Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein]
APOE affects the susceptibility to Simvastatin

PMID:8289597 PMID:8461338 PMID:11849659 PMID:11947894 PMID:12901521 More...

NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein F

decreases expression

Simvastatin results in decreased expression of APOF mRNA

NCBI chr 7:1,285,222...1,286,659
Ensembl chr 7:700,762...701,946

G

apolipoprotein M

decreases expression
increases expression
multiple interactions

Simvastatin results in decreased expression of APOM mRNA
Simvastatin results in increased expression of APOM mRNA; Simvastatin results in increased expression of APOM protein
T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM protein]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein]

PMID:21729290 PMID:22160096

NCBI chr20:3,695,618...3,698,218
Ensembl chr20:3,688,413...3,693,550

G

amyloid beta precursor protein

multiple interactions
decreases activity

oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]

PMID:17241114 PMID:28734741

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561

G

Rho GTPase activating protein 29

decreases expression

Simvastatin results in decreased expression of ARHGAP29 mRNA

NCBI chr 2:210,060,036...210,132,572
Ensembl chr 2:210,071,199...210,132,028

G

Rho GTPase activating protein 4

increases expression

Simvastatin results in increased expression of ARHGAP4 mRNA

NCBI chr X:156,787,566...156,802,841
Ensembl chr X:151,632,454...151,651,128

G

Rho/Rac guanine nucleotide exchange factor 2

increases expression

Simvastatin results in increased expression of ARHGEF2 mRNA

NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:174,062,976...174,118,355

G

argininosuccinate synthase 1

decreases expression

Simvastatin results in decreased expression of ASS1 mRNA

NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:14,747,368...14,796,903

G

activating transcription factor 2

increases phosphorylation

Simvastatin results in increased phosphorylation of ATF2 protein

NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 3

increases expression

Simvastatin results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 6

increases expression

Simvastatin results in increased expression of ATF6 mRNA; Simvastatin results in increased expression of ATF6 protein

NCBI chr13:85,460,312...85,639,959
Ensembl chr13:82,930,034...83,107,177

G

ATM serine/threonine kinase

multiple interactions

Simvastatin results in increased phosphorylation of and results in increased activity of ATM protein

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:53,831,093...53,932,437

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Simvastatin results in increased expression of ATP2A2 mRNA; Simvastatin results in increased expression of ATP2A2 protein

NCBI chr12:39,733,519...39,782,942
Ensembl chr12:34,072,683...34,122,101

G

ATPase H+ transporting V1 subunit E1

increases expression

Simvastatin results in increased expression of ATP6V1E1 mRNA

NCBI chr 4:154,022,358...154,044,486
Ensembl chr 4:154,022,358...154,044,584

G

aurora kinase A

decreases expression

Simvastatin results in decreased expression of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:161,128,313...161,144,390

G

axin 2

affects expression

Simvastatin affects the expression of AXIN2 mRNA

NCBI chr10:94,393,379...94,426,579
Ensembl chr10:93,899,245...93,926,231

G

Axl receptor tyrosine kinase

decreases expression

Simvastatin results in decreased expression of AXL mRNA

NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:81,265,088...81,296,265

G

BCL2-associated agonist of cell death

multiple interactions
decreases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]
IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]

PMID:12438947 PMID:27734117

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

affects localization
increases expression

Simvastatin affects the localization of BAX protein
Simvastatin results in increased expression of BAX protein
Simvastatin results in increased expression of BAX mRNA
Simvastatin results in increased expression of BAX mRNA; Simvastatin results in increased expression of BAX protein

PMID:12557325 PMID:17901590 PMID:20045437 PMID:25300705

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions
increases expression
affects localization

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]
Simvastatin results in increased expression of BBC3 mRNA; Simvastatin results in increased expression of BBC3 protein
Simvastatin affects the localization of BBC3 protein

PMID:17428261 PMID:20045437 PMID:21199873 PMID:37956312

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter]
Simvastatin results in decreased expression of BCL2 protein
Simvastatin results in increased expression of BCL2 mRNA; Simvastatin results in increased expression of BCL2 protein
Simvastatin results in decreased expression of BCL2 mRNA; Simvastatin results in decreased expression of BCL2 protein

PMID:17241114 PMID:17277159 PMID:17901590 PMID:18031796 PMID:18521906 More...

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]
Simvastatin results in decreased expression of BCL2L1 protein

PMID:17277159 PMID:18521906 PMID:20060890

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

brain-derived neurotrophic factor

increases expression
multiple interactions

Simvastatin results in increased expression of BDNF
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA]

PMID:18047562 PMID:20851742

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615

G

bone gamma-carboxyglutamate protein

increases expression
multiple interactions
increases secretion

Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA
Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA; Simvastatin results in increased expression of BGLAP protein
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]
[Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP
Simvastatin results in increased secretion of BGLAP protein

PMID:12914771 PMID:14601315 PMID:14973129 PMID:15953866 PMID:17252541 More...

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:173,838,518...173,839,495

G

basic helix-loop-helix family, member a15

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of BHLHA15 mRNA

NCBI chr12:15,534,123...15,538,299
Ensembl chr12:10,420,467...10,424,713

G

baculoviral IAP repeat-containing 2

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]
Simvastatin results in decreased expression of BIRC2 protein

PMID:17277159 PMID:18521906 PMID:19343037

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

multiple interactions

Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]

PMID:17277159 PMID:19343037

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

multiple interactions
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein]
Simvastatin results in decreased expression of BIRC5 mRNA; Simvastatin results in decreased expression of BIRC5 protein

PMID:17277159 PMID:20464445

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 1

increases expression

Simvastatin results in increased expression of BMP1 mRNA

NCBI chr15:51,961,310...52,005,597
Ensembl chr15:45,551,603...45,595,776

G

bone morphogenetic protein 2

increases secretion
increases expression
multiple interactions

Simvastatin results in increased secretion of BMP2 protein
Simvastatin results in increased expression of BMP2 mRNA; Simvastatin results in increased expression of BMP2 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BMP2 mRNA]
Simvastatin results in increased expression of BMP2; Simvastatin results in increased expression of BMP2 mRNA
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]

PMID:10814523 PMID:11162604 PMID:12914771 PMID:16470222 PMID:17252541 More...

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein receptor type 2

affects expression
increases stability
increases expression

Simvastatin affects the expression of BMPR2 mRNA
Simvastatin results in increased stability of BMPR2 mRNA
Simvastatin results in increased expression of BMPR2 protein

NCBI chr 9:68,685,942...68,801,353
Ensembl chr 9:61,190,566...61,301,809

G

BCL2 interacting protein 3

increases expression

Simvastatin results in increased expression of BNIP3 mRNA

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:193,708,167...193,725,359

G

complement C5a receptor 1

decreases expression

Simvastatin results in decreased expression of C5AR1 mRNA

NCBI chr 1:86,077,309...86,088,001

G

calcium voltage-gated channel subunit alpha1 C

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein]
Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein

NCBI chr 4:153,431,169...154,051,932
Ensembl chr 4:151,764,138...152,379,648

G

calcium voltage-gated channel subunit alpha1 H

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H protein]
Simvastatin results in decreased expression of CACNA1H mRNA; Simvastatin results in decreased expression of CACNA1H protein

NCBI chr10:14,894,630...14,952,317
Ensembl chr10:14,390,113...14,448,376

G

calbindin 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in decreased expression of CALB1 mRNA]

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:29,375,642...29,402,431

G

calbindin 2

decreases expression

Simvastatin results in decreased expression of CALB2 protein

NCBI chr19:55,023,849...55,050,858
Ensembl chr19:38,114,424...38,141,438

G

caldesmon 1

decreases expression

Simvastatin results in decreased expression of CALD1 mRNA; Simvastatin results in decreased expression of CALD1 protein

NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:63,265,942...63,446,932

G

calmodulin-like 3

increases expression

Simvastatin results in increased expression of CALML3 mRNA

NCBI chr17:71,329,438...71,333,068
Ensembl chr17:66,419,882...66,423,175

G

calpain 1

increases expression

Simvastatin results in increased expression of CAPN1 mRNA

PMID:18664198 PMID:19253821

NCBI chr 1:212,705,219...212,736,134
Ensembl chr 1:203,277,344...203,300,177

G

capping actin protein of muscle Z-line subunit alpha 1

decreases expression

Simvastatin results in decreased expression of CAPZA1 protein

NCBI chr 2:195,008,035...195,053,100
Ensembl chr 2:192,319,702...192,364,480

G

capping actin protein of muscle Z-line subunit alpha 2

decreases expression

Simvastatin results in decreased expression of CAPZA2 protein

NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864

G

caspase 1

decreases activity
multiple interactions

Simvastatin results in decreased activity of CASP1 protein
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of CASP1 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]

PMID:16054375 PMID:30408459 PMID:35762198

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383

G

caspase 12

multiple interactions

Simvastatin results in increased cleavage of and results in increased activity of CASP12 protein

NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

multiple interactions
increases cleavage
increases activity
decreases activity
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of CASP3 protein modified form]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein
Simvastatin results in increased cleavage of CASP3 protein
Simvastatin results in decreased activity of CASP3 protein
Simvastatin results in increased expression of CASP3 mRNA; Simvastatin results in increased expression of CASP3 protein
carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; PD 150606 inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of CASP3 mRNA]; Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]; Simvastatin results in decreased expression of and results in decreased activity of CASP3 protein; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]
[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]

PMID:11868908 PMID:12557325 PMID:12962723 PMID:14527821 PMID:15200425 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

multiple interactions

Simvastatin results in increased cleavage of and results in increased activity of CASP6 protein

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:218,466,076...218,478,502

G

caspase 7

multiple interactions
increases activity

Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP7 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP7 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP7 protein

PMID:19253821 PMID:20045437 PMID:20427495

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity
multiple interactions
increases cleavage

Simvastatin results in increased activity of CASP8 protein
Simvastatin results in increased cleavage of and results in increased activity of CASP8 protein
Simvastatin results in increased cleavage of CASP8 protein
Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP8 protein]

PMID:12962723 PMID:15705602 PMID:20464445 PMID:20883752 PMID:21910007

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity
decreases activity
increases cleavage

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP9 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP9 protein

PMID:12438947 PMID:12962723 PMID:15705602 PMID:16470222 PMID:19253821 More...

Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases expression
multiple interactions
increases activity

Simvastatin results in decreased expression of CAT mRNA
carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]]; Simvastatin inhibits the reaction [Diazepam results in decreased activity of CAT protein]; Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]
Simvastatin results in increased activity of CAT protein

PMID:17479860 PMID:20883752 PMID:27111380 PMID:29071762

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA]
Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV1 protein]
Simvastatin results in decreased expression of CAV1 protein
Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]

PMID:16698853 PMID:18224302 PMID:19816600

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:45,634,918...45,673,705

G

caveolin 2

multiple interactions

Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV2 protein]

NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:45,616,712...45,624,244

G

cystathionine beta synthase

multiple interactions

Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein]

NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,708,090...9,732,764

G

C-C motif chemokine ligand 2

multiple interactions
decreases expression
affects expression
decreases response to substance

[Simvastatin co-treated with Ramipril] results in decreased expression of CCL2 protein; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CCL2 protein
Simvastatin affects the expression of CCL2 mRNA
Simvastatin results in decreased expression of CCL2 mRNA; Simvastatin results in decreased expression of CCL2 protein
Simvastatin results in decreased susceptibility to CCL2 protein

PMID:12117737 PMID:12818400 PMID:15184351 PMID:15781755 PMID:15824212 More...

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

decreases expression

Simvastatin results in decreased expression of CCL20 mRNA

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]
Simvastatin results in decreased expression of CCL3 mRNA

PMID:16321392 PMID:16414398

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression
decreases expression

Simvastatin results in increased expression of CCL5 mRNA
Simvastatin results in decreased expression of CCL5 protein
Simvastatin results in decreased expression of CCL5 mRNA

PMID:17112859 PMID:17183729 PMID:17449418

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]
Simvastatin results in decreased expression of CCN1 mRNA

PMID:17428261 PMID:20191585

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

multiple interactions
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein]
Simvastatin results in decreased expression of CCN2 mRNA; Simvastatin results in decreased expression of CCN2 protein
Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]
Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein]

PMID:15200425 PMID:15298857 PMID:15677772 PMID:19080365 PMID:19099753 More...

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

decreases expression
multiple interactions

Simvastatin results in decreased expression of CCNA2 mRNA
Simvastatin results in decreased expression of CCNA2 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]

PMID:17428261 PMID:26577051

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

multiple interactions
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]
Simvastatin results in decreased expression of CCND1 mRNA; Simvastatin results in decreased expression of CCND1 protein

PMID:17277159 PMID:17428261 PMID:20878096

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:90,781,949...90,791,101

G

C-C motif chemokine receptor 1

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]
Simvastatin results in decreased expression of CCR1 mRNA

PMID:16321392 PMID:16414398

NCBI chr 8:132,433,711...132,439,266

G

C-C motif chemokine receptor 2

multiple interactions
decreases expression

[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]
Simvastatin results in decreased expression of CCR2 mRNA; Simvastatin results in decreased expression of CCR2 protein

PMID:15781755 PMID:16321392 PMID:16414398 PMID:16781696 PMID:17449418

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 4

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]

NCBI chr 8:123,054,505...123,060,244
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 5

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]
Simvastatin results in decreased expression of CCR5 protein
Simvastatin results in decreased expression of CCR5 mRNA

PMID:16321392 PMID:17112859 PMID:17449418

NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:123,752,325...123,759,260

G

CD14 molecule

decreases expression

Simvastatin results in decreased expression of CD14 mRNA

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,335,340...28,337,261

G

CD151 molecule (Raph blood group)

decreases expression

Simvastatin results in decreased expression of CD151 mRNA

NCBI chr 1:205,994,300...205,998,307
Ensembl chr 1:196,565,181...196,568,753

G

CD24 molecule

increases expression

Simvastatin results in increased expression of CD24 mRNA

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:47,073,512...47,079,662

G

CD27 molecule

decreases expression

Simvastatin results in decreased expression of CD27 mRNA

NCBI chr 4:159,716,932...159,721,823
Ensembl chr 4:158,030,703...158,035,592

G

CD2-associated protein

increases expression

Simvastatin results in increased expression of CD2AP mRNA

NCBI chr 9:25,580,071...25,679,968
Ensembl chr 9:18,086,984...18,182,199

G

CD40 molecule

decreases expression
multiple interactions

Simvastatin results in decreased expression of CD40 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]

PMID:16387846 PMID:17169357 PMID:17507688

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:153,790,449...153,805,534

G

CD40 ligand

decreases expression
multiple interactions
increases expression

Simvastatin results in decreased expression of CD40LG protein; Simvastatin results in decreased expression of CD40LG protein modified form
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]
Simvastatin results in increased expression of CD40LG protein

PMID:17169357 PMID:18269829 PMID:21330348

NCBI chr X:140,164,341...140,176,057
Ensembl chr X:135,126,969...135,138,306

G

CD44 molecule

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CD44 protein]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]
Simvastatin results in decreased expression of CD44 mRNA; Simvastatin results in decreased expression of CD44 protein

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620

G

Cd80 molecule

decreases expression

Simvastatin results in decreased expression of CD80 mRNA

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:62,254,624...62,292,030

G

CD83 molecule

decreases expression

Simvastatin results in decreased expression of CD83 protein

NCBI chr17:21,093,281...21,113,223
Ensembl chr17:20,887,309...20,907,083

G

CD86 molecule

decreases expression

Simvastatin results in decreased expression of CD86 protein

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:64,163,828...64,200,818

G

cell division cycle 25B

affects expression

Simvastatin affects the expression of CDC25B mRNA; Simvastatin affects the expression of CDC25B protein

NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:118,407,128...118,417,272

G

cell division cycle 42

decreases activity

Simvastatin results in decreased activity of CDC42 protein

NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:149,553,724...149,593,111

G

cell division cycle 45

decreases expression

Simvastatin results in decreased expression of CDC45 mRNA

NCBI chr11:95,689,702...95,714,980
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 6

decreases expression

Simvastatin results in decreased expression of CDC6 mRNA

NCBI chr10:84,360,361...84,374,239
Ensembl chr10:83,864,638...83,878,011

G

cadherin 5

increases expression

Simvastatin results in increased expression of CDH5 mRNA; Simvastatin results in increased expression of CDH5 protein

NCBI chr19:821,875...860,931
Ensembl chr19:815,411...854,368

G

cyclin-dependent kinase 1

decreases expression
multiple interactions

Simvastatin results in decreased expression of CDK1 mRNA; Simvastatin results in decreased expression of CDK1 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]

PMID:17428261 PMID:20878096 PMID:26577051

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

multiple interactions
decreases expression
decreases activity

[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; [Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein
Simvastatin results in decreased expression of CDK2 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]
Simvastatin results in decreased activity of CDK2 protein

PMID:10412745 PMID:17928568 PMID:18804536 PMID:20878096 PMID:26577051

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression
decreases activity

Simvastatin results in decreased expression of CDK4 protein
Simvastatin results in decreased activity of CDK4 protein

PMID:18804536 PMID:20878096

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 5

increases expression

Simvastatin results in increased expression of CDK5

NCBI chr 4:11,647,098...11,651,606
Ensembl chr 4:10,754,687...10,760,112

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of CDKN1A protein]; Simvastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein]
Simvastatin results in increased expression of CDKN1A mRNA; Simvastatin results in increased expression of CDKN1A protein

PMID:15625077 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18625202 More...

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

[Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein
Simvastatin results in increased expression of CDKN1B mRNA; Simvastatin results in increased expression of CDKN1B protein

PMID:12963647 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18804536 More...

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 1C

increases expression

Simvastatin results in increased expression of CDKN1C mRNA

NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:198,655,407...198,658,048

G

cyclin-dependent kinase inhibitor 2A

increases expression

Simvastatin results in increased expression of CDKN2A protein

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149

G

cyclin dependent kinase inhibitor 2D

increases expression

Simvastatin results in increased expression of CDKN2D mRNA; Simvastatin results in increased expression of CDKN2D protein

NCBI chr 8:28,108,036...28,110,809
Ensembl chr 8:19,831,866...19,834,674

G

chromatin licensing and DNA replication factor 1

decreases expression

Simvastatin results in decreased expression of CDT1 mRNA

NCBI chr19:67,529,249...67,534,195
Ensembl chr19:50,620,713...50,625,659

G

CCAAT/enhancer binding protein zeta

multiple interactions

Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]

NCBI chr 6:21,872,071...21,889,755
Ensembl chr 6:16,119,872...16,137,600

G

carboxylesterase 1D

multiple interactions

Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 protein]
Simvastatin inhibits the reaction [CES1 protein results in increased hydrolysis of remdesivir]

PMID:33383043 PMID:34774545

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression
decreases expression

Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]
Simvastatin results in increased expression of CFLAR mRNA; Simvastatin results in increased expression of CFLAR protein
Simvastatin results in decreased expression of CFLAR protein; Simvastatin results in decreased expression of CFLAR protein alternative form

PMID:17277159 PMID:18521906 PMID:19262002 PMID:21910007

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:60,185,452...60,237,034

G

CF transmembrane conductance regulator

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR protein]

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756

G

choline O-acetyltransferase

multiple interactions

Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]

NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,657,362...7,717,093

G

cholinergic receptor, muscarinic 5

multiple interactions

Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]

NCBI chr 3:119,739,229...119,791,630
Ensembl chr 3:99,284,846...99,337,252

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions
increases expression
increases phosphorylation

artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of CHUK protein]
Simvastatin results in increased expression of CHUK mRNA

PMID:18463201 PMID:19262002

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:242,959,760...242,995,065

G

class II, major histocompatibility complex, transactivator

multiple interactions

Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]

NCBI chr10:5,646,854...5,694,393
Ensembl chr10:5,140,178...5,187,440

G

creatine kinase, M-type

multiple interactions
increases secretion
decreases expression

[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein
Simvastatin results in increased secretion of CKM protein
carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]
Simvastatin results in decreased expression of CKM protein

PMID:8611662 PMID:19252767 PMID:29071762 PMID:35762198

NCBI chr 1:88,189,382...88,199,717
Ensembl chr 1:79,061,456...79,071,720

G

chloride voltage-gated channel 3

multiple interactions
decreases expression

Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]
Simvastatin results in decreased expression of CLCN3 protein

NCBI chr16:34,138,004...34,210,984
Ensembl chr16:29,127,419...29,200,119

G

claudin 18

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 protein]

NCBI chr 8:109,125,819...109,145,110
Ensembl chr 8:100,247,633...100,273,351

G

claudin 4

multiple interactions

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 protein]

NCBI chr12:27,388,160...27,389,958
Ensembl chr12:21,751,331...21,753,436

G

collagen type XI alpha 1 chain

increases expression

Simvastatin results in increased expression of COL11A1 mRNA

NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XII alpha 1 chain

increases expression

Simvastatin results in increased expression of COL12A1 mRNA

NCBI chr 8:89,427,834...89,545,886
Ensembl chr 8:80,547,593...80,665,686

G

collagen type XIII alpha 1 chain

decreases response to substance

COL13A1 SNP results in decreased susceptibility to Simvastatin

NCBI chr20:30,326,744...30,466,800
Ensembl chr20:29,783,965...29,924,032

G

collagen type I alpha 1 chain

multiple interactions
increases expression
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]; Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter]
Simvastatin results in increased expression of COL1A1 mRNA

PMID:10412775 PMID:14973129 PMID:16274305 PMID:16575855 PMID:17252541 More...

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]

PMID:18628692 PMID:19912653

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:129,098,786...129,127,546

G

collagen type III alpha 1 chain

increases expression
decreases expression

Simvastatin results in increased expression of COL3A1 mRNA
Simvastatin results in decreased expression of COL3A1 mRNA

PMID:10412775 PMID:16274305 PMID:16414398 PMID:17183729

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 1 chain

decreases expression

Simvastatin results in decreased expression of COL4A1 mRNA

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:78,183,533...78,294,412

G

collagen type V alpha 1 chain

increases expression

Simvastatin results in increased expression of COL5A1 mRNA

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:11,208,512...11,354,588

G

collagen type VI alpha 2 chain

increases expression

Simvastatin results in increased expression of COL6A2 mRNA

NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,767...12,057,564

G

collagen type VII alpha 1 chain

increases expression

Simvastatin results in increased expression of COL7A1 mRNA

NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:109,604,861...109,637,252

G

coronin 1A

decreases expression

Simvastatin results in decreased expression of CORO1A protein

NCBI chr 1:190,726,129...190,731,133
Ensembl chr 1:181,295,562...181,300,534

G

cAMP responsive element binding protein 1

multiple interactions

Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

C-reactive protein

decreases expression
multiple interactions

Simvastatin results in decreased expression of CRP protein
[Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in increased expression of CRP protein]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]; Simvastatin inhibits the reaction [ethinyl estradiol-desogestrel combination results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein]

PMID:15184351 PMID:15824212 PMID:17105841 PMID:18023360 PMID:18420099 More...

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178

G

citrate synthase

multiple interactions
increases activity

[Simvastatin co-treated with Lipopolysaccharides] results in increased activity of CS protein
Simvastatin results in increased activity of CS protein

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:758,345...791,421

G

chondroitin sulfate proteoglycan 4

increases expression

Simvastatin results in increased expression of CSPG4 mRNA

NCBI chr 8:66,160,942...66,195,987
Ensembl chr 8:57,264,962...57,300,010

G

cardiotrophin 1

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]

PMID:16534557 PMID:18400235 PMID:19100119

NCBI chr 1:191,758,512...191,771,259
Ensembl chr 1:182,328,090...182,333,335

G

cytotoxic T-lymphocyte-associated protein 4

decreases expression

Simvastatin results in decreased expression of CTLA4 mRNA

NCBI chr 9:69,812,859...69,819,959
Ensembl chr 9:62,319,312...62,324,963

G

catenin alpha-like 1

decreases expression

Simvastatin results in decreased expression of CTNNAL1 mRNA

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

catenin beta 1

multiple interactions
increases expression

CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]
Simvastatin results in increased expression of CTNNB1 protein
Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein]

PMID:18004065 PMID:22058016

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin L

increases expression

Simvastatin results in increased expression of CTSL mRNA

NCBI chr17:770,104...776,266
Ensembl chr17:764,309...770,548

G

cathepsin S

multiple interactions

Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS protein]

NCBI chr 2:185,775,316...185,803,440
Ensembl chr 2:183,086,437...183,114,483

G

cortactin

affects localization
multiple interactions

Simvastatin affects the localization of CTTN protein
Simvastatin affects the reaction [F2 affects the localization of CTTN protein]

NCBI chr 1:209,029,048...209,064,577
Ensembl chr 1:199,599,710...199,635,164

G

C-X3-C motif chemokine receptor 1

decreases expression

Simvastatin results in decreased expression of CX3CR1 mRNA

NCBI chr 8:128,661,294...128,679,048
Ensembl chr 8:119,782,595...119,800,014

G

C-X-C motif chemokine ligand 10

multiple interactions
decreases expression

Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL10 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL10 protein]
Simvastatin results in decreased expression of CXCL10 mRNA; Simvastatin results in decreased expression of CXCL10 protein

PMID:15187114 PMID:16414398 PMID:17449418 PMID:22305382

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 12

increases expression

Simvastatin results in increased expression of CXCL12

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 16

decreases expression

Simvastatin results in decreased expression of CXCL16 mRNA

NCBI chr10:55,665,355...55,669,950
Ensembl chr10:55,166,723...55,171,592

G

C-X-C motif chemokine ligand 2

decreases expression

Simvastatin results in decreased expression of CXCL2 mRNA; Simvastatin results in decreased expression of CXCL2 protein

PMID:21330348 PMID:21441352

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

decreases expression

Simvastatin results in decreased expression of CXCL1 mRNA; Simvastatin results in decreased expression of CXCL1 protein

PMID:21330348 PMID:21441352

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 2

decreases expression

Simvastatin results in decreased expression of CXCR2 mRNA

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:75,729,115...75,739,425

G

C-X-C motif chemokine receptor 4

decreases expression
increases expression

Simvastatin results in decreased expression of CXCR4 mRNA
Simvastatin results in increased expression of CXCR4

PMID:16414398 PMID:19591934

NCBI chr13:42,630,383...42,634,288
Ensembl chr13:40,077,976...40,081,883

G

cytochrome b-245 alpha chain

affects response to substance

CYBA gene SNP affects the susceptibility to Simvastatin

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:50,487,597...50,495,721

G

cytochrome b-245 beta chain

multiple interactions

Simvastatin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein]

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11A1 mRNA; [Simvastatin co-treated with resveratrol] results in decreased expression of CYP11A1 mRNA

PMID:24524197 PMID:25055962

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 11, subfamily b, polypeptide 2

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B1 mRNA

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 11, subfamily b, polypeptide 3

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B2 mRNA

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:106,808,559...106,814,048

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression
multiple interactions

Simvastatin results in decreased expression of CYP17A1 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP17A1 mRNA; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; resveratrol promotes the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; Simvastatin promotes the reaction [resveratrol results in decreased expression of CYP17A1 mRNA]

PMID:21918126 PMID:24524197 PMID:25055962

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Simvastatin results in decreased activity of CYP1A1 protein

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Simvastatin results in decreased activity of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP27A1 mRNA]

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

Simvastatin results in increased expression of CYP2B6 mRNA

NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity

Simvastatin results in decreased activity of CYP2C8 protein

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects response to substance

CYP2D6 polymorphism affects the susceptibility to Simvastatin

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 39, subfamily a, polypeptide 1

decreases expression

Simvastatin results in decreased expression of CYP39A1 mRNA

NCBI chr 9:24,727,817...24,804,060
Ensembl chr 9:17,230,455...17,306,775

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects response to substance
increases metabolic processing
increases expression
affects metabolic processing
decreases expression
decreases activity

Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]
CYP3A4 polymorphism affects the susceptibility to Simvastatin
[Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; telaprevir inhibits the reaction [CYP3A4 protein results in increased metabolism of Simvastatin]
Simvastatin results in increased expression of CYP3A4 mRNA
CYP3A4 protein affects the metabolism of Simvastatin
Simvastatin results in decreased expression of CYP3A4 mRNA; Simvastatin results in decreased expression of CYP3A4 protein

PMID:12505310 PMID:15650881 PMID:16011971 PMID:17041008 PMID:19802823 More...

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

affects response to substance

CYP3A5 polymorphism affects the susceptibility to Simvastatin

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 46, subfamily a, polypeptide 1

decreases expression

Simvastatin results in decreased expression of CYP46A1 mRNA

NCBI chr 6:133,011,948...133,039,167
Ensembl chr 6:127,243,315...127,274,760

G

cytochrome P450, family 51

increases expression

Simvastatin results in increased expression of CYP51 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 protein]

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:19,376,974...19,386,688

G

DBF4-CDC7 kinase regulatory subunit

decreases expression

Simvastatin results in decreased expression of DBF4 mRNA

NCBI chr 4:26,631,491...26,656,080
Ensembl chr 4:25,676,634...25,701,066

G

D-box binding PAR bZIP transcription factor

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of DBP mRNA]

NCBI chr 1:105,312,256...105,317,205
Ensembl chr 1:96,175,440...96,180,745

G

doublecortin

increases expression

Simvastatin results in increased expression of DCX

NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476

G

dimethylarginine dimethylaminohydrolase 1

decreases expression

Simvastatin results in decreased expression of DDAH1 mRNA

NCBI chr 2:237,327,812...237,460,624
Ensembl chr 2:234,667,491...234,799,339

G

diacylglycerol O-acyltransferase 1

increases expression
increases activity

Simvastatin results in increased expression of DGAT1 mRNA
Simvastatin results in increased activity of DGAT1 protein

NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:108,218,524...108,234,299

G

24-dehydrocholesterol reductase

increases expression

Simvastatin results in increased expression of DHCR24
Simvastatin results in increased expression of DHCR24 mRNA
Simvastatin results in increased expression of DHCR24 mRNA; Simvastatin results in increased expression of DHCR24 protein

PMID:21987590 PMID:25055962

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

affects response to substance
affects expression
multiple interactions

DHCR7 mutant form affects the susceptibility to Simvastatin
Simvastatin affects the expression of DHCR7 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of DHCR7 mRNA
Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol]
Hydroxychloroquine affects the reaction [Simvastatin affects the expression of DHCR7 mRNA]; Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol]

PMID:15896653 PMID:16446309 PMID:19365639 PMID:25055962 PMID:28975700

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:199,015,081...199,031,055

G

diablo, IAP-binding mitochondrial protein

affects localization
multiple interactions

Simvastatin affects the localization of DIABLO protein
DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:33,055,263...33,070,387

G

dickkopf WNT signaling pathway inhibitor 1

multiple interactions

DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA]

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:228,381,521...228,385,202

G

delta like canonical Notch ligand 4

increases expression

Simvastatin results in increased expression of DLL4 mRNA

NCBI chr 3:126,770,945...126,780,769
Ensembl chr 3:106,316,986...106,326,931

G

dynamin 1-like

affects localization
increases expression

Simvastatin affects the localization of DNM1L protein
Simvastatin results in increased expression of DNM1L protein

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:84,581,216...84,631,482

G

dopamine receptor D1

multiple interactions
increases expression

SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]
Simvastatin results in increased expression of DRD1 mRNA; Simvastatin results in increased expression of DRD1 protein

NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

increases expression

Simvastatin results in increased expression of DRD2 mRNA; Simvastatin results in increased expression of DRD2 protein

NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:49,708,927...49,772,875

G

dentin sialophosphoprotein

increases expression

Simvastatin results in increased expression of DSPP mRNA

NCBI chr14:5,870,232...5,876,339
Ensembl chr14:5,565,629...5,571,672

G

dual specificity phosphatase 1

decreases expression

Simvastatin results in decreased expression of DUSP1 mRNA; Simvastatin results in decreased expression of DUSP1 protein

NCBI chr10:17,184,853...17,187,646

G

E2F transcription factor 1

decreases expression

Simvastatin results in decreased expression of E2F1 mRNA

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:143,049,478...143,075,361

G

ELL associated factor 2

decreases response to substance

EAF2 SNP results in decreased susceptibility to Simvastatin

NCBI chr11:77,465,585...77,509,993
Ensembl chr11:63,960,200...64,004,610

G

endothelin 1

decreases secretion
decreases expression
multiple interactions

Simvastatin results in decreased secretion of EDN1 protein
Simvastatin results in decreased expression of EDN1 mRNA
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 protein]; Simvastatin results in increased expression of and results in increased secretion of EDN1 protein
Simvastatin results in decreased expression of EDN1 mRNA; Simvastatin results in decreased expression of EDN1 protein
Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDN1 mRNA]

PMID:16375908 PMID:18390205 PMID:19099753 PMID:20369390 PMID:20644009 More...

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

multiple interactions

Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDNRA mRNA]

PMID:19505368 PMID:22022327

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:30,233,571...30,297,049

G

epidermal growth factor receptor

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

decreases expression

Simvastatin results in decreased expression of EGR1 protein

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 4E binding protein 1

decreases phosphorylation
multiple interactions

Simvastatin results in decreased phosphorylation of EIF4EBP1 protein
IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]

PMID:22144680 PMID:27734117

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:64,790,226...64,805,984

G

enolase 1

decreases expression

Simvastatin results in decreased expression of ENO1 protein

NCBI chr 5:166,002,867...166,014,252
Ensembl chr 5:160,719,951...160,731,336
Ensembl chr 3:160,719,951...160,731,336

G

ectonucleoside triphosphate diphosphohydrolase 1

multiple interactions

Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein]

NCBI chr 1:249,374,810...249,502,310
Ensembl chr 1:239,425,430...239,552,317

G

Eph receptor A3

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA3 mRNA

NCBI chr11:14,585,041...14,920,721
Ensembl chr11:1,140,985...1,473,900

G

Eph receptor A8

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA8 mRNA

NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399

G

erythropoietin

multiple interactions

Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA]

NCBI chr12:24,841,285...24,844,725
Ensembl chr12:19,204,508...19,207,946

G

erythropoietin receptor

multiple interactions

Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPOR protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA]

NCBI chr 8:28,765,738...28,770,371
Ensembl chr 8:20,489,678...20,494,257

G

coagulation factor II, thrombin

multiple interactions
decreases activity

Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]; Simvastatin affects the reaction [F2 affects the localization of CTTN protein]; Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein]

PMID:12067895 PMID:14630613

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:77,596,198...77,609,486

G

coagulation factor III, tissue factor

multiple interactions
decreases activity
decreases expression
affects response to substance
increases expression

geranylgeraniol inhibits the reaction [Simvastatin results in decreased expression of F3]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of F3]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein]
Simvastatin results in decreased activity of F3 protein
F3 polymorphism affects the susceptibility to Simvastatin
Simvastatin results in increased expression of F3 mRNA; Simvastatin results in increased expression of F3 protein
Simvastatin results in decreased expression of F3; Simvastatin results in decreased expression of F3 mRNA; Simvastatin results in decreased expression of F3 protein

PMID:9081680 PMID:10830219 PMID:12753293 PMID:12818400 PMID:15824212 More...

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid synthase

increases expression

Simvastatin results in increased expression of FASN mRNA

PMID:11728391 PMID:12056585

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

F-box protein 32

increases expression
multiple interactions

Simvastatin results in increased expression of FBXO32 mRNA; Simvastatin results in increased expression of FBXO32 protein
FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]

PMID:19001041 PMID:25300705 PMID:27734117 PMID:33034787

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:89,730,232...89,765,436

G

farnesyl diphosphate farnesyl transferase 1

increases expression
multiple interactions
increases activity

Simvastatin results in increased expression of FDFT1 protein
Simvastatin results in increased expression of FDFT1 mRNA
resveratrol inhibits the reaction [Simvastatin results in increased expression of FDFT1 mRNA]
Simvastatin results in increased activity of FDFT1 protein

PMID:8517861 PMID:12518039 PMID:23386644

NCBI chr15:41,588,114...41,616,168
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

increases expression
multiple interactions

Simvastatin results in increased expression of FDPS mRNA
resveratrol inhibits the reaction [Simvastatin results in increased expression of FDPS mRNA]

NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:174,486,665...174,507,776

G

fibroblast growth factor 19

multiple interactions

Simvastatin inhibits the reaction [Dietary Fats results in increased expression of FGF19 mRNA]

NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:200,056,644...200,060,287

G

fibroblast growth factor 2

increases expression

Simvastatin results in increased expression of FGF2

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221

G

FKBP prolyl isomerase 1A

decreases expression

Simvastatin results in decreased expression of FKBP1A mRNA

NCBI chr 3:160,500,748...160,520,492
Ensembl chr 3:140,040,278...140,060,743

G

FKBP prolyl isomerase 4

increases expression

Simvastatin results in increased expression of FKBP4 mRNA

NCBI chr 4:163,389,464...163,397,918
Ensembl chr 4:161,703,379...161,711,833

G

flotillin 1

decreases expression

Simvastatin results in decreased expression of FLOT1 protein

NCBI chr20:2,922,662...2,932,906
Ensembl chr20:2,917,137...2,927,978

G

Fms related receptor tyrosine kinase 1

multiple interactions
increases expression

Simvastatin inhibits the reaction [Streptozocin results in increased expression of FLT1 mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of FLT1 protein]
Simvastatin results in increased expression of FLT1 mRNA

PMID:19109527 PMID:20821229

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:7,297,292...7,468,626

G

fibronectin 1

decreases expression
increases expression

Simvastatin results in decreased expression of FN1 mRNA
Simvastatin results in increased expression of FN1 mRNA

PMID:10412775 PMID:15855201 PMID:16274305 PMID:16414398

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression
decreases localization

farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of FOS mRNA]
Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]
FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FOS protein]
Simvastatin results in decreased localization of FOS protein

PMID:12753293 PMID:12963647 PMID:15187114 PMID:16005304 PMID:19100119

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Simvastatin results in increased expression of FOSL1 protein

NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:202,754,529...202,764,930

G

FOS like 2, AP-1 transcription factor subunit

multiple interactions

Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]

NCBI chr 6:30,017,952...30,039,269
Ensembl chr 6:24,300,956...24,320,034

G

forkhead box O1

affects localization
decreases phosphorylation
multiple interactions
decreases localization
increases phosphorylation

Simvastatin affects the localization of FOXO1 protein
Simvastatin results in decreased phosphorylation of FOXO1 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of FOXO1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein]
Simvastatin results in decreased localization of FOXO1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased localization of FOXO1 protein]
Simvastatin results in increased phosphorylation of FOXO1 protein

PMID:12438947 PMID:18826357 PMID:19001041 PMID:33034787

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box O3

multiple interactions
affects localization
decreases phosphorylation
decreases expression
increases phosphorylation

Acetylcysteine inhibits the reaction [Simvastatin results in increased phosphorylation of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]
Simvastatin results in decreased phosphorylation of FOXO3 protein
Simvastatin results in decreased expression of FOXO3 protein

PMID:19001041 PMID:20883752 PMID:27734117

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561

G

forkhead box P3

increases expression
decreases expression
affects methylation
multiple interactions

Simvastatin results in increased expression of FOXP3
Simvastatin results in decreased expression of FOXP3 mRNA
Simvastatin affects the methylation of FOXP3 promoter
IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of FOXP3]

PMID:20408897 PMID:20491794 PMID:22305382

NCBI chr X:17,580,380...17,601,181
Ensembl chr X:14,908,494...14,923,838

G

follistatin

multiple interactions

FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein]

NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:46,123,439...46,130,571

G

frizzled class receptor 2

increases expression

Simvastatin results in increased expression of FZD2 mRNA

NCBI chr10:88,061,988...88,063,898
Ensembl chr10:87,561,326...87,565,334

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804

G

glyceraldehyde-3-phosphate dehydrogenase

decreases expression

Simvastatin results in decreased expression of GAPDH mRNA

NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:157,962,343...157,966,235

G

GATA binding protein 6

increases expression

Simvastatin results in increased expression of GATA6 mRNA; Simvastatin results in increased expression of GATA6 protein

NCBI chr18:2,460,909...2,492,322
Ensembl chr18:2,188,121...2,219,532

G

GDP dissociation inhibitor 2

decreases expression

Simvastatin results in decreased expression of GDI2 protein

NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366

G

glial cell derived neurotrophic factor

increases expression

Simvastatin results in increased expression of GDNF

NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:56,895,010...56,917,209

G

GDNF family receptor alpha 1

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of GFRA1 mRNA

NCBI chr 1:267,325,297...267,557,037
Ensembl chr 1:257,321,742...257,551,473

G

gap junction protein, alpha 1

multiple interactions

GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Simvastatin affects the localization of and results in decreased phosphorylation of GJA1 protein

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, beta 2

increases expression

Simvastatin results in increased expression of GJB2 mRNA

NCBI chr15:35,375,977...35,393,817
Ensembl chr15:31,260,357...31,278,177

G

galactosidase, beta 1

multiple interactions

Simvastatin inhibits the reaction [Coal Ash results in increased expression of GLB1 protein]

NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:114,085,508...114,158,127

G

glutathione peroxidase 1

decreases expression
multiple interactions

Simvastatin results in decreased expression of GPX1 mRNA
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA]

PMID:20883752 PMID:28734741

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

increases expression

Simvastatin results in increased expression of GPX2 mRNA

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:95,493,589...95,496,877

G

glycogen synthase kinase 3 beta

increases expression
multiple interactions

Simvastatin results in increased expression of GSK3B
Simvastatin results in increased expression of GSK3B protein modified form
Simvastatin inhibits the reaction [Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GSK3B protein]

PMID:18004065 PMID:18047562 PMID:19461118

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione S-transferase pi 1

multiple interactions

Simvastatin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226

G

H2A.X variant histone

increases phosphorylation

Simvastatin results in increased phosphorylation of H2AX protein

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

hes family bHLH transcription factor 5

increases expression

Simvastatin results in increased expression of HES5 mRNA

NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:165,522,234...165,523,001

G

hypoxia inducible factor 1 subunit alpha

increases expression
decreases expression
multiple interactions

Simvastatin results in increased expression of HIF1A protein
Simvastatin results in decreased expression of HIF1A mRNA
HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]

PMID:18356691 PMID:21844074

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group box 1

multiple interactions

Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholecalciferol] results in increased expression of HMGB1 mRNA]
[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein]

PMID:20519084 PMID:25412314

NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases response to substance
decreases activity
increases expression
increases activity
multiple interactions
affects response to substance

HMGCR exon alternative form results in decreased susceptibility to Simvastatin
Simvastatin results in decreased activity of HMGCR protein
Simvastatin results in increased expression of HMGCR mRNA; Simvastatin results in increased expression of HMGCR protein
Simvastatin results in increased activity of HMGCR protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin results in increased expression of and results in decreased activity of HMGCR protein; Simvastatin results in increased expression of and results in increased activity of HMGCR protein
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA]
[HMGCR intron polymorphism affects the expression of HMGCR exon alternative form] which results in decreased susceptibility to Simvastatin; [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; [Simvastatin co-treated with Ezetimibe] results in increased expression of HMGCR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; Resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin affects the reaction [Hydroxychloroquine affects the expression of HMGCR mRNA]; Simvastatin results in increased expression of and results in increased activity of HMGCR protein
HMGCR intron polymorphism affects the susceptibility to Simvastatin; HMGCR polymorphism affects the susceptibility to Simvastatin

PMID:1627634 PMID:8517861 PMID:8593127 PMID:9512650 PMID:10357840 More...

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

multiple interactions
increases response to substance
increases expression
increases activity
decreases expression
increases stability

[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]]
HMOX1 gene mutant form results in increased susceptibility to Simvastatin
Simvastatin results in increased expression of HMOX1 mRNA; Simvastatin results in increased expression of HMOX1 protein
Simvastatin results in increased activity of HMOX1 protein
Simvastatin results in decreased expression of HMOX1 mRNA
Simvastatin results in increased stability of HMOX1 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased stability of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; tin protoporphyrin IX inhibits the reaction [Simvastatin results in increased expression of HMOX1 protein]

PMID:16375908 PMID:16414398 PMID:16628357 PMID:17928392 PMID:18073186 More...

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079

G

HNF1 homeobox A

increases expression

Simvastatin results in increased expression of HNF1A mRNA

NCBI chr12:47,299,171...47,333,457
Ensembl chr12:41,645,587...41,672,104

G

HRas proto-oncogene, GTPase

multiple interactions
decreases activity

Farnesol inhibits the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of HRAS protein]; Simvastatin results in decreased prenylation of and results in decreased localization of HRAS protein
Simvastatin results in decreased activity of HRAS

PMID:11914545 PMID:12477733 PMID:18625914 PMID:19360310

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:196,296,263...196,300,615

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

[Simvastatin co-treated with resveratrol] results in decreased expression of HSD3B1 mRNA

NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999

G

heat shock transcription factor 1

affects localization

Simvastatin affects the localization of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein 90 alpha family class A member 1

increases expression

Simvastatin results in increased expression of HSP90AA1 protein

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 4

increases expression

Simvastatin results in increased expression of HSPA4 protein

NCBI chr10:37,908,866...37,951,994
Ensembl chr10:37,408,025...37,449,001

G

heat shock protein family A (Hsp70) member 5

increases expression

Simvastatin results in increased expression of HSPA5 mRNA; Simvastatin results in increased expression of HSPA5 protein

PMID:18664198 PMID:19253821

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

decreases expression

Simvastatin results in decreased expression of HSPA8 protein

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259

G

HtrA serine peptidase 2

affects localization

Simvastatin affects the localization of HTRA2 protein

NCBI chr 4:117,114,631...117,117,793
Ensembl chr 4:115,556,916...115,560,095

G

integrin-binding sialoprotein

increases expression

Simvastatin results in increased expression of IBSP mRNA

NCBI chr14:5,744,497...5,757,242
Ensembl chr14:5,439,829...5,452,693

G

intercellular adhesion molecule 1

multiple interactions
decreases expression

farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Simvastatin affects the expression of and affects the secretion of ICAM1 protein; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of ICAM1 protein modified form]
Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein
Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein; Simvastatin results in decreased expression of ICAM1 protein modified form

PMID:10946302 PMID:12615677 PMID:14602771 PMID:15234187 PMID:16054375 More...

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

increases expression

Simvastatin results in increased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:141,211,267...141,212,419

G

isopentenyl-diphosphate delta isomerase 1

increases expression

Simvastatin results in increased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:61,629,594...61,637,357

G

indoleamine 2,3-dioxygenase 1

increases expression

Simvastatin results in increased expression of IDO1

NCBI chr16:74,133,259...74,145,328
Ensembl chr16:67,430,578...67,442,730

G

interferon gamma

multiple interactions
increases secretion
increases expression

IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2]
Simvastatin results in increased secretion of IFNG protein
Simvastatin results in increased expression of IFNG mRNA

PMID:11219190 PMID:16321392 PMID:17507688 PMID:18453621 PMID:19589242 More...

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

multiple interactions

[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein]

PMID:17327694 PMID:27734117

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

decreases expression
multiple interactions
increases expression

Simvastatin results in decreased expression of IGF1R; Simvastatin results in decreased expression of IGF1R mRNA; Simvastatin results in decreased expression of IGF1R protein
[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]
Simvastatin results in increased expression of IGF1R protein alternative form

PMID:17158816 PMID:17327694 PMID:18489904 PMID:27734117

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor binding protein 6

increases expression

Simvastatin results in increased expression of IGFBP6 mRNA

NCBI chr 7:135,154,919...135,159,550
Ensembl chr 7:133,276,234...133,280,966

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions
increases phosphorylation
decreases expression

artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of IKBKB protein]
Simvastatin results in decreased expression of IKBKB mRNA

PMID:17277159 PMID:18463201

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:69,319,554...69,373,250

G

interleukin 10

increases expression
multiple interactions

Simvastatin results in increased expression of IL10
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein]]; [Lipopolysaccharides co-treated with Simvastatin] results in increased expression of and results in increased secretion of IL10 protein; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein]
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein]
Simvastatin results in increased expression of IL10 mRNA; Simvastatin results in increased expression of IL10 protein

PMID:15883752 PMID:20491794 PMID:21925249 PMID:25674200 PMID:33774062

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions
increases expression

FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B protein]; Simvastatin promotes the reaction [Pam(3)CSK(4) peptide results in increased expression of IL12B protein]; Simvastatin promotes the reaction [resiquimod results in increased expression of IL12B protein]

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903

G

interleukin 13

decreases expression

Simvastatin results in decreased expression of IL13 mRNA; Simvastatin results in decreased expression of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:37,790,130...37,792,737

G

interleukin 16

multiple interactions

[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of IL16 mRNA

NCBI chr 1:147,026,852...147,127,177
Ensembl chr 1:137,617,944...137,718,130

G

interleukin 17A

multiple interactions
decreases secretion
decreases expression

IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL17A mRNA]

PMID:18453621 PMID:21856936

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 17F

decreases secretion

Simvastatin results in decreased secretion of IL17F protein

NCBI chr 9:30,686,532...30,697,918
Ensembl chr 9:23,190,100...23,201,482

G

interleukin 18

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]]; Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]
Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL18 protein]

PMID:18660453 PMID:27377765

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

multiple interactions

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]

PMID:15705589 PMID:15728660

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases secretion
decreases expression

1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B mRNA]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA]
Simvastatin results in decreased secretion of IL1B protein
Simvastatin results in decreased expression of IL1B mRNA; Simvastatin results in decreased expression of IL1B protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

PMID:10946302 PMID:12829860 PMID:15883752 PMID:16054375 PMID:17075836 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 2

decreases expression

Simvastatin results in decreased expression of IL1R2 mRNA

NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:42,384,433...42,424,725

G

interleukin 1 receptor-like 1

decreases expression

Simvastatin results in decreased expression of IL1RL1 mRNA

NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:42,697,192...42,727,256

G

interleukin 2

multiple interactions

IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 20 receptor subunit beta

increases expression

Simvastatin results in increased expression of IL20RB mRNA

NCBI chr 8:109,858,108...109,896,066
Ensembl chr 8:100,980,383...101,009,942

G

interleukin 21

decreases expression
decreases secretion

Simvastatin results in decreased expression of IL21 mRNA
Simvastatin results in decreased secretion of IL21 protein

PMID:18453621 PMID:21856936

NCBI chr 2:122,045,240...122,055,142
Ensembl chr 2:120,119,444...120,126,996

G

interleukin 22

decreases secretion

Simvastatin results in decreased secretion of IL22 protein

NCBI chr 7:55,687,061...55,691,526
Ensembl chr 7:53,801,206...53,806,186

G

interleukin 23 subunit alpha

decreases expression

Simvastatin results in decreased expression of IL23A mRNA

PMID:18453621 PMID:22305382

NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:721,809...723,923

G

interleukin 25

decreases expression

Simvastatin results in decreased expression of IL25 mRNA

NCBI chr15:32,378,750...32,382,141
Ensembl chr15:28,408,842...28,411,893

G

interleukin 27

increases expression
increases secretion
multiple interactions

Simvastatin results in increased expression of IL27 mRNA
Simvastatin results in increased secretion of IL27 protein
IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]

NCBI chr 1:190,603,684...190,609,292
Ensembl chr 1:181,173,372...181,178,582

G

interleukin 2 receptor subunit alpha

affects expression
decreases expression

Simvastatin affects the expression of IL2RA protein
Simvastatin results in decreased expression of IL2RA mRNA

PMID:16387846 PMID:18453621

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:66,849,974...66,898,697

G

interleukin 4

multiple interactions
decreases expression
increases secretion
increases expression

IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]
Simvastatin results in decreased expression of IL4 mRNA; Simvastatin results in decreased expression of IL4 protein
Simvastatin results in increased secretion of IL4 protein
Simvastatin results in increased expression of IL4 mRNA

PMID:17169357 PMID:18453621

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750

G

interleukin 4 receptor

decreases expression

Simvastatin results in decreased expression of IL4R mRNA
Simvastatin results in decreased expression of IL4RA mRNA

PMID:16414398 PMID:18453621

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:180,115,120...180,139,980

G

interleukin 6

multiple interactions
affects secretion
decreases secretion
decreases expression
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL6 mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Simvastatin results in decreased expression of and results in decreased secretion of IL6 protein
Simvastatin affects the secretion of IL6 protein
Simvastatin results in decreased secretion of IL6 protein
Simvastatin results in decreased expression of IL6 mRNA; Simvastatin results in decreased expression of IL6 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]
Simvastatin results in increased expression of IL6 mRNA
Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]

PMID:12117737 PMID:15665042 PMID:15883752 PMID:16387846 PMID:16424782 More...

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INHA mRNA

NCBI chr 9:84,443,109...84,446,010
Ensembl chr 9:76,993,589...76,997,248

G

insulin induced gene 2

decreases expression

Simvastatin results in decreased expression of INSIG2 mRNA

NCBI chr13:35,025,160...35,052,937
Ensembl chr13:32,473,742...32,494,923

G

insulin-like 3

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INSL3 mRNA

NCBI chr16:18,432,668...18,434,539
Ensembl chr16:18,384,829...18,400,560

G

interferon regulatory factor 1

multiple interactions

Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]

NCBI chr10:38,417,935...38,424,946
Ensembl chr10:37,916,670...37,924,166

G

interferon regulatory factor 4

decreases expression
multiple interactions

Simvastatin results in decreased expression of IRF4 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein]
Simvastatin results in decreased expression of IRF4 mRNA; Simvastatin results in decreased expression of IRF4 protein

PMID:21856936 PMID:33034787

NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,721,811...33,740,070

G

insulin receptor substrate 1

multiple interactions

Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]

NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:83,548,944...83,606,122

G

integrin subunit alpha L

affects binding
decreases expression
multiple interactions

Simvastatin binds to [ITGAL protein binds to ITGB2 protein]
Simvastatin results in decreased expression of ITGAL mRNA
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL]

PMID:12615677 PMID:15041742 PMID:16828882

NCBI chr 1:191,348,424...191,386,228
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit alpha M

decreases expression
multiple interactions

Simvastatin results in decreased expression of ITGAM mRNA; Simvastatin results in decreased expression of ITGAM protein
Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein]

PMID:16414398 PMID:21330348 PMID:21441352

NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 1

decreases expression

Simvastatin results in decreased expression of ITGB1 mRNA; Simvastatin results in decreased expression of ITGB1 protein

PMID:17428261 PMID:21874229

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 2

affects binding
decreases expression
multiple interactions

Simvastatin binds to [ITGAL protein binds to ITGB2 protein]
Simvastatin results in decreased expression of ITGB2 mRNA
Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2]
Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein]

PMID:12615677 PMID:15041742 PMID:21330348

NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,061,430...11,097,600

G

integrin subunit beta 3 binding protein

decreases expression

Simvastatin results in decreased expression of ITGB3BP mRNA

NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704

G

integrin subunit beta 4

affects expression
increases expression

Simvastatin affects the expression of ITGB4 mRNA; Simvastatin affects the expression of ITGB4 protein
Simvastatin results in increased expression of ITGB4 mRNA; Simvastatin results in increased expression of ITGB4 protein

PMID:14630613 PMID:19110722

NCBI chr10:101,705,592...101,741,933
Ensembl chr10:101,206,665...101,243,012

G

integrin subunit beta like 1

decreases expression

Simvastatin results in decreased expression of ITGBL1 mRNA

NCBI chr15:107,186,792...107,448,335
Ensembl chr15:100,780,184...101,041,733

G

Janus kinase 1

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

multiple interactions
decreases phosphorylation
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]
Simvastatin results in decreased phosphorylation of JAK2 protein
Simvastatin results in decreased expression of JAK2 mRNA

PMID:16414398 PMID:16534557 PMID:18400235 PMID:19100119

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression
increases phosphorylation
decreases localization

pyrazolanthrone inhibits the reaction [Simvastatin results in increased phosphorylation of JUN protein]
Simvastatin results in decreased expression of JUN mRNA
Simvastatin results in decreased localization of JUN protein
JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of JUN protein]

PMID:12753293 PMID:12963647 PMID:15187114 PMID:15488325 PMID:17125918

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]

NCBI chr19:40,081,126...40,082,910
Ensembl chr19:23,176,294...23,178,035

G

potassium voltage-gated channel subfamily H member 2

decreases localization
multiple interactions
decreases activity

Simvastatin results in decreased localization of KCNH2 protein
Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein]

PMID:21525004 PMID:30086269

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008

G

kinase insert domain receptor

increases expression
multiple interactions

Simvastatin results in increased expression of KDR mRNA; Simvastatin results in increased expression of KDR protein
Simvastatin inhibits the reaction [Streptozocin results in increased expression of KDR mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of KDR protein]

PMID:15572054 PMID:19109527 PMID:20821229

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,217,871...32,261,018

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of KIT mRNA

NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,548,877...32,624,652

G

KLF transcription factor 10

multiple interactions

[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]

NCBI chr 7:71,352,612...71,358,680
Ensembl chr 7:69,465,619...69,473,994

G

KLF transcription factor 16

increases expression

Simvastatin results in increased expression of KLF16 mRNA

NCBI chr 7:9,789,185...9,799,004
Ensembl chr 7:9,138,503...9,148,317

G

KLF transcription factor 2

increases expression
decreases expression
multiple interactions

Simvastatin results in increased expression of KLF2 mRNA
Simvastatin results in decreased expression of KLF2 mRNA
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of KLF2 mRNA]

PMID:17428261 PMID:20493886 PMID:20737288 PMID:22305382

NCBI chr16:17,555,136...17,557,768
Ensembl chr16:17,514,552...17,523,944

G

KLF transcription factor 6

increases expression

Simvastatin results in increased expression of KLF6 mRNA

NCBI chr17:69,449,483...69,458,478
Ensembl chr17:64,531,463...64,588,570

G

killer cell lectin like receptor B1

decreases expression

Simvastatin results in decreased expression of KLRF1 mRNA

NCBI chr 4:164,142,323...164,161,018
Ensembl chr 4:162,456,294...162,474,989

G

KRAS proto-oncogene, GTPase

decreases prenylation

Simvastatin results in decreased prenylation of KRAS protein

NCBI chr 4:179,916,255...179,949,613

G

keratin 13

increases expression

Simvastatin results in increased expression of KRT13 mRNA

NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084

G

keratin 15

increases expression

Simvastatin results in increased expression of KRT15 mRNA

NCBI chr10:85,567,197...85,571,014
Ensembl chr10:85,066,802...85,171,799

G

keratin 17

increases expression

Simvastatin results in increased expression of KRT17 mRNA

NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392

G

LBH regulator of WNT signaling pathway

increases expression

Simvastatin results in increased expression of LBH mRNA

NCBI chr 6:28,321,040...28,344,855
Ensembl chr 6:22,568,834...22,593,079

G

lipopolysaccharide binding protein

decreases expression

Simvastatin results in decreased expression of LBP mRNA

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:146,954,015...146,981,586

G

lecithin cholesterol acyltransferase

increases activity
decreases expression

Simvastatin results in increased activity of LCAT protein
Simvastatin results in decreased expression of LCAT mRNA

PMID:21241519 PMID:25055962

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231

G

low density lipoprotein receptor

multiple interactions
increases expression
increases activity
affects response to substance

[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Simvastatin co-treated with Ezetimibe] results in increased expression of LDLR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]
Simvastatin results in increased expression of LDLR mRNA; Simvastatin results in increased expression of LDLR protein
Simvastatin results in increased activity of LDLR protein
Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA]
LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin; LDLR mutant form affects the susceptibility to Simvastatin

PMID:1627634 PMID:8457250 PMID:8593127 PMID:9633944 PMID:10208479 More...

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580

G

lymphoid enhancer binding factor 1

increases expression

Simvastatin results in increased expression of LEF1 mRNA

NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:219,666,592...219,779,794

G

leptin

multiple interactions
decreases secretion
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; GGTI 298 inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; GGTI 298 inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]
Simvastatin inhibits the reaction [Poloxamer results in increased secretion of LEP protein]
Simvastatin results in decreased expression of LEP mRNA; Simvastatin results in decreased expression of LEP mRNA alternative form

PMID:19254925 PMID:29071762

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262

G

leptin receptor

affects response to substance

LEPR polymorphism affects the susceptibility to Simvastatin

PMID:14625131 PMID:18854995

NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:116,289,823...116,475,908

G

luteinizing hormone subunit beta

multiple interactions

Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of LHB protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of LHB protein]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

LIF, interleukin 6 family cytokine

multiple interactions

[Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]

NCBI chr14:83,354,602...83,364,053
Ensembl chr14:79,134,574...79,140,482

G

lipopolysaccharide-induced TNF factor

decreases expression

Simvastatin results in decreased expression of LITAF mRNA

NCBI chr10:5,163,258...5,199,930
Ensembl chr10:4,625,552...4,692,763

G

lysyl oxidase

decreases expression

Simvastatin results in decreased expression of LOX mRNA

NCBI chr18:48,162,889...48,175,640
Ensembl chr18:45,967,343...46,041,477

G

lipoprotein lipase

decreases expression
increases expression

Simvastatin results in decreased expression of LPL
Simvastatin results in increased expression of LPL protein

PMID:2009092 PMID:19216230

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 6

decreases expression

Simvastatin results in decreased expression of LRP6 mRNA

NCBI chr 4:168,997,937...169,131,716
Ensembl chr 4:167,270,353...167,400,497

G

leucine rich repeat containing 2

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of LRRC2 mRNA

NCBI chr 8:110,936,119...110,969,189
Ensembl chr 8:110,938,165...110,969,185

G

lymphotoxin beta

decreases expression

Simvastatin results in decreased expression of LTB mRNA

NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,627,537...3,629,381

G

mitotic arrest deficient 2 like 1

decreases expression

Simvastatin results in decreased expression of MAD2L1 mRNA

NCBI chr 4:97,236,419...97,247,603
Ensembl chr 4:95,906,817...95,913,470

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

Simvastatin results in increased expression of MAP1LC3B protein
[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form; Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form]

PMID:23817226 PMID:25412314

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 14

decreases expression

Simvastatin results in decreased expression of MAP3K14 mRNA

NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523

G

mitogen activated protein kinase kinase kinase 7

multiple interactions

Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein]

NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:46,357,931...46,415,597

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation
increases phosphorylation
decreases activity

[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
Simvastatin results in decreased phosphorylation of MAPK1 protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK1 protein
Simvastatin results in increased phosphorylation of MAPK1 protein
Simvastatin results in decreased activity of MAPK1 protein

PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions
decreases expression

Simvastatin results in increased phosphorylation of and results in increased activity of MAPK14 protein
Simvastatin results in decreased expression of MAPK14 mRNA

PMID:16414398 PMID:17928392

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation
increases phosphorylation
decreases activity

[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK3 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
Simvastatin results in decreased phosphorylation of MAPK3 protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK3 protein
Simvastatin results in increased phosphorylation of MAPK3 protein
Simvastatin results in decreased activity of MAPK3 protein

PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases activity

farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]
Simvastatin results in increased activity of MAPK8 protein
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]

PMID:15187114 PMID:18047562 PMID:18310456

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases activity

Simvastatin results in increased activity of MAPK9 protein

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178

G

microtubule-associated protein tau

affects expression

Simvastatin affects the expression of MAPT

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129

G

myoglobin

multiple interactions

Simvastatin inhibits the reaction [Poloxamer results in increased secretion of MB protein]

NCBI chr 7:110,640,511...110,647,742
Ensembl chr 7:108,759,904...108,767,383

G

minichromosome maintenance complex component 4

decreases expression

Simvastatin results in decreased expression of MCM4 mRNA

NCBI chr11:98,762,599...98,776,300
Ensembl chr11:85,258,443...85,272,144

G

malate dehydrogenase 1

decreases expression

Simvastatin results in decreased expression of MDH1 protein

NCBI chr14:99,831,934...99,847,227
Ensembl chr14:95,630,306...95,645,925

G

MDM2 proto-oncogene

increases phosphorylation
multiple interactions

Simvastatin results in increased phosphorylation of MDM2 protein
Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:53,290,664...53,314,915

G

MER proto-oncogene, tyrosine kinase

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of MERTK mRNA

NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:115,939,351...116,046,554

G

microRNA 221

decreases expression

Simvastatin results in decreased expression of MIR221

NCBI chr X:6,023,182...6,023,290
Ensembl chr X:3,429,465...3,429,573

G

marker of proliferation Ki-67

decreases expression

Simvastatin results in decreased expression of MKI67 protein

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 1

multiple interactions
increases expression
decreases secretion
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]
Simvastatin results in increased expression of MMP1 mRNA
Simvastatin results in decreased secretion of MMP1 mRNA; Simvastatin results in decreased secretion of MMP1 protein

PMID:17303772 PMID:17428261 PMID:18625914 PMID:31260663

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 10

increases expression

Simvastatin results in increased expression of MMP10 mRNA

NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 12

increases expression

Simvastatin results in increased expression of MMP12 mRNA

NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:4,581,785...4,599,611

G

matrix metallopeptidase 13

increases expression
multiple interactions

Simvastatin results in increased expression of MMP13 mRNA
Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]

PMID:16274305 PMID:17428261 PMID:31260663

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

decreases activity
increases activity
decreases expression
multiple interactions

Simvastatin results in decreased activity of MMP2 protein
Simvastatin results in increased activity of MMP2 protein
Simvastatin results in decreased expression of MMP2 protein
Simvastatin results in decreased expression of MMP2 mRNA
Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 protein]
Simvastatin inhibits the reaction [Monocrotaline results in increased expression of MMP2 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP2 protein

PMID:15210533 PMID:17038636 PMID:17158816 PMID:17169357 PMID:18309148 More...

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 28

increases expression

Simvastatin results in increased expression of MMP28 mRNA

NCBI chr10:68,241,138...68,264,866
Ensembl chr10:68,241,138...68,264,866

G

matrix metallopeptidase 3

decreases expression
multiple interactions

Simvastatin results in decreased expression of MMP3 mRNA
Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]

PMID:16414398 PMID:31260663

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 8

multiple interactions

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP8 mRNA]

NCBI chr 8:13,008,873...13,018,729
Ensembl chr 8:4,724,029...4,733,520

G

matrix metallopeptidase 9

multiple interactions
increases activity
decreases expression
decreases activity

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA]
Simvastatin results in increased activity of MMP9 protein
Simvastatin results in decreased expression of MMP9 mRNA; Simvastatin results in decreased expression of MMP9 protein
Simvastatin results in decreased activity of MMP9 protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of MMP9 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP9 protein
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 protein]

PMID:15107580 PMID:15210533 PMID:15537504 PMID:15728660 PMID:16002570 More...

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions
decreases activity
decreases expression

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein]
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]
Simvastatin results in decreased activity of MPO protein
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein]
Simvastatin results in decreased expression of MPO protein

PMID:15665042 PMID:17038636 PMID:21764683 PMID:33774062

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819

G

muscle RAS oncogene homolog

multiple interactions

Simvastatin inhibits the reaction [Glucose results in increased activity of MRAS protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MRAS protein]

PMID:18569938 PMID:19299917

NCBI chr 8:108,823,374...108,886,104
Ensembl chr 8:99,944,036...99,996,408

G

mitochondrial ribosomal protein S31

decreases response to substance

MRPS31 SNP results in decreased susceptibility to Simvastatin

NCBI chr16:69,601,349...69,621,609
Ensembl chr16:69,601,349...69,630,654

G

myostatin

multiple interactions
increases expression

5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Simvastatin results in increased expression of and results in increased secretion of MSTN protein
Simvastatin results in increased expression of MSTN mRNA; Simvastatin results in increased expression of MSTN protein

NCBI chr 9:55,944,513...55,950,913
Ensembl chr 9:48,452,533...48,458,933

G

metallothionein 1

increases expression

Simvastatin results in increased expression of MT1A mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

methylenetetrahydrofolate reductase

multiple interactions
increases expression
affects response to substance

Homocysteine inhibits the reaction [Simvastatin results in increased expression of MTHFR protein modified form]; Simvastatin promotes the reaction [Homocysteine results in increased expression of MTHFR protein]
MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein]
MTHFR affects the susceptibility to Simvastatin

NCBI chr 5:163,748,346...163,768,141
Ensembl chr 5:158,465,296...158,483,797

G

mechanistic target of rapamycin kinase

decreases phosphorylation
multiple interactions

Simvastatin results in decreased phosphorylation of MTOR protein
FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein]

PMID:22144680 PMID:33034787

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MUC5AC protein]
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]

PMID:19024099 PMID:20359552

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:196,864,336...196,896,475

G

mevalonate diphosphate decarboxylase

increases expression

Simvastatin results in increased expression of MVD mRNA

NCBI chr19:67,404,911...67,414,974
Ensembl chr19:50,496,367...50,507,971

G

mevalonate kinase

increases expression
multiple interactions

Simvastatin results in increased expression of MVK mRNA
[MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]

PMID:12477733 PMID:25055962

NCBI chr12:47,802,002...47,819,503
Ensembl chr12:42,141,384...42,158,882

G

myosin binding protein H

increases expression

Simvastatin results in increased expression of MYBPH mRNA

NCBI chr13:45,653,156...45,660,893
Ensembl chr13:45,653,234...45,660,893

G

myosin heavy chain 10

decreases expression

Simvastatin results in decreased expression of MYH10 protein

NCBI chr10:53,393,901...53,525,174
Ensembl chr10:53,394,389...53,525,165

G

myosin heavy chain 6

increases expression

Simvastatin results in increased expression of MYH6 mRNA

NCBI chr15:32,388,102...32,413,663
Ensembl chr15:28,417,616...28,441,720

G

N-myc downstream regulated 1

decreases expression

Simvastatin results in decreased expression of NDRG1 protein

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

nuclear factor of activated T-cells 3

multiple interactions
increases localization
decreases localization

Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter]
Simvastatin results in increased localization of NFATC3 protein
Simvastatin results in decreased localization of NFATC3 protein alternative form

NCBI chr19:50,870,464...50,944,992
Ensembl chr19:33,960,852...34,035,150

G

NFE2 like bZIP transcription factor 2

increases localization
increases expression
multiple interactions

Simvastatin results in increased localization of NFE2L2 protein
Simvastatin results in increased expression of NFE2L2 mRNA
MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; Simvastatin results in increased expression of and affects the localization of NFE2L2 protein
Mevalonic Acid affects the reaction [Simvastatin results in increased localization of NFE2L2 protein]
NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]

PMID:17928392 PMID:18787804 PMID:30513525

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions
decreases expression
decreases activity
decreases localization
increases localization

artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of NFKB1 protein]; Simvastatin results in increased localization of and results in increased activity of NFKB1 protein
Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]
Simvastatin results in decreased expression of NFKB1 mRNA
Simvastatin results in decreased activity of NFKB1 protein
Simvastatin results in decreased localization of NFKB1 protein

PMID:12753293 PMID:17038636 PMID:17277159 PMID:18463201 PMID:21465237 More...

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions
increases phosphorylation

artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of NFKBIA protein]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of NFKBIA protein]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]]

PMID:15705589 PMID:17075836 PMID:17178392 PMID:17277159 PMID:18073186 More...

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

neuroligin 3

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NLGN3 mRNA]

NCBI chr X:70,469,251...70,497,380
Ensembl chr X:66,429,458...66,451,876

G

NLR family, pyrin domain containing 3

multiple interactions

Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of NLRP3 mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]

PMID:30408459 PMID:35762198

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811

G

noggin

multiple interactions

NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]

NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,128,712...74,130,339

G

nitric oxide synthase 2

multiple interactions
decreases expression
increases expression

Simvastatin promotes the reaction [Doxorubicin results in increased expression of NOS2 protein]
Simvastatin results in decreased expression of NOS2 mRNA; Simvastatin results in decreased expression of NOS2 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]
Simvastatin results in increased expression of NOS2 mRNA; Simvastatin results in increased expression of NOS2 protein
Homocysteine affects the reaction [Simvastatin results in increased expression of NOS2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; Simvastatin promotes the reaction [Homocysteine results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]

PMID:10188333 PMID:11470468 PMID:15705589 PMID:16414398 PMID:17729120 More...

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression
decreases expression
multiple interactions
increases phosphorylation

Simvastatin results in increased expression of NOS3; Simvastatin results in increased expression of NOS3 mRNA; Simvastatin results in increased expression of NOS3 protein
Simvastatin results in decreased expression of NOS3 mRNA; Simvastatin results in decreased expression of NOS3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of NOS3 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]
Simvastatin results in increased phosphorylation of NOS3 protein
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Smoke analog affects the expression of NOS3 mRNA]; Simvastatin results in increased expression of and results in increased phosphorylation of and results in increased activity of NOS3 protein

PMID:10188333 PMID:11470468 PMID:11947894 PMID:12379581 PMID:12406854 More...

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166

G

notch receptor 1

increases cleavage
increases expression

Simvastatin results in increased cleavage of NOTCH1 protein
Simvastatin results in increased expression of NOTCH1 mRNA

NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:9,278,086...9,323,531

G

notch receptor 4

increases expression

Simvastatin results in increased expression of NOTCH4 mRNA

NCBI chr20:4,164,969...4,189,072
Ensembl chr20:4,160,445...4,184,465

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

Simvastatin results in decreased expression of NPC1L1 mRNA

NCBI chr14:85,285,387...85,305,050
Ensembl chr14:81,071,451...81,091,113

G

NPHS2 stomatin family member, podocin

increases expression

Simvastatin results in increased expression of NPHS2 mRNA

NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313

G

natriuretic peptide A

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]
Simvastatin results in decreased expression of NPPA mRNA

PMID:16029635 PMID:16534557

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

decreases expression

Simvastatin results in decreased expression of NPPB; Simvastatin results in decreased expression of NPPB protein

PMID:16628357 PMID:21124329

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:158,416,866...158,418,168

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA]
Simvastatin results in increased expression of NQO1 mRNA; Simvastatin results in increased expression of NQO1 protein

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 1

multiple interactions

[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of NR0B1 mRNA

NCBI chr X:54,707,658...54,711,786
Ensembl chr X:50,756,886...50,761,011

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NR1D1 mRNA]

NCBI chr10:84,224,599...84,231,812
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group H, member 3

decreases expression

Simvastatin results in decreased expression of NR1H3 mRNA

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 protein]

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

Simvastatin results in increased activity of NR1I2 protein
[Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter]

PMID:15802384 PMID:17041008 PMID:24204015

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases activity

Simvastatin results in increased activity of NR1I3 protein

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 4, group A, member 3

multiple interactions

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA]

NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:62,361,822...62,402,733

G

neuropilin 1

decreases response to substance

NRP1 SNP results in decreased susceptibility to Simvastatin

NCBI chr19:73,256,557...73,411,705
Ensembl chr19:56,359,455...56,513,633

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

decreases expression

Simvastatin results in decreased expression of NSDHL mRNA

NCBI chr X:155,817,301...155,848,224
Ensembl chr X:150,775,080...150,807,142

G

neurotrophic receptor tyrosine kinase 1

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK1 mRNA

NCBI chr 2:175,534,844...175,551,664
Ensembl chr 2:173,236,963...173,253,770

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK2 mRNA

NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,559,043...5,869,136

G

occludin

increases expression

Simvastatin results in increased expression of OCLN

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:31,657,220...31,764,150

G

oxidized low density lipoprotein receptor 1

decreases expression

Simvastatin results in decreased expression of OLR1 mRNA

NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:162,926,439...162,948,523

G

oxysterol binding protein-like 1A

decreases expression

Simvastatin results in decreased expression of OSBPL1A mRNA

NCBI chr18:3,904,006...4,094,635
Ensembl chr18:3,904,006...4,094,585

G

oncostatin M

multiple interactions

Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]; Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein]

NCBI chr14:83,327,202...83,332,073
Ensembl chr14:79,104,344...79,108,313

G

prolyl 4-hydroxylase subunit beta

decreases expression

Simvastatin results in decreased expression of P4HB mRNA

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:105,836,982...105,848,500

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage
decreases cleavage

[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; pifithrin inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of PARP1 protein modified form]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]
IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]
Simvastatin inhibits the reaction [Glucose results in increased activity of PARP1 protein]
Simvastatin results in decreased cleavage of PARP1 mRNA

PMID:16054375 PMID:18004065 PMID:20045437 PMID:20464445 PMID:21910007 More...

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

decreases expression

Simvastatin results in decreased expression of PCNA mRNA; Simvastatin results in decreased expression of PCNA protein

PMID:17428261 PMID:18824851

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995

G

proprotein convertase subtilisin/kexin type 9

multiple interactions

[Simvastatin co-treated with Ezetimibe] results in increased expression of PCSK9 mRNA

NCBI chr 5:126,440,102...126,462,507
Ensembl chr 5:121,211,278...121,233,688

G

phosphodiesterase 4B

multiple interactions

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDE4B mRNA]

NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:116,799,971...117,367,696

G

platelet derived growth factor subunit A

decreases expression

Simvastatin results in decreased expression of PDGFA mRNA

NCBI chr12:20,759,366...20,780,337
Ensembl chr12:15,645,541...15,666,497

G

platelet derived growth factor subunit B

decreases expression
decreases activity
multiple interactions

Simvastatin results in decreased expression of PDGFB protein
Simvastatin results in decreased expression of PDGFB mRNA
Simvastatin results in decreased activity of PDGFB protein
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDGFB mRNA]
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of PDGFB protein]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]

PMID:8231022 PMID:10412745 PMID:10412775 PMID:15728660 PMID:16373842

NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:111,540,345...111,557,984

G

platelet derived growth factor receptor alpha

decreases expression

Simvastatin results in decreased expression of PDGFRA mRNA

NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,005,839...33,054,335

G

platelet derived growth factor receptor beta

decreases expression
multiple interactions

Simvastatin results in decreased expression of PDGFRB mRNA
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of PDGFRB mRNA

PMID:10412775 PMID:28263720

NCBI chr18:56,770,348...56,809,228
Ensembl chr18:54,499,964...54,538,843

G

pyruvate dehydrogenase kinase 2

increases expression

Simvastatin results in increased expression of PDK2 mRNA

NCBI chr10:80,469,388...80,483,988
Ensembl chr10:79,972,556...79,987,085

G

pyruvate dehydrogenase kinase 4

increases expression

Simvastatin results in increased expression of PDK4 mRNA

PMID:19001041 PMID:19262002

NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:33,589,799...33,601,850

G

platelet and endothelial cell adhesion molecule 1

increases expression

Simvastatin results in increased expression of PECAM1 mRNA

NCBI chr10:92,090,263...92,152,002
Ensembl chr10:91,590,521...91,652,116

G

prohibitin 2

decreases expression

Simvastatin results in decreased expression of PHB2 protein

NCBI chr 4:159,203,948...159,208,561
Ensembl chr 4:157,517,577...157,522,272

G

phosphatidylinositol glycan anchor biosynthesis, class C

decreases expression

Simvastatin results in decreased expression of PIGC mRNA

NCBI chr13:74,343,619...74,346,148
Ensembl chr13:74,296,854...74,346,211

G

paired-like homeodomain 2

decreases expression

Simvastatin results in decreased expression of PITX2 mRNA

NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293

G

protein kinase, membrane associated tyrosine/threonine 1

decreases expression

Simvastatin results in decreased expression of PKMYT1 mRNA

NCBI chr10:13,252,805...13,263,584
Ensembl chr10:12,748,237...12,758,995

G

phospholipase A2 group IIA

multiple interactions

Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of PLA2G2A protein]

NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:151,076,442...151,079,014

G

phospholipase A2 group VII

multiple interactions

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PLA2G7 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G7 mRNA]

NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:17,362,225...17,404,476

G

plasminogen activator, tissue type

multiple interactions
decreases expression
increases activity
increases expression

geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT]
Simvastatin results in decreased expression of PLAT mRNA
Simvastatin results in increased activity of PLAT protein
Simvastatin results in increased expression of PLAT; Simvastatin results in increased expression of PLAT mRNA; Simvastatin results in increased expression of PLAT protein

PMID:12371961 PMID:12753293 PMID:16414398

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223

G

plasminogen activator, urokinase

decreases expression

Simvastatin results in decreased expression of PLAU mRNA

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775

G

phospholipase C, gamma 2

increases expression

Simvastatin results in increased expression of PLCG2 mRNA

NCBI chr19:62,456,196...62,592,684
Ensembl chr19:45,547,416...45,683,930

G

polo-like kinase 2

decreases expression

Simvastatin results in decreased expression of PLK2 mRNA

NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:41,969,176...41,974,947

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3

decreases expression

Simvastatin results in decreased expression of PLOD3 mRNA

NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960

G

plexin D1

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of PLXND1 mRNA

NCBI chr 4:150,675,377...150,715,706
Ensembl chr 4:149,002,784...149,043,244

G

phorbol-12-myristate-13-acetate-induced protein 1

affects localization
increases expression
multiple interactions

Simvastatin affects the localization of PMAIP1 protein
Simvastatin results in increased expression of PMAIP1 mRNA; Simvastatin results in increased expression of PMAIP1 protein
pifithrin inhibits the reaction [Simvastatin results in increased expression of PMAIP1 mRNA]

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:59,986,017...59,992,429

G

phosphomevalonate kinase

increases expression

Simvastatin results in increased expression of PMVK mRNA

NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:174,876,657...174,886,364

G

protein-O-mannosyltransferase 1

increases expression

Simvastatin results in increased expression of POMT1 mRNA

NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581

G

paraoxonase 1

multiple interactions
increases expression

farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; PON1 gene polymorphism affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]; Simvastatin results in increased expression of and results in increased activity of PON1 protein; Squalene inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]

PMID:14500290 PMID:15690306 PMID:16238680

NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions

Simvastatin results in increased expression of PPARA mRNA
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA protein]; Simvastatin promotes the reaction [Zymosan results in increased expression of PPARA]
PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA]

PMID:15234187 PMID:18981156 PMID:19001041 PMID:20835264 PMID:21323892

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases expression

[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]
Simvastatin results in decreased expression of PPARG
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG protein]

PMID:15781755 PMID:19216230 PMID:20835264

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:43,482,803...43,593,425

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

multiple interactions

geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein]

NCBI chr 1:93,708,269...93,718,218
Ensembl chr 1:84,586,627...84,590,671

G

DNA primase subunit 1

decreases expression

Simvastatin results in decreased expression of PRIM1 mRNA

NCBI chr 7:1,031,436...1,047,134
Ensembl chr 7:431,805...462,526

G

protein kinase AMP-activated catalytic subunit alpha 1

increases expression

Simvastatin results in increased expression of PRKAA1 mRNA

NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978

G

presenilin 1

increases expression

Simvastatin results in increased expression of PSEN1 mRNA

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650

G

platelet-activating factor receptor

decreases expression

Simvastatin results in decreased expression of PTAFR mRNA

NCBI chr 5:150,049,322...150,079,060
Ensembl chr 5:144,765,976...144,795,251

G

phosphatase and tensin homolog

increases expression

Simvastatin results in increased expression of PTEN mRNA; Simvastatin results in increased expression of PTEN protein

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin E synthase

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES protein]
Simvastatin results in decreased expression of PTGES protein

NCBI chr 3:34,575,643...34,586,987

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases expression
increases expression

JTE 013 inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]
Simvastatin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein]
Simvastatin results in decreased expression of PTGS2 protein
Simvastatin results in increased expression of PTGS2 mRNA
Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2]

PMID:17038636 PMID:17277159 PMID:17901590 PMID:18612546 PMID:19225232 More...

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2

decreases activity

Simvastatin results in decreased activity of PTK2 protein

NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:105,126,728...105,331,783

G

paxillin

multiple interactions
decreases phosphorylation
affects localization

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]
Simvastatin results in decreased phosphorylation of PXN protein
Simvastatin affects the localization of PXN protein

NCBI chr12:46,721,546...46,768,706
Ensembl chr12:41,060,791...41,107,931

G

Rac family small GTPase 1

multiple interactions
decreases activity
increases activity
decreases expression
increases expression
affects localization

Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; Simvastatin affects the localization of and results in decreased activity of RAC1 protein; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of RAC1 protein]
Simvastatin results in decreased activity of RAC1 protein
Simvastatin results in increased activity of RAC1 protein
Simvastatin results in decreased expression of RAC1
Simvastatin results in increased expression of RAC1 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of RAC1 protein]
Simvastatin affects the localization of RAC1 protein

PMID:16698853 PMID:17169357 PMID:17303772 PMID:17513949 PMID:18625914 More...

NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251

G

Rac family small GTPase 2

affects localization
decreases activity

Simvastatin affects the localization of RAC2 protein
Simvastatin results in decreased activity of RAC2 protein

PMID:17169357 PMID:20045437

NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:110,116,260...110,128,720

G

Rac family small GTPase 3

affects localization

Simvastatin affects the localization of RAC3 protein

NCBI chr10:106,501,133...106,503,569
Ensembl chr10:105,993,087...106,005,260

G

Rac GTPase-activating protein 1

decreases expression

Simvastatin results in decreased expression of RACGAP1 mRNA

NCBI chr 7:132,629,789...132,659,738
Ensembl chr 7:130,750,936...130,780,831

G

Raf-1 proto-oncogene, serine/threonine kinase

decreases activity
multiple interactions

Simvastatin results in decreased activity of RAF1 protein
Simvastatin inhibits the reaction [Streptozocin results in increased expression of RAF1 protein]

PMID:18569938 PMID:19360310

NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:148,679,530...148,740,317

G

RAP1A, member of RAS oncogene family

decreases prenylation
decreases expression
decreases geranoylation
multiple interactions

Simvastatin results in decreased prenylation of RAP1A protein
Simvastatin results in decreased expression of RAP1A protein alternative form
Simvastatin results in decreased geranoylation of RAP1A protein
Simvastatin results in decreased geranoylation of and results in decreased prenylation of RAP1A protein
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of RAP1A protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RAP1A protein

PMID:20018177 PMID:22120639 PMID:25578243 PMID:37956312

NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:193,208,635...193,286,501

G

RAS protein-specific guanine nucleotide-releasing factor 1

affects phosphorylation
affects localization

Simvastatin affects the phosphorylation of RASGRF1 protein
Simvastatin affects the localization of RASGRF1 protein

NCBI chr 8:99,324,986...99,454,099
Ensembl chr 8:90,445,154...90,574,269

G

RB transcriptional corepressor 1

decreases phosphorylation

Simvastatin results in decreased phosphorylation of RB1 protein

PMID:17928568 PMID:18804536

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases expression
decreases localization
increases localization

artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of RELA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of RELA protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of RELA protein]; Simvastatin results in increased localization of and results in increased activity of RELA protein
Simvastatin results in decreased expression of RELA protein
Simvastatin results in decreased expression of RELA mRNA; Simvastatin results in decreased expression of RELA protein
Simvastatin results in decreased localization of RELA protein
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Homocysteine inhibits the reaction [Simvastatin results in decreased expression of RELA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]]
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of RELA protein]

PMID:12753293 PMID:15705589 PMID:16414398 PMID:17038636 PMID:17075836 More...

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

ret proto-oncogene

multiple interactions

[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of RET mRNA

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:151,326,431...151,368,176

G

resistin

multiple interactions

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]

NCBI chr12:6,508,653...6,511,115
Ensembl chr12:1,710,881...1,712,620

G

replication factor C subunit 5

decreases expression

Simvastatin results in decreased expression of RFC5 mRNA

NCBI chr12:44,868,322...44,877,879
Ensembl chr12:39,207,484...39,217,312

G

regulator of G-protein signaling 2

increases expression

Simvastatin results in increased expression of RGS2 mRNA

NCBI chr13:58,350,063...58,352,666
Ensembl chr13:55,798,829...55,802,385

G

ras homolog family member A

multiple interactions
decreases prenylation
affects localization
increases expression
increases localization
decreases expression
decreases activity

farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeraniol inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin affects the localization of and results in decreased activity of RHOA protein; Simvastatin inhibits the reaction [geranylgeranyl pyrophosphate affects the localization of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin results in decreased localization of and results in decreased activity of RHOA protein; Simvastatin results in increased localization of and results in decreased prenylation of RHOA protein
Simvastatin results in decreased prenylation of RHOA protein
Simvastatin affects the localization of RHOA protein
Simvastatin results in increased expression of RHOA protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]
Simvastatin results in increased expression of RHOA mRNA
Simvastatin results in decreased expression of RHOA; Simvastatin results in decreased expression of RHOA protein
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of RHOA]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RHOA protein

PMID:12477733 PMID:14630613 PMID:15200425 PMID:16005304 PMID:16470222 More...

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746

G

ras homolog family member C

increases expression

Simvastatin results in increased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

receptor interacting serine/threonine kinase 1

multiple interactions

[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; [Simvastatin co-treated with Metformin] results in increased expression of RIPK1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]]

NCBI chr17:31,044,983...31,077,167
Ensembl chr17:30,839,650...30,871,824

G

receptor-interacting serine-threonine kinase 3

multiple interactions

[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]]

NCBI chr15:33,253,071...33,262,025
Ensembl chr15:29,283,145...29,292,121

G

RAR-related orphan receptor C

multiple interactions
decreases expression

IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RORC mRNA]

NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:182,009,286...182,034,907

G

ribosomal protein L39

increases expression

Simvastatin results in increased expression of RPL39 mRNA

NCBI chr  X:116,327,216...116,330,211
Ensembl chr18:6,326,330...6,326,692
Ensembl chr  X:6,326,330...6,326,692
Ensembl chr  X:6,326,330...6,326,692
Ensembl chr15:6,326,330...6,326,692
Ensembl chr20:6,326,330...6,326,692
Ensembl chr 7:6,326,330...6,326,692

G

ribosomal protein S10

increases expression

Simvastatin results in increased expression of RPS10 mRNA

NCBI chr20:5,694,313...5,698,922
Ensembl chr20:5,694,313...5,699,044
Ensembl chr 6:5,694,313...5,699,044
Ensembl chr 6:5,694,313...5,699,044

G

ribosomal protein S6

multiple interactions
decreases phosphorylation

IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

ribosomal protein S6 kinase B1

multiple interactions
decreases phosphorylation

FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]

PMID:27734117 PMID:33034787

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908

G

RT1 class Ia, locus A2

affects expression

Simvastatin affects the expression of HLA-E mRNA

NCBI chr20:4,872,720...4,876,425

G

RT1 class II, locus Bb

affects expression

Simvastatin affects the expression of HLA-DQB1 mRNA

NCBI chr20:4,598,475...4,604,118
Ensembl chr20:4,596,559...4,607,597

G

RT1 class I, locus CE5

affects expression

Simvastatin affects the expression of HLA-F mRNA

NCBI chr20:3,407,880...3,484,130

G

RT1 class II, locus Da

multiple interactions

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]

NCBI chr20:4,515,393...4,520,387
Ensembl chr20:4,512,911...4,518,455

G

RT1 class II, locus DMa

decreases expression

Simvastatin results in decreased expression of RT1-DMA mRNA

NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,707,028...4,710,432

G

RUNX family transcription factor 2

increases expression
multiple interactions

Simvastatin results in increased expression of RUNX2
Simvastatin results in increased expression of RUNX2 mRNA
DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]

PMID:18310456 PMID:20381859 PMID:20417880 PMID:22058016

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:16,167,482...16,492,167

G

ryanodine receptor 2

increases expression

Simvastatin results in increased expression of RYR2 mRNA; Simvastatin results in increased expression of RYR2 protein

NCBI chr17:63,081,527...63,667,141
Ensembl chr17:58,389,925...58,975,142

G

S100 calcium binding protein A6

increases expression
multiple interactions

Simvastatin results in increased expression of S100A6 mRNA
Simvastatin results in increased expression of S100A6 mRNA; Simvastatin results in increased expression of S100A6 protein
Simvastatin results in increased expression of and results in increased localization of S100A6 protein

PMID:14973129 PMID:17428261

NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:176,100,899...176,102,180

G

S100 calcium binding protein A8

increases expression

Simvastatin results in increased expression of S100A8 mRNA

NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

increases expression

Simvastatin results in increased expression of S100A9 mRNA

NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:176,190,361...176,193,230

G

sphingosine-1-phosphate receptor 1

increases expression

Simvastatin results in increased expression of S1PR1 mRNA

NCBI chr 2:206,309,715...206,314,070
Ensembl chr 2:203,621,587...203,629,681

G

sphingosine-1-phosphate receptor 3

increases expression
decreases expression

Simvastatin results in increased expression of S1PR3 mRNA
Simvastatin results in decreased expression of S1PR3 mRNA

PMID:18612546 PMID:18981156

NCBI chr17:13,932,773...13,946,213
Ensembl chr17:13,781,050...13,794,505

G

SREBF chaperone

affects response to substance

SCAP polymorphism affects the susceptibility to Simvastatin

NCBI chr 8:119,184,366...119,239,086
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class B, member 1

multiple interactions
increases expression

PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1]
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SCARB1 mRNA; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 mRNA]; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 protein]
Simvastatin results in increased expression of SCARB1; Simvastatin results in increased expression of SCARB1 mRNA; Simvastatin results in increased expression of SCARB1 protein

PMID:18981156 PMID:20025956 PMID:21241519 PMID:25055962 PMID:33383043

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647

G

syndecan 1

decreases expression

Simvastatin results in decreased expression of SDC1 mRNA

NCBI chr 6:37,282,041...37,304,503
Ensembl chr 6:31,562,739...31,585,264

G

syndecan 4

decreases expression

Simvastatin results in decreased expression of SDC4 mRNA

NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:153,154,896...153,173,580

G

selectin E

multiple interactions
affects expression
decreases expression

farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of SELE protein modified form]
Simvastatin affects the expression of SELE protein

PMID:10946302 PMID:14602771 PMID:16740276 PMID:21994025

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:76,403,304...76,412,741

G

selectin P

multiple interactions
decreases expression

Simvastatin inhibits the reaction [staphylococcal alpha-toxin results in increased expression of SELP protein]
Simvastatin results in decreased expression of SELP mRNA

PMID:12379581 PMID:16414398

NCBI chr13:79,009,379...79,044,994
Ensembl chr13:76,476,295...76,511,845

G

serpin family E member 1

decreases expression
decreases secretion
decreases activity
multiple interactions

Simvastatin results in decreased expression of SERPINE1 mRNA; Simvastatin results in decreased expression of SERPINE1 protein
Simvastatin results in decreased secretion of SERPINE1 protein
Simvastatin results in decreased activity of SERPINE1 protein
[Simvastatin co-treated with Dexamethasone] results in increased secretion of SERPINE1 protein

PMID:16375908 PMID:16414398 PMID:17513194 PMID:21524281

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657

G

sestrin 2

increases expression

Simvastatin results in increased expression of SESN2 mRNA

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:144,701,530...144,721,260

G

sestrin 3

decreases expression

Simvastatin results in decreased expression of SESN3 mRNA

NCBI chr 8:19,415,307...19,470,943
Ensembl chr 8:11,133,678...11,185,842

G

serum/glucocorticoid regulated kinase 2

multiple interactions

[Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter]

NCBI chr 3:172,063,625...172,089,000
Ensembl chr 3:151,644,102...151,669,480

G

solute carrier family 10 member 1

decreases expression

Simvastatin results in decreased expression of SLC10A1 mRNA

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 38, member 4

increases expression

Simvastatin results in increased expression of SLC38A4 mRNA

NCBI chr 7:130,022,039...130,082,169
Ensembl chr 7:128,144,807...128,202,995

G

solute carrier family 6 member 4

increases activity

Simvastatin results in increased activity of SLC6A4 protein

NCBI chr10:62,322,688...62,357,060
Ensembl chr10:61,826,123...61,858,384

G

SMAD family member 1

multiple interactions
increases phosphorylation
increases expression

Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]
Simvastatin results in increased phosphorylation of SMAD1 protein
Simvastatin results in increased expression of SMAD1 mRNA

PMID:18310456 PMID:20417880

NCBI chr19:45,417,430...45,477,962
Ensembl chr19:28,513,131...28,573,651

G

SMAD family member 2

decreases phosphorylation
multiple interactions
increases phosphorylation
increases expression

Simvastatin results in decreased phosphorylation of SMAD2 protein
FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein]
Simvastatin results in increased expression of SMAD2 mRNA

PMID:18310456 PMID:19659652 PMID:33034787

NCBI chr18:72,124,792...72,193,345
Ensembl chr18:69,850,377...69,912,323

G

SMAD family member 3

increases expression
multiple interactions
increases phosphorylation
decreases phosphorylation

Simvastatin results in increased expression of SMAD3 mRNA
FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein]
Simvastatin results in decreased phosphorylation of SMAD3 protein

PMID:18310456 PMID:19659652 PMID:33034787

NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:64,110,039...64,236,960

G

SMAD family member 5

multiple interactions

Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]

NCBI chr17:7,867,640...7,896,983
Ensembl chr17:7,864,720...7,891,634

G

SMAD family member 9

multiple interactions

Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]

NCBI chr 2:141,106,668...141,156,477
Ensembl chr 2:138,986,471...139,006,307

G

sorting nexin 17

decreases expression
multiple interactions

Simvastatin results in decreased expression of SNX17 mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SNX17 mRNA

NCBI chr 6:30,897,500...30,902,972
Ensembl chr 6:25,177,391...25,183,030

G

sterol O-acyltransferase 1

increases expression

Simvastatin results in increased expression of SOAT1 mRNA

NCBI chr13:71,105,178...71,147,776
Ensembl chr13:68,552,317...68,597,494

G

suppressor of cytokine signaling 3

increases expression

Simvastatin results in increased expression of SOCS3 mRNA

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,193,537...103,197,787

G

suppressor of cytokine signaling 4

increases expression

Simvastatin results in increased expression of SOCS4 mRNA; Simvastatin results in increased expression of SOCS4 protein

NCBI chr15:23,003,130...23,017,615
Ensembl chr15:20,523,183...20,542,494

G

suppressor of cytokine signaling 7

increases expression

Simvastatin results in increased expression of SOCS7 mRNA

NCBI chr10:82,848,525...82,885,201
Ensembl chr10:82,351,680...82,388,830

G

superoxide dismutase 2

decreases expression

Simvastatin results in decreased expression of SOD2 mRNA

PMID:16414398 PMID:20883752

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

superoxide dismutase 3

multiple interactions

Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD3 mRNA]

NCBI chr14:62,822,865...62,828,602
Ensembl chr14:58,609,958...58,615,990

G

Sp1 transcription factor

multiple interactions

Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter]

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:133,541,491...133,571,961

G

Sp7 transcription factor

multiple interactions
increases expression

CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA]
Simvastatin results in increased expression of SP7; Simvastatin results in increased expression of SP7 mRNA; Simvastatin results in increased expression of SP7 protein

PMID:20564244 PMID:22058016

NCBI chr 7:135,363,193...135,373,376
Ensembl chr 7:133,484,609...133,494,847

G

spondin 2

increases expression

Simvastatin results in increased expression of SPON2 mRNA

NCBI chr14:81,713,070...81,742,510
Ensembl chr14:77,511,901...77,517,996

G

secreted phosphoprotein 1

decreases expression
increases expression

Simvastatin results in decreased expression of SPP1 mRNA
Simvastatin results in increased expression of SPP1 protein

PMID:12914771 PMID:14601315 PMID:21076490 PMID:21109955 PMID:22058016

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162

G

sequestosome 1

multiple interactions

[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

increases localization
decreases expression

Simvastatin results in increased localization of SREBF1 protein
Simvastatin results in decreased expression of SREBF1 mRNA

PMID:17655842 PMID:25055962

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]
Simvastatin results in increased expression of SREBF2 mRNA
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of SREBF2 mRNA]; Simvastatin results in increased activity of and results in increased localization of SREBF2 protein
Simvastatin results in increased expression of SREBF2 protein modified form

PMID:12056585 PMID:14500290 PMID:20018177

NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:113,663,202...113,720,848

G

steroidogenic acute regulatory protein

increases expression
multiple interactions

Simvastatin results in increased expression of STAR mRNA
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of STAR mRNA

PMID:24524197 PMID:25055962

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 1

multiple interactions
decreases activity
decreases expression
decreases phosphorylation

Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT1 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]
Simvastatin results in decreased activity of STAT1 protein
Simvastatin results in decreased expression of STAT1 mRNA; Simvastatin results in decreased expression of STAT1 protein
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]

PMID:16534557 PMID:17507688 PMID:18453621 PMID:19886038 PMID:21268089

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

decreases activity
decreases phosphorylation
multiple interactions
affects expression

Simvastatin results in decreased activity of STAT3 protein
Simvastatin results in decreased phosphorylation of STAT3 protein
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of STAT3 protein]
Simvastatin affects the expression of STAT3 protein
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT3 protein]

PMID:16534557 PMID:17507688 PMID:18400235 PMID:18453621 PMID:19100119 More...

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 5A

affects expression

Simvastatin affects the expression of STAT5A protein

NCBI chr10:86,285,859...86,310,187
Ensembl chr10:85,785,537...85,809,866

G

signal transducer and activator of transcription 6

affects expression

Simvastatin affects the expression of STAT6 protein

NCBI chr 7:65,365,505...65,382,825
Ensembl chr 7:63,479,642...63,498,495

G

serine/threonine kinase 11

increases phosphorylation

Simvastatin results in increased phosphorylation of STK11 protein

NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:9,575,269...9,591,315

G

TGF-beta activated kinase 1/MAP3K7 binding protein 1

multiple interactions

Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein]

NCBI chr 7:113,556,157...113,587,351
Ensembl chr 7:111,686,371...111,707,058

G

TRAF family member-associated NFKB activator

multiple interactions

[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of TANK mRNA

NCBI chr 3:46,114,230...46,190,270
Ensembl chr 3:46,114,274...46,190,264

G

thromboxane A synthase 1

decreases expression
increases expression

Simvastatin results in decreased expression of TBXAS1 mRNA
Simvastatin results in increased expression of TBXAS1 mRNA

PMID:16414398 PMID:20659230

NCBI chr 4:68,631,841...68,803,959
Ensembl chr 4:67,665,007...67,837,096

G

TEK receptor tyrosine kinase

multiple interactions
increases expression

Simvastatin inhibits the reaction [Streptozocin results in increased expression of TEK mRNA]; Simvastatin results in increased expression of and results in increased activity of TEK protein
Simvastatin results in increased expression of TEK; Simvastatin results in increased expression of TEK mRNA

PMID:18544044 PMID:20821229

NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:109,607,077...109,733,804

G

transferrin

multiple interactions

Simvastatin inhibits the reaction [TNF results in increased expression of TF]

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:103,767,995...103,816,511

G

transferrin receptor

affects expression

Simvastatin affects the expression of TFRC protein

NCBI chr11:81,668,478...81,690,318
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

multiple interactions
decreases expression
increases activity
increases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein]
Simvastatin results in decreased expression of TGFB1 mRNA; Simvastatin results in decreased expression of TGFB1 protein
Simvastatin results in increased activity of TGFB1 protein
Simvastatin results in increased expression of TGFB1 mRNA
Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]

PMID:15298857 PMID:15677772 PMID:15855201 PMID:16320597 PMID:19080365 More...

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 2

multiple interactions
decreases expression

Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TGFBR2 mRNA]
Simvastatin results in decreased expression of TGFBR2 mRNA

PMID:16320597 PMID:16373842

NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:115,794,537...115,883,228

G

thrombomodulin

increases expression
multiple interactions

Simvastatin results in increased expression of THBD mRNA; Simvastatin results in increased expression of THBD protein
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of THBD mRNA]

PMID:14630613 PMID:16375908 PMID:20493886 PMID:20737288

NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:135,862,835...135,867,193

G

thrombospondin 1

decreases expression

Simvastatin results in decreased expression of THBS1 mRNA

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:105,056,292...105,071,440

G

TIMP metallopeptidase inhibitor 1

multiple interactions
decreases expression

Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of TIMP1 mRNA]

PMID:16414398 PMID:20137537 PMID:22022327

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

multiple interactions
decreases expression

Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP2 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP2 mRNA]

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:103,531,505...103,590,611

G

toll-like receptor 2

increases expression
multiple interactions

Simvastatin results in increased expression of TLR2 protein
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 protein]

PMID:16387846 PMID:16443229

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

increases expression
multiple interactions
decreases expression

Simvastatin results in increased expression of TLR4 protein
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]
Simvastatin results in decreased expression of TLR4 mRNA; Simvastatin results in decreased expression of TLR4 protein

PMID:16387846 PMID:16443229 PMID:19166837

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628

G

transmembrane 7 superfamily member 2

increases expression

Simvastatin results in increased expression of TM7SF2 mRNA

NCBI chr 1:212,785,217...212,789,572
Ensembl chr 1:203,355,931...203,360,270

G

tenascin C

decreases expression

Simvastatin results in decreased expression of TNC mRNA

NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:77,375,851...77,460,624

G

tumor necrosis factor

multiple interactions
affects secretion
decreases secretion
decreases expression
increases expression
increases secretion
decreases activity

geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of TF]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CXCL8 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA]
Simvastatin affects the secretion of TNF protein
Simvastatin results in decreased secretion of TNF protein
Simvastatin results in decreased expression of TNF mRNA; Simvastatin results in decreased expression of TNF protein
Simvastatin results in increased expression of TNF mRNA
Simvastatin results in increased secretion of TNF protein
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Guanidines inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL15 mRNA]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
Simvastatin results in decreased activity of TNF; Simvastatin results in decreased activity of TNF protein
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; [Lipopolysaccharides co-treated with Simvastatin] results in increased expression of and results in increased secretion of TNF protein; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA]

PMID:10946302 PMID:12117737 PMID:12615677 PMID:12753293 PMID:12829860 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

increases expression

Simvastatin results in increased expression of TNFRSF11B mRNA

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:85,566,520...85,594,538

G

TNF receptor superfamily member 1A

decreases expression

Simvastatin results in decreased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:158,150,820...158,163,591

G

TNF receptor superfamily member 1B

decreases expression

Simvastatin results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:157,070,642...157,104,206

G

TNF receptor superfamily member 4

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]
Simvastatin results in decreased expression of TNFRSF4 mRNA; Simvastatin results in decreased expression of TNFRSF4 protein

NCBI chr 5:171,889,134...171,891,824
Ensembl chr 5:166,606,909...166,609,599

G

TNF superfamily member 10

multiple interactions
increases response to substance

[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]
TNFSF10 protein results in increased susceptibility to Simvastatin

NCBI chr 2:112,136,550...112,155,903
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 4

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]
Simvastatin results in decreased expression of TNFSF4 mRNA; Simvastatin results in decreased expression of TNFSF4 protein

NCBI chr13:76,256,654...76,280,133
Ensembl chr13:73,723,329...73,746,788

G

troponin I3, cardiac type

multiple interactions

Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]

NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:69,299,900...69,303,580

G

tumor protein p53

multiple interactions
increases expression
increases phosphorylation

pifithrin inhibits the reaction [Simvastatin results in increased expression of TP53 protein]; Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]; Simvastatin results in increased expression of and results in increased phosphorylation of TP53 protein
Simvastatin results in increased expression of TP53 mRNA; Simvastatin results in increased expression of TP53 mutant form; Simvastatin results in increased expression of TP53 protein
Simvastatin results in increased phosphorylation of TP53 protein

PMID:15625077 PMID:18804536 PMID:20045437 PMID:21199873

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

tumor protein, translationally-controlled 1

decreases expression

Simvastatin results in decreased expression of TPT1 protein

NCBI chr15:57,562,217...57,568,968
Ensembl chr15:51,146,154...51,159,625

G

TNFRSF1A-associated via death domain

decreases expression

Simvastatin results in decreased expression of TRADD mRNA

NCBI chr19:50,046,057...50,048,158
Ensembl chr19:33,136,138...33,142,638

G

Tnf receptor-associated factor 2

decreases expression

Simvastatin results in decreased expression of TRAF2 mRNA

NCBI chr 3:28,740,098...28,764,752
Ensembl chr 3:8,341,951...8,366,538

G

tripartite motif containing 63

increases expression
multiple interactions

Simvastatin results in increased expression of TRIM63 mRNA
Simvastatin results in increased expression of TRIM63 mRNA; Simvastatin results in increased expression of TRIM63 protein
FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]

PMID:19001041 PMID:27734117 PMID:33034787

NCBI chr 5:151,817,209...151,831,026
Ensembl chr 5:146,533,507...146,547,322

G

thioredoxin reductase 1

decreases expression

Simvastatin results in decreased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863

G

thymidylate synthetase

decreases expression

Simvastatin results in decreased expression of TYMS mRNA; Simvastatin results in decreased expression of TYMS protein

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:113,313,452...113,329,536

G

vasodilator-stimulated phosphoprotein

decreases phosphorylation

Simvastatin results in decreased phosphorylation of VASP protein

NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:78,910,011...78,925,061

G

vascular cell adhesion molecule 1

multiple interactions
decreases expression

Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of VCAM1 protein modified form]
Simvastatin results in decreased expression of VCAM1 mRNA; Simvastatin results in decreased expression of VCAM1 protein
Simvastatin results in decreased expression of VCAM1 mRNA; Simvastatin results in decreased expression of VCAM1 protein; Simvastatin results in decreased expression of VCAM1 protein modified form

PMID:10946302 PMID:14602771 PMID:15234187 PMID:17105841 PMID:17169357 More...

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958

G

vinculin

affects localization

Simvastatin affects the localization of VCL protein

NCBI chr15:3,315,069...3,404,891
Ensembl chr15:3,265,815...3,355,606

G

voltage-dependent anion channel 1

decreases expression

Simvastatin results in decreased expression of VDAC1 protein

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:36,532,244...36,559,640

G

vitamin D receptor

increases expression

Simvastatin results in increased expression of VDR mRNA

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

multiple interactions
increases expression
increases secretion
decreases expression

geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]
Simvastatin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA protein]
Simvastatin results in increased expression of VEGFA mRNA; Simvastatin results in increased expression of VEGFA protein
Simvastatin results in increased secretion of VEGFA protein
Simvastatin results in increased expression of VEGFA; Simvastatin results in increased expression of VEGFA mRNA
Simvastatin results in decreased expression of VEGFA protein

PMID:15572054 PMID:16424782 PMID:17277159 PMID:18316203 PMID:18356691 More...

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

decreases expression

Simvastatin results in decreased expression of VIM protein

PMID:14973129 PMID:15855201

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187

G

von Willebrand factor

increases expression

Simvastatin results in increased expression of VWF mRNA; Simvastatin results in increased expression of VWF protein

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:158,360,152...158,491,539

G

Wnt family member 4

multiple interactions
increases expression

Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT4 mRNA]
Simvastatin results in increased expression of WNT4 protein

NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:149,514,018...149,532,859

G

Wnt family member 5A

multiple interactions
increases expression

Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA]
Simvastatin results in increased expression of WNT5A mRNA; Simvastatin results in increased expression of WNT5A protein

PMID:18004065 PMID:19968183

NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,697,032...3,718,234

G

X-box binding protein 1

decreases expression

Simvastatin results in decreased expression of XBP1 protein

NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693

G

X-linked inhibitor of apoptosis

decreases expression

Simvastatin results in decreased expression of XIAP mRNA; Simvastatin results in decreased expression of XIAP protein

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:120,897,907...120,934,700

G

zinc finger protein 866

decreases expression

Simvastatin results in decreased expression of CXCL5 mRNA

NCBI chr16:19,653,966...19,675,968
Ensembl chr16:19,668,258...19,675,932

Yangonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
increases expression

NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein]
yangonin results in increased expression of ABCB11 mRNA; yangonin results in increased expression of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

multiple interactions

yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 protein]

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238

G

cyclin B1

multiple interactions

pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCNB1 mRNA]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCNB1 protein]]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCNB1 mRNA]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCNB1 protein]

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions
increases expression

pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCND1 mRNA]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCND1 protein]]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCND1 mRNA]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CCND1 protein]
yangonin results in increased expression of CCND1 protein

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

carboxylesterase 1D

decreases activity
multiple interactions

yangonin results in decreased activity of CES1 protein
yangonin inhibits the reaction [[CES1 protein results in increased metabolism of Oseltamivir] which results in increased abundance of oseltamivir carboxylate]

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

yangonin results in increased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450 family 7 subfamily A member 1

decreases expression
multiple interactions

yangonin results in decreased expression of CYP7A1 mRNA
NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

yangonin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 mRNA]

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:121,557,062...121,580,166

G

forkhead box M1

multiple interactions
increases expression

NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 mRNA]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 protein]]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 mRNA]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 protein]
yangonin results in increased expression of FOXM1 protein

NCBI chr 4:163,325,628...163,338,100
Ensembl chr 4:161,638,816...161,650,684

G

interleukin 1 beta

multiple interactions

NR1H4 promotes the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]]; yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 mRNA]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
affects response to substance
increases expression

yangonin binds to and results in increased activity of NR1H4 protein
NR1H4 promotes the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]]; NR1H4 promotes the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of RELA protein]]; NR1H4 promotes the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA]]; NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA]]; NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]]; NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein]]; NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of FOXM1 protein]]; yangonin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NR1H4 protein]
NR1H4 affects the susceptibility to yangonin
yangonin results in increased expression of NR1H4 mRNA

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

NR1H4 promotes the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of RELA protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of RELA mRNA]]; yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of RELA mRNA]; yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 10 member 1

multiple interactions

NR1H4 promotes the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; yangonin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670

G

sulfotransferase family 2A member 1

increases expression
multiple interactions

yangonin results in increased expression of SULT2A1 mRNA
yangonin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of SULT2A1 mRNA]

NCBI chr 1:84,582,011...84,639,001
Ensembl chr 1:74,911,100...75,508,134

G

tumor necrosis factor

multiple interactions

NR1H4 promotes the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA]]; pregna-4,17-diene-3,16-dione inhibits the reaction [yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA]]; yangonin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19909
chemical entity	19907
atom	19907
nonmetal atom	19831
oxygen atom	19572
oxygen molecular entity	19572
organooxygen compound	19216
oxacycle	17921
pyrans	1167
(-)-secologanin	0
(E)-cladodionen	0
(Z)-cladodionen	0
(Z)-vermelhotin	0
2,3,4a,6,7,8-hexaahydro-pyrano[2,3-b]cyclopenta[d]pyran-9-one	0
2,3-Dehydro-1,8-cineole	0
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2R,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3R,6R)-3-amino-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2R,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2R,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3S,6S)-3-amino-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-amino-6-ethyl-4-thiophen-2-yl-8-(thiophen-2-ylmethylidene)-5,7-dihydro-4H-pyrano[3,2-c]pyridine-3-carbonitrile	0
2-cyclopropyl-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
24-dehydrozincophorin	0
3-Carbomethoxy-6-benzyl-4-pyrone	0
4-carboxy-2-hydroxymuconate semialdehyde hemiacetal	0
4R,7S,11S*,2H-3,4,4a,5a,7,8-hexhydro-4-hydroxy-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
4RS,7RS,11RS,2H-3,4,4a,5a,7,8-hexahydro-4-hydroxy-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
4RS,7SR,11SR,2H-3,4,4a,5a,7,8-hexahydro-4-hydroxy-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
5'-hydroxy-asperentin-8-O-methylether	0
5'-hydroxyasperentin	0
5-dihydro-4-formyl-6-hydroxy-2-hydroxymethyl-6-methyl-2H-pyran	0
6-hydroxy-5-methoxy-3-methyl-3, 6-dihydro-2H-pyran-4-carboxylic acid	0
7,10-Dihydroxydeacetyldihydrobotrydial-1	0
7,10-dihydroxydeacetyldihydrobotrydial-1(10)-ene	0
7RS,11RS,2H-3,4,4a,5a,7,8-hexahydro-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
Anhydroisocochlioquinone A	0
Arthripenoid F	0
Aspergilsmin C	0
Aspergilsmin D	0
Avermectin A1a aglycone	0
Avermectin A1b aglycone	0
Avermectin B1a aglycone	0
Avermectin B1b aglycone	0
Bisbynin	0
Biscopyran	0
Butopyronoxyl	0
Chelidonic acid	0
Citrifuran B	0
Citrifuran C	0
Cladodionen	0
Cladosporiumin I	0
Cochlioquinone F	0
Cortistatin F	0
Costatone	0
Cycloepoxytriol A	0
Cycloepoxytriol B	0
Diospentenol A	0
Diospentenol B	0
FR901463	0
FR901464	0
FR901465	0
Fulvoplumierin	0
Isochromophilone A	0
Isochromophilone B	0
Laricinin A	0
N-(cyclopropylmethyl)-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3R,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3S,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(4-thiazolyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3S,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3R,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(4-thiazolyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3S,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3S,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
Nakienone C	0
Nectripenoid B	0
Penostatin D	0
Pestaloporonin A	0
Pestaloporonin B	0
Prugosene B1	0
Prugosene B2	0
SCHEMBL17148379	0
Sequoiatone B	0
Sequoiatone C	0
Stereumin R	0
Vermelhotin	0
Waol acid	0
Wortmannilactone G	0
aglaiabbreviatin D	0
asperentin +	51
asperentin-8-methyl ether	0
chaetoxanthone C	0
griseochelin	0
ligstroside	0
lucidumoside C	0
nerol oxide	0
oleoside 11-methyl ester	0
oleuropein +	36
oleuropein aglycone	0
polyketomycin	0
pyran +	423
pyrancarbaldehyde +	0
pyrandicarboxylic acid +	0
pyrandione +	8
pyranmonocarboxylic acid +	0
pyranone +	1133
secoxyloganin	0
Path 2
Term	Annotations
CHEBI ontology	19909
subatomic particle	19907
composite particle	19907
hadron	19907
baryon	19907
nucleon	19907
atomic nucleus	19907
atom	19907
main group element atom	19846
p-block element atom	19846
carbon group element atom	19784
carbon atom	19781
organic molecular entity	19781
organic molecule	19735
organic cyclic compound	19528
organic heterocyclic compound	18895
organic heteromonocyclic compound	17825
pyrans	1167
(-)-secologanin	0
(E)-cladodionen	0
(Z)-cladodionen	0
(Z)-vermelhotin	0
2,3,4a,6,7,8-hexaahydro-pyrano[2,3-b]cyclopenta[d]pyran-9-one	0
2,3-Dehydro-1,8-cineole	0
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2R,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3R,6R)-3-amino-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2R,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2R,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2R,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2R,3S,6S)-3-amino-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3R,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3R,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3S,6R)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester	0
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(propylcarbamoylamino)-3,6-dihydro-2H-pyran-6-yl]-N-(2-phenylethyl)acetamide	0
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid	0
2-[(2S,3S,6S)-3-[[(cyclohexylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(phenylmethyl)acetamide	0
2-[(2S,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide	0
2-amino-6-ethyl-4-thiophen-2-yl-8-(thiophen-2-ylmethylidene)-5,7-dihydro-4H-pyrano[3,2-c]pyridine-3-carbonitrile	0
2-cyclopropyl-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
2-cyclopropyl-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]acetamide	0
24-dehydrozincophorin	0
3-Carbomethoxy-6-benzyl-4-pyrone	0
4-carboxy-2-hydroxymuconate semialdehyde hemiacetal	0
4R,7S,11S*,2H-3,4,4a,5a,7,8-hexhydro-4-hydroxy-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
4RS,7RS,11RS,2H-3,4,4a,5a,7,8-hexahydro-4-hydroxy-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
4RS,7SR,11SR,2H-3,4,4a,5a,7,8-hexahydro-4-hydroxy-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
5'-hydroxy-asperentin-8-O-methylether	0
5'-hydroxyasperentin	0
5-dihydro-4-formyl-6-hydroxy-2-hydroxymethyl-6-methyl-2H-pyran	0
6-hydroxy-5-methoxy-3-methyl-3, 6-dihydro-2H-pyran-4-carboxylic acid	0
7,10-Dihydroxydeacetyldihydrobotrydial-1	0
7,10-dihydroxydeacetyldihydrobotrydial-1(10)-ene	0
7RS,11RS,2H-3,4,4a,5a,7,8-hexahydro-pyrano[2,3-b]cyclopenta[d]pyran-9(6H)-one	0
Anhydroisocochlioquinone A	0
Arthripenoid F	0
Aspergilsmin C	0
Aspergilsmin D	0
Avermectin A1a aglycone	0
Avermectin A1b aglycone	0
Avermectin B1a aglycone	0
Avermectin B1b aglycone	0
Bisbynin	0
Biscopyran	0
Butopyronoxyl	0
Chelidonic acid	0
Citrifuran B	0
Citrifuran C	0
Cladodionen	0
Cladosporiumin I	0
Cochlioquinone F	0
Cortistatin F	0
Costatone	0
Cycloepoxytriol A	0
Cycloepoxytriol B	0
Diospentenol A	0
Diospentenol B	0
FR901463	0
FR901464	0
FR901465	0
Fulvoplumierin	0
Isochromophilone A	0
Isochromophilone B	0
Laricinin A	0
N-(cyclopropylmethyl)-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-(cyclopropylmethyl)-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[(1-methyl-4-imidazolyl)sulfonylamino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3R,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3R,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3S,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(4-thiazolyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2R,3S,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2R,3S,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2R,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3R,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3R,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3R,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(4-thiazolyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6R)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3S,6R)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide	0
N-[(2S,3S,6S)-6-[2-(cyclobutylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]cyclopropanecarboxamide	0
N-[(2S,3S,6S)-6-[2-(cyclohexylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]propanamide	0
N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2R,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3R,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6R)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-[3-(dimethylamino)propyl]-2-[(2S,3S,6S)-3-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo(propylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide	0
Nakienone C	0
Nectripenoid B	0
Penostatin D	0
Pestaloporonin A	0
Pestaloporonin B	0
Prugosene B1	0
Prugosene B2	0
SCHEMBL17148379	0
Sequoiatone B	0
Sequoiatone C	0
Stereumin R	0
Vermelhotin	0
Waol acid	0
Wortmannilactone G	0
aglaiabbreviatin D	0
asperentin +	51
asperentin-8-methyl ether	0
chaetoxanthone C	0
griseochelin	0
ligstroside	0
lucidumoside C	0
nerol oxide	0
oleoside 11-methyl ester	0
oleuropein +	36
oleuropein aglycone	0
polyketomycin	0
pyran +	423
pyrancarbaldehyde +	0
pyrandicarboxylic acid +	0
pyrandione +	8
pyranmonocarboxylic acid +	0
pyranone +	1133
secoxyloganin	0

paths to the root